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Foreword 
An ageing population, population growth, technological advances and increasing expectations of the 
health system will continue to sharpen our focus on a system that delivers value for money. 
Pressure to deliver more with Australian health budgets will continue to grow. 
Ensuring our scarce health resources are directed to where they can be most effective in improving 
the health and quality of life of all Australiansparticularly for those with the poorest health 
outcomesis a crucial task for those managing our health systems. 
This groundbreaking major five-year study, funded by the National Health and Medical Research 
Council (NHMRC), and run under the auspices of the Centre for Burden of Disease and Cost-
Effectiveness at the University of Queensland and Deakin Health Economics at Deakin University, 
must be a foundation for a more effective system for health. 
Expertly led by Professor Theo Vos of the University of Queensland, in association with Professor 
Rob Carter from Deakin University, this research underpins a comprehensive analysis of the value of 
many health advancement strategies to address the burden of preventable death and disease in 
Australia.  
Importantly, the findings demonstrate how to achieve not only a more efficient system of health, 
but also a fairer system. The report’s focus on deeply entrenched health inequalities facing 
Indigenous Australians paints a striking picturewe simply must do more to improve the physical 
and mental health of those experiencing social, economic or geographical disadvantage.  
This report has evaluated the cost-effectiveness of 150 preventive health interventions, addressing 
areas such as mental health, diabetes, tobacco use, alcohol use, nutrition, body weight, physical 
activity, blood pressure, blood cholesterol and bone mineral density. 
It challenges us to learn more from intervention experiences in tobacco control and sun safety, 
which have demonstrated enormous benefit in the past from well-targeted and sustained activity. 
Similar success is possible in areas such as alcohol use and obesity, which have received low levels of 
investment in past decades. Additional investment, however, should not be at the expense of 
continuing effort in the areas in which we are making inroads.  
As the community and decision-makers become more aware of the need to allocate more resources 
to and take some tough decisions about prevention, it is vital that action be based on the best 
available evidence, not on speculation or anecdotal evidence. The importance of this landmark 
volume is that it shows the possibilities of evidence-based decision-making on prevention. It also 
clearly shows where more research is needed. 
In addition to identifying what we must do more of, the report suggests what we should do less of, 
to achieve a healthier community and a health system that delivers better value for money.  
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This report is the largest and most rigorous evaluation of preventive strategies undertaken 
anywhere in the world, and challenges us to think more deeply about the value of health to society 
and the strategies to achieve a healthier and fairer society. 
We invite you to use the learnings in this landmark report to guide your contribution to the debate 
on how we may design a system for health that values effectiveness, equity and efficiency, and how 
we can promote preventive action on the basis of the best available evidence. 
 
 
Professor Mike Daube  Todd Harper 
President  Chief Executive Officer 
Public Health Association of Australia  Victorian Health Promotion Foundation 
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Executive summary  
 
0.1 Introduction 
Governments are aware that ‘informed purchasing’ is central to efforts to harness health expenditure 
growth and use available budgets more efficiently. Informed purchasing, however, requires reliable 
information on the costs and health outcomes of current practice and of options for change. Such 
information enables governments to: 
• direct available resources towards best-practice cost-effective services; 
• modify not cost-effective services to improve their cost-effectiveness; 
• discontinue not cost-effective services that cannot be made more cost-effective or be justified on 
other compelling grounds; and 
• target services to those in need, as opposed to people with low-risk profiles who are unlikely to 
benefit in a cost-effective manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 0.1 Overview of ACE–Prevention methods 
In economic evaluation the costs and benefits of health interventions are compared to make a 
judgement about value for money; that is, to answer the question: ‘relative to cost, does 
intervention A provide greater health benefits than intervention B?’ ACE–Prevention makes an 
important contribution to the evidence base for priority setting in prevention by: 
• its comprehensive evaluation of prevention for non-communicable disease in Australia; 
• using comparable methods across all 150 interventions; and 
• evaluating combinations of prevention approaches for major topic areas (such as alcohol, diet, 
cardiovascular risks) and for the most cost-effective interventions packages across topic areas. 
To ensure valid comparisons between results: 
• each intervention is modelled to apply to the relevant people in the 2003 Australian population 
and the costs and health outcomes are measured for as long as they occur, often over a 
lifetime; 
• all results are expressed as a cost per disability-adjusted life year (DALY) averted, where: - the DALY is a measure of the difference in healthy time lived comparing an intervention 
scenario with ‘current practice’ or ‘do nothing’; the disability adjustment reflects the severity 
of disease or disability. More DALYs ‘saved’ means a longer life, a life with less disability, or a 
combination of these;  - costs take into account the expenditure required to implement each health intervention as 
well as the downstream consequences for disease treatment; 
• best available evidence on effectiveness is derived from the international literature, preferably 
using estimates that are pooled across all available studies; 
• costs and outcomes are modelled based on realistic expectations of how interventions would be 
implemented under routine health service conditions in Australia; 
• uncertainty is explicitly quantified and presented around all results; and 
• stakeholders from government, health non-government organisations, academia and service 
providers provided guidance to the researchers during the five-year course of the project and 
helped to formulate conclusions taking the technical results into consideration, together with 
other policy relevant considerations such acceptability, feasibility and equity. 
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In this report we present the results from a National Health and Medical Research Council Health 
Services Research Grant (ACE–Prevention). We evaluated 123 preventive interventions and 27 
treatment interventions. We also adapted our general population models to estimate the cost-
effectiveness of 21 interventions for the Indigenous population. ACE–Prevention is a significant 
achievement, more than doubling the published economic appraisal research on health 
promotion/illness prevention in Australia. While not purporting to be exhaustive, ACE–Prevention does 
provide an extensive and balanced coverage of the available evidence base for priority-setting in the 
prevention of non-communicable disease in Australia. Following are our main findings together with 
the strengths and limitations of our work and key messages. Box 0.1 provides an overview of ACE–
Prevention methods. 
 
0.2 Main findings for the general population 
0.2.1 Results classified by size of health impact 
A large impact on population health (i.e. >100,000 DALYs prevented per intervention) can be achieved 
by a limited number of cost-effective interventions (Table 0.1):  
• taxation of tobacco, alcohol and unhealthy foods;  
• a mandatory limit on salt in just three basic food items (bread, cereals and margarine);  
• improving the efficiency of blood pressure- and cholesterol-lowering drugs using an absolute risk 
approach and choosing the most cost-effective generic drugs (or potentially introducing a low-cost 
polypill that combines three blood-pressure-lowering drugs and one cholesterol-lowering drug 
into one single pill);  
• gastric banding for severe obesity; and  
• an intensive SunSmart campaign.  
Key second-stage filter considerations for these interventions are: 
• the evidence base (Table 2.2) is ‘likely’ for the taxation and regulation interventions, ‘sufficient’ for 
the treatment interventions and ‘limited’ for SunSmart (based on a comparison of skin cancer 
rates between states); 
• taxation and regulation changes have low implementation costs, but do involve ‘political costs’ 
that require political will to overcome; 
• the proposed changes for blood pressure and cholesterol involve stakeholder acceptability issues 
for practitioners that would need to be carefully managed; and 
• government subsidies for gastric banding would need to be accompanied by explicit guidelines, 
e.g. restricting access to people with severe obesity who have demonstrably failed to lose weight 
by diet and exercise. 
There are more cost-effective interventions with a moderate impact on population health (between 
10,000 and 100,000 DALYs prevented per intervention). The main missed opportunities at the national 
level among these are screening programs for pre-diabetes, chronic kidney disease and low bone 
mineral density in elderly women. There is good evidence for the effectiveness of the drug and lifestyle 
treatments that are recommended for the high-risk individuals identified by such screening programs. 
Smoking cessation aids, pedometers and mass media for physical activity are other approaches with 
moderate population health impact. We note that a considerable health impact of physical activity can 
be achieved without reducing body weight.  
Of the cost-effective interventions with a small population health impact (<10,000 DALYs per 
intervention), the growing list of potential preventive measures for mental disorders deserves special 
mention. Hepatitis B and HPV vaccination are cost-effective measures for preventing cirrhosis and 
cancers. 
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Table 0.1 Lifetime health outcomes, intervention costs and cost offsets for the most cost-effective preventive interventions 
with the largest population health impact 
 (Lifetime, discounted)  
Intervention 
DALYs 
prevented 
Intervention costs 
(A$ billion) 
Cost offsets 
(A$ billion) 
Taxation    
Tobacco tax 30% 270,000 0.02 –0.7 
Alcohol tax 30% 100,000 0.02 –0.5 
Alcohol volumetric tax 10% above current excise on spirits 110,000 0.02 –0.7 
Unhealthy foods tax 10% 170,000 0.02 –3.5 
Regulation    
Mandatory salt limits on processed food 110,000 0.07 –1.5 
Preventive treatments    
Three blood-pressure-lowering drugs to replace current 
practice of preventive drug treatments* 
20,000 –1.9† –0.3 
Polypill to replace current practice*  60,000 –7.0† –0.8 
Laparoscopic gastric banding (body mass index >35) 140,000 3.7 –2.9 
Health promotion    
Intensive SunSmart  120,000 2.0 –0.3 
DALY, disability-adjusted life year 
* We estimate a lifetime health benefit of 230,000 DALYs prevented from current practice. The polypill or a combination of 
blood-pressure-lowering drugs targeting by absolute cardiovascular disease risk and ‘realistic’ assumptions on uptake and 
adherence would lead to large cost savings and some greater health gain additional to the 230,000 DALYs of current practice 
(hence we classify these as interventions with a large impact greater than 100,000 lifetime DALYs). 
† The current practice of blood pressure- and cholesterol-lowering treatments is inefficient and hence the negative costs (i.e. 
cost savings) if replaced by more efficient treatment. 
0.2.2 Results classified by cost-effectiveness result 
For clarity of presentation, we have ‘triaged’ our cost-effectiveness results into five categories and 
then within each category reported on broader issues that impact on policy decisions. The categories 
are:  
• dominant: interventions that both improve health and achieve net cost savings; 
• very cost-effective: interventions that improve health at a cost of less than $10,000 per DALY 
prevented; 
• cost-effective: interventions that improve health at a cost of between $10,000 and $50,000 per 
DALY prevented; 
• not cost-effective: interventions that improve health at a cost of more than $50,000 per DALY 
prevented; and 
• dominated: interventions for which more cost-effective alternatives are available. 
In ACE–Prevention we assumed a decision threshold of ‘$50,000 per DALY prevented’ to determine 
whether an intervention was ‘cost-effective’ or not. There is no consensus on the cut-off point for such 
a threshold, but there are rules of thumb related to available national income and empirical evidence 
on funding decisions. It is not uncommon to use GDP per capita as a reference point for national 
income. In the UK, for example, the National Institute for Health and Clinical Excellence has used a 
threshold (£20,000–30,000) that reflects the UK GDP per capita. Similarly, our threshold approximates 
the Australian GDP per capita. Our threshold also reflects available empirical evidence on what 
constitutes acceptable value for money in Australia, including recommendations of the Pharmaceutical 
Benefits Advisory Committee [1] and government decisions in public health [2, 3]. We add another 
threshold of $10,000 per DALY to distinguish very cost-effective interventions. 
 
The results for the 123 preventive and 27 treatment interventions evaluated are classified by triage 
category in Table 0.2. All 150 interventions are included in Table 0.4 at the end of this Executive 
Summary (see Table 0.4), with full documentation (including multiple variations of some interventions) 
in Appendix 2 and discussion in Section 3. Our key observations are: 
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• Many interventions for prevention have very strong cost-effectiveness credentials (43 that are 
either dominant or cost less than $10,000 per DALY prevented). Such interventions should only be 
ignored if decision-makers have very serious reservations about the evidence base or are facing 
insurmountable problems in relation to stakeholder acceptability or feasibility of implementation.  
• Another group of interventions (31) are good value for money compared to the decision threshold 
of less than $50,000 per DALY prevented. 
• Many interventions for prevention have poor cost-effectiveness credentials (38); an insufficient 
evidence base (4); are associated with more harm than benefit (‘dominated’: 2); or are dominated 
by more cost-effective alternatives (2). It is vital to recognise that prevention is not always value 
for money and is not always ‘better than cure’. These interventions should only be implemented if 
there are compelling social justice reasons to do so (e.g. the ‘rule of rescue’ or special equity 
needs) or, for dominated interventions, an important ‘clinical place’ rationale can be 
demonstrated. 
Table 0.2 Cost-effectiveness results for preventive and treatment interventions by topic area: total population 
Topic area Total Dominant Very  
cost-effective 
($0–
10,000/DALY) 
Cost-effective 
($10,000–
50,000/DALY) 
Not  
cost-effective 
(>$50,000/ 
DALY) 
Dominated Insufficient 
evidence 
Preventive interventions 
Alcohol 9 4 3 2 – – – 
Tobacco* 8 2 3 – – – – 
Physical activity 6 2 2 2 – – – 
Nutrition 26 3 1 3 19  – 
Body mass 9 1 1 2 4 – 1 
Blood pressure/ 
cholesterol 
13 2 2 7 – 2  
Osteoporosis 3 1 – 1 1 – – 
Illicit drugs 2 – – 1 1 – – 
Cancer 9 – – 5 3 1 – 
Diabetes 7 – – 5 1 1 – 
Kidney disease 2 1 – 1 – – – 
Mental disorders 11 2 5 2 1 – 1 
Cardiovascular disease 1 – – – – – 1 
Other prevention 11 4 1 – 5 – 1 
Infectious disease 6 1 2 – 3 – – 
Total 123 23 20 31 38 4 4 
  
Treatment interventions  
Alcohol 2 – – – 2 – – 
Illicit drugs 1 – 1 – – – – 
Cancer 1 – – 1  – – 
Kidney disease 2 – – 1 1 – – 
Mental disorders 10 1 4 5 – – – 
Cardiovascular disease 5 – 1 2 2 – – 
Other treatment 6 1 2 1 – – 2 
Total 27 2 8 10 5 – 2 
DALY, disability-adjusted life year 
* Analyses for three tobacco control interventions have not yet been completed. 
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It follows that there are strong economic grounds to implement/expand interventions in the dominant 
and very cost-effective groups and contract/terminate interventions in the not cost-effective or 
dominated groups. The potential for such informed purchasing applies not only across different risk 
factor or disease areas, but also within priority problem areas. Nutrition, obesity, mental disorders and 
diabetes are vital areas for preventive action, for example, but all contain interventions that range from 
very cost-effective to not cost-effective.  
Comparison of the preventive and benchmark interventions suggests that the benchmarks considered 
have a similar spread across the cost-effectiveness triage categories. The need for informed purchasing 
applies across the board – not just in prevention. It is worth mentioning that the benchmark 
interventions generally had stronger evidence credentials than the prevention group. The evidence 
platform for prevention must remain a focus in research and policy funding; particularly for policy 
initiatives and community-based interventions that have the potential to have large health impacts. 
0.2.3 Optimal intervention mix for selected risk factors and health problems 
For the main topic areas, we have analysed combinations of interventions to identify the optimal 
prevention mix. We can then contrast this against current practice; that is, the level at which these 
preventive interventions are currently implemented. This approach better reflects reality for many 
decision-makers, where interventions are normally combined into strategies to deal with policy issues. 
Also, the experience of decades of tobacco control suggests that a multi-pronged approach is required 
to successfully deal with a health problem [4, 5]. Our key findings are: 
• Current practice in blood pressure- and cholesterol-lowering is inefficient. Large immediate cost 
savings are available if prevention is targeted by absolute risk rather than individual risk factor 
thresholds and if the most cost-effective, generic drugs are prescribed rather than expensive ones. 
If a polypill (a combination of three generic blood-pressure-lowering drugs – diuretic, calcium 
channel blocker and ACE (angiotensin-converting enzyme) inhibitor – at half strength and a statin 
in a single pill) were introduced at an annual cost of $200 per person treated, the immediate cost 
savings would be much greater still. The package would prevent more than 500,000 DALYs over 
the lifetime of the 2003 Australian population. 
• A 10% tax on unhealthy foods and lap banding for very obese people could avert 270,000 DALYs 
caused by obesity. A diet and exercise program for overweight people identified in primary care, 
while considered cost-effective, would contribute just a tiny additional health gain to the package 
of obesity interventions. 
• Taxation, advertising bans, an increase in minimum legal drinking age to age 21, brief intervention 
by a GP, licensing controls, drink driving mass media and random breath testing form the optimal 
mix of cost-effective alcohol control interventions. Of these, a 30% increase in tax, or a volumetric 
tax at 10% above the current excise on spirits, would achieve more than 90% of the 120,000 DALY 
health gain estimated for the package. 
• Pedometers, mass media campaigns, GP interventions with or without referral to an exercise 
physiologist and TravelSmart (a program to encourage more active transport) can address 60,000 
lifetime DALYs due to physical inactivity. 
• Screening for chronic kidney disease and treatment with ACE inhibitors would lead to greater 
health gain than is currently achieved by the combined dialysis and kidney transplant program. 
This initiative would lead to large cost savings by preventing people from reaching end-stage 
kidney failure.  
• We are yet to complete cost-effectiveness analyses of three tobacco control interventions. 
However, there is no doubt that past control measures have been effective, cost-effective and 
successful in reducing the prevalence of smoking in Australia. We have established that tobacco 
tax increases and cessation aids are very cost-effective interventions. The potential for health gain 
from smoking cessation or prevention of smoking uptake is so great that additional regulatory and 
mass media approaches are likely to be very cost-effective. 
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0.2.4 Cost-effectiveness of combined intervention packages 
The different risk factor and disease interventions in the ‘dominant’ and ‘very cost-effective’ triage 
groups have been modelled independently, but many have common disease outcomes. To determine 
the combined effect of these interventions on the total costs and health outcomes of the intervention 
packages, the interventions have been re-evaluated in a model that integrates all relevant risk factors 
and disease parameters. For comparison, we also simulated current practice. The key results are: 
• The package of 20 ‘dominant’ interventions could avert one million DALYs over the lifetime of the 
2003 Australian population. Eighty per cent of this health gain could be achieved with the taxation 
and regulation interventions on salt, alcohol and tobacco, and the polypill for cardiovascular 
disease prevention. 
• The ‘dominant’ intervention package would cost $4.6 billion, but could avert $11 billion in health 
care costs. Fourteen per cent of the investment would be required in the first year, with lower 
annual costs thereafter for ongoing delivery of drugs for cardiovascular disease prevention. The 
healthcare costs saved would reach a peak around 12 years after intervention.  
• Costs of implementing the ‘dominant’ package are substantially less than those for blood pressure- 
and cholesterol-lowering drugs for preventing cardiovascular disease. The taxation and regulation 
interventions also reduce the need for cardiovascular disease drugs that remain expensive even if 
prescribed most efficiently.  
• Adding interventions with cost-effectiveness between zero and $10,000 per DALY prevented to the 
‘dominant’ package leads to substantially greater upfront costs of intervention. Total cost of the 
‘dominant’ and ‘very cost-effective’ package would be $13 billion, but this would be more than 
matched over time by $14 billion in reduced costs of health care. A total of 1.4 million DALYs 
would be averted, 400,000 DALYs more than for the ‘dominant’ package alone.  
 
0.3 Main findings for the Indigenous population 
Our decision to undertake separate analyses for the Indigenous population reflects our experience that 
key evaluation parameters are all significantly different. These include the target disease burden; the 
prevalence and distribution of harmful exposures; the effectiveness of intervention strategies; the type 
of effective health service models; the acceptability to stakeholders; and the cost of implementing 
interventions. To inform policy decisions, health services need to be evaluated separately for the 
Indigenous and non-Indigenous populations, but undertaken in a way that enables meaningful analysis 
across and within these two populations. What makes this task more challenging is that conventional 
cost-effectiveness information may not provide sufficient economic guidance in Indigenous health, 
where ‘community health gain’ and ‘cultural security’ have special significance. Here we report on the 
cost-effectiveness results in a select number of topic areas for the Indigenous population achieved 
under the ACE–Prevention project. Further work is planned to extend this research program and to 
include separate analyses using an Indigenous concept-of-benefit, as well as outcomes measured in 
DALYs. 
 
Our results that involve adaptation of mainstream analyses were either assumed to operate from 
mainstream health services, with model parameters adjusted for target population, participation and 
adherence rates; or they were assumed to operate from Aboriginal community controlled health 
services (ACCHS), with model parameters adjusted using our Indigenous Health Service Delivery 
Template. The template adjusted cost parameters as well as participation and adherence assumptions.  
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0.3.1 Cost-effectiveness results 
In Section 4 we report on 19 interventions (Table 4.4) that were adapted from analyses undertaken for 
the general population (17 prevention and 2 treatment interventions). In Table 0.3, these results are 
presented in the cost-effectiveness triage categories. Interventions that were modelled separately for 
delivery by mainstream health services and by ACCHS have been counted once. For the Indigenous 
population results, we included an additional cost-effectiveness category ($50,000–150,000 per DALY 
prevented) in recognition of the special equity considerations that apply to Indigenous health.  
The key results are: 
• The polypill (at $200 per person per year) is a cost-saving intervention if delivered via mainstream 
services to all Indigenous Australians over the age of 35. Delivery by ACCHS is very cost-effective, 
but no longer cost-saving. Delivery by ACCHS would, however, lead to greater health gain because 
of improved Indigenous access to health services (via greater utilisation of services and adherence 
to treatment).  
• Of the individual drugs, diuretics and ACE inhibitors delivered by mainstream services are cost-
effective, but the addition of statins or the delivery of ACE inhibitors by ACCHS have a cost-
effectiveness ratio one to three times the decision threshold for the total population ($50,000 per 
DALY prevented). It is important to note, however, that equity concerns could be expressed as a 
greater willingness to pay more for the same health gain. 
• Vaccination for hepatitis B and screening for chronic kidney disease are cost-saving or very cost-
effective interventions because of the high rates of disease in the Indigenous population. 
Screening for pre-diabetes followed by drug (metformin or acarbose) and lifestyle interventions is 
cost-effective. As in the total population the cost-effectiveness ratio for dialysis and transplant is 
higher than $50,000 per DALY but the same argument applies: that it is established life-saving 
practice and unlikely to change. 
• While the Looma lifestyle intervention (a community-based intervention encouraging physical 
activity and healthy eating practices) would rate highly on cultural security, it has very poor cost-
effectiveness credentials measured as a ‘traditional’ cost per DALY prevented. This reflects the 
small change in risk factor levels measured during the study. Further evaluation would be 
warranted using an expanded concept-of-benefit measurement, which is under development. 
• Application of an equity weight would improve the cost-effectiveness of all the Indigenous 
population results, but this adjustment is still work in progress. 
Table 0.3 Cost-effectiveness results for preventive and treatment interventions by topic area: Indigenous population 
Topic area Total Dominant Very  
cost-effective  
($0–
10,000/DALY) 
Cost-effective 
($10,000–
50,000/DALY) 
Not 
cost-effective 
($50,000–
150,000/DALY) 
Not  
cost-effective 
(>$150,000/DALY) 
Dominated 
or 
insufficient 
evidence 
Blood pressure/ 
cholesterol 
5 – 1 1 2 1 – 
Diabetes 7 – – 5 1 1 – 
Kidney disease 4 2 – – 2  – 
Hepatitis B 3 3 – – –  – 
Total 19 5 1 6 5 2 0 
 
DALY, disability-adjusted life year 
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0.4 Strengths and limitations 
The greatest strength of ACE–Prevention is the number of interventions evaluated using consistent 
methods. We covered the most important strategies for main diseases and risk factors. While greater 
detail is possible within topic areas, we are confident that we provide a comprehensive overview of the 
current evidence base of prevention and how it applies to the context of Australian health services.  
Another important strength is that ACE–Prevention couples a large volume of work with technical 
rigour. Key factors in achieving technical rigour are: 
• Interventions were evaluated as an integral part of the work on priority-setting in prevention using 
consistent methods and assumptions. 
• Best available evidence of efficacy was evaluated and adjusted to reflect effectiveness under 
routine health service conditions in Australia.  
• Analyses are based on a comprehensive and consistent set of disease and risk factor parameters 
pertaining to the Australian population from the Australian Burden of Disease study [6].  
• Costs of interventions and future disease treatment costs are based on Australian data and 
estimated in a consistent manner across all interventions following a detailed protocol.  
• Cost-effectiveness results are presented with adjustment for uncertainty and variation in key 
assumptions.  
• Cost-effectiveness results are also presented for the ideal package of interventions for major topic 
areas and can be contrasted with current practice to identify areas of inefficiency. This is 
important as decisions are not taken in isolation and the implementation of one intervention can 
influence the cost-effectiveness of another.  
• While much of the research endeavour focused on ensuring the technical rigour of the cost-
effectiveness analyses, we also put emphasis on ‘due process’ involving stakeholders from 
governments, health non-government organisations, academics and service providers. They 
provided invaluable advice on the selection of interventions, modelling methods, interpretation of 
results, formulation of policy-relevant recommendations and a dissemination strategy.  
Weaknesses and/or methodological challenges in our research include: 
• We could not include a number of prevention strategies for which there was no evidence of 
effectiveness. That is, there has been no long-term, independent, well-funded, sustained media 
campaign on alcohol and therefore no evidence on effectiveness. However, there is evidence that 
such media campaigns on tobacco have been effective. The least this suggests is that applying the 
same approach to other health problems has promise. We did include a cost-effectiveness analysis 
of a media campaign on physical activity, albeit based on limited evidence of effectiveness.  
• Interventions were modelled targeting the Australian population of 2003 who would be eligible 
(depending on the focus of each intervention). This means that after the baseline year 2003, our 
models deal with a dwindling cohort rather than the dynamic Australian population over time. 
• It was not possible to specify identical assumptions for the duration of all interventions. Some 
interventions are clearly implemented as a ‘once-off’ (taxation and regulation interventions); 
others are intended to extend for life; while a large number fall in between. We applied the 
principle that duration should be based on the inherent characteristics of the intervention in 
‘steady-state’ operation. 
• For many interventions there was little or no information in the literature on design characteristics 
that would sustain longer term impacts. We therefore incorporate a decay function as an 
important assumption in our models. This is one of the reasons we report less favourable cost-
effectiveness ratios than other studies.  
• A number of modelling approaches were used in ACE–Prevention. Importantly, our large combined 
model produced results of health gain that were systematically lower by up to 25% than those 
estimated in the individual risk factor models. The reasons for this ‘model uncertainty’ will be 
explored in greater detail in academic publications. 
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• While the inclusion of second-stage filter criteria has been welcomed and embraced by policy-
makers, there are opportunities to add more empirical evidence to these considerations. An 
example is the work we started with the Indigenous Steering Committee on how to incorporate 
aspects of health benefits that are important to Indigenous Australians, such as community health 
gain and cultural security. Also remaining is a significant gap in the literature on how best to 
incorporate equity concerns into measures of efficiency for special needs groups.  
 
0.5 Key messages and recommendations 
ACE–Prevention has provided a solid platform for policy action on the prevention of non-communicable 
disease in Australia. In particular there is now sufficient evidence: 
• to justify immediate funding of the most cost-effective opportunities for health gain through 
prevention and thereby reduce pressure on healthcare services. Recommended action includes: - a 30% increase in tax on tobacco (which is close to the 25% tax increase announced in the May 
2010 budget); - a tax increase on alcohol, preferably changing to a volumetric taxation at a level 10% above the 
current excise on spirits; - a taxation of 10% on non-core unhealthy foods; - mandatory limits on salt in bread, margarine and cereals; - a shift to screening for absolute cardiovascular risk and targeted treatments with the most cost-
effective generic drugs; - pursuit of the introduction of a low-cost generic polypill (not containing aspirin) for 
cardiovascular prevention;  - expansion of access to lap band surgery for the severely obese; and - increased funding for SunSmart programs, accompanied by rigorous evaluation to strengthen the 
evidence base for its effectiveness. 
• to make the tough but necessary reallocation of funding towards best-practice prevention 
activities with strong cost-effectiveness credentials and away from prevention activities with poor 
cost-effectiveness credentials, including: - inefficient current practice in cardiovascular preventive treatment; - prostate-specific antigen (PSA) testing for prostate cancer; - aspirin for primary prevention of cardiovascular disease; - most approaches promoting fruit and vegetable intake and weight loss programs; and - school-based illicit drug interventions. 
• to argue for expanded funding of a larger package of health promotion and illness prevention 
interventions where funds can be spent wisely, particularly for those interventions either not 
implemented at all or under-funded. These include: - screening for pre-diabetes, chronic kidney disease, low bone mineral density in elderly women; - subsidising nicotine replacement therapies; and - a range of interventions promoting physical activity (pedometers, mass media, GP prescription 
or referrals). 
• to introduce a number of cost-effective preventive interventions for mental disorders (screening 
for minor depression in adults, childhood depression and anxiety; problem-solving after a suicide 
attempt; and early psychosis intervention) accompanied by rigorous evaluation to expand the 
evidence base that is still thin and short-term; and 
• to invest in evaluation research to contribute to the evidence base of prevention, particularly for 
policy initiatives and community-based interventions that have the potential to have large health 
impacts but that we had to model based on suggestive rather than solid evidence. This concerns 
most of the population-wide taxation, regulatory and mass media interventions. 
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Table 0.4 Interventions in ACE–Prevention 
Intervention 
number* 
Alcohol Intervention 
type 
1 Volumetric tax (revenue-neutral) P 
10 General tax 30% P 
14 Advertising bans P 
15 Minimum legal drinking age to 21  P 
16 Brief intervention via GPs P 
17 Licensing controls P 
18 Drink drive mass media P 
19 Random breath testing P 
20 Brief intervention and telemarketing and support P 
195 Residential treatment and naltrexone T 
196 Residential treatment T 
 Tobacco  
21 Cessation aid: varenicline P 
22 Cessation aid: bupropion P 
23 Cessation aid: nicotine replacement therapy P 
28 Taxation +30% with indexation in line with inflation P 
29 Taxation +30% P 
34 Package of current population-wide strategies of tobacco control (not including taxation) P 
35 Brief intervention via GPs P 
36 QUIT line versus extended QUIT line P 
 Physical activity  
37 Pedometers P 
38 Mass media P 
39 TravelSmart P 
40 GP prescription P 
41 GP referral to exercise physiologist P 
42 Internet intervention P 
 Nutrition  
43–65 23 dietary counselling/health information interventions on fruit & vegetable intake [67–86] P 
66 Dietary advice on salt (>140 mmHg) P 
68 Tick program to reduce salt intake from processed food P 
69 Mandatory salt limits for processed food P 
 Body mass  
70 Lighten Up program: weight loss, fruit and vegetable intake, physical activity P 
71 Diet and exercise for BMI>25 P 
72 Low-fat diet for BMI>25 P 
73 Sibutramine for BMI>30 P 
74 Orlistat for BMI>30 P 
75 Front-of-pack ‘traffic light’ nutrition labelling P 
76 Taxation +10% on unhealthy food with indexation in line with inflation P 
77 Gastric banding for BMI>35 P 
78 Weight Watchers P 
 Blood pressure and cholesterol  
79 Current practice P 
80 Community heart health program P 
81 Dietary counselling by a dietitian >5% CVD risk P 
84 Dietary counselling by a GP >5% CVD risk P 
87 Phytosterol supplementation >5% CVD risk P 
90 Statins >5% CVD risk P 
93 Statins and ezitimibe >5% CVD risk P 
96 Low-dose diuretics >5% CVD risk P 
99 Beta blockers >5% CVD risk P 
102 Calcium channel blockers >5% CVD risk P 
105 ACE inhibitors >5% CVD risk P 
111 Polypill $200 >5% CVD risk P 
132 Polypill $200, ages 55+  P 
 
11 
 
 Osteoporosis   
137 Screen and alendronate for women aged 70–89  P 
138 Screen and raloxifene for women aged 70–90  P 
139 Mass media campaign: physical activity P 
 Illicit drugs  
140 School-based drug prevention: Gatehouse project P 
141 Random roadside drug testing P 
196 CBT for individuals with cannabis dependence P 
 Cancer  
144 Pap screen 2-yearly for women from age 18 (current practice) P 
147 HPV DNA test screen 3-yearly from age 18 P 
148 Pap and HPV DNA test screen 3-yearly for women from age 18 P 
151 HPV vaccination and Pap screen 2-yearly for women from age 18  P 
154 HPV vaccination and HPV DNA test screen 3-yearly from age 18 P 
155 HPV vaccination and combined Pap and HPV DNA test screen 3-yearly for women from age 18 P 
158 SunSmart program (with optimal investment) P 
159 Screen prostate cancer for men with PSA test P 
160 Anal cytology for men having sex with men P 
197 Trastuzumab for early breast cancer; 9-week course T 
 Diabetes  
167 Screen pre-diabetes and dietary advice P 
168 Screen pre-diabetes and exercise physiologist P 
169 Screen pre-diabetes and dietary advice and exercise physiologist P 
170 Screen pre-diabetes and drug: rosiglitazone P 
171 Screen pre-diabetes and drug: metformin P 
172 Screen pre-diabetes and drug: acarbose P 
173 Screen pre-diabetes and drug: orlistat P 
 Kidney disease  
174 Screen chronic kidney disease and ACE inhibitor (non-diabetics) P 
175 Screen chronic kidney disease and ACE inhibitor (diabetics) P 
200 Current renal replacement therapy versus dialysis only T 
201 Dialysis only T 
 Mental disorders  
176 Screen and bibliotherapy for prevention of depression P 
177 Screen and group psychological treatment for prevention of depression P 
178 Screen and psychological treatment for prevention of post-partum depression P 
179 Screen and psychological intervention for prevention of childhood/adolescent depression P 
180 Screen and bibliotherapy for the prevention of childhood/adolescent depression P 
181 Problem-solving therapy for reduction of deliberate self-harm (suicide) P 
182 Emergency contact cards for the reduction of deliberate self-harm (suicide) P 
183 Gun ownership legislation and gun buy-back scheme for reduction in suicide P 
184 Responsible media reporting for reduction of suicide P 
185 Treatment for individuals at ultra-high risk for psychosis P 
186 Parenting intervention for prevention of childhood anxiety disorders P 
202 TCAs for major depressive episodes plus 6 months continuation  T 
203 SSRIs for major depressive episodes plus 6 months continuation  T 
204 Individual CBT treatment of major depressive episodes by psychologist T 
205 Group CBT treatment of major depressive episodes by psychologist T 
206 Bibliotherapy for major depressive episodes T 
207 5-year maintenance therapy with TCAs following a major depressive episode T 
208 5-year maintenance therapy with SSRIs following a major depressive episode T 
209 Individual maintenance CBT by a psychologist  T 
210 Group maintenance CBT by a psychologist T 
211 Early psychosis prevention and intervention centre T 
 Cardiovascular disease  
108 Aspirin  P 
212 Early stenting for acute myocardial infarction T 
213 Angioplasty coated stents: general population T 
214 Bypass surgery and stents versus optimal medical treatment T 
215 Rehabilitation following acute myocardial infarction T 
216 Angioplasty with coated stents: diabetic population T 
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 Other prevention  
161 Universal infant hepatitis B vaccination P 
163 Universal vaccine and additional immunoglobulin for infants born to hepatitis B carrier mothers P 
164 High-risk infant hepatitis B vaccination P 
166 Selective vaccine and immunoglobulin to infants born to hepatitis B carrier mothers  P 
187 Screen by regular vision testing  P 
188 Ranibizumab for age-related macular degeneration P 
189 Public water fluoridation for all towns >1000 people (89% coverage) P 
191 Annual dental check, ages 12–17: oral examination only P 
192 Annual dental check, ages 12–17: oral examination and X-ray and clean P 
193 Annual dental check, ages 12–17: oral examination, X-ray, clean, scale and sealant P 
225 Varicella zoster vaccination at age 50 P 
 Infectious disease  
225 Universal influenza vaccination, ages 50–64  P 
227 Needle exchange program for prevention of HIV and hepatitis P 
228 Intermittent pre-exposure prophylaxis for HIV P 
229 Circumcision for all men having sex with men for HIV P 
230 Early antiretrovirals for HIV P 
231 Post-exposure prophylaxis for HIV P 
 Other treatment  
218 Asthma clinic, including benefits from emergency department visits and days off from work T 
220 Hip replacement for osteoarthritis T 
221 Knee replacement for osteoarthritis T 
222 Eradication with triple therapy for Helicobacter pylori in patients with peptic ulcer T 
223 Eradication therapy for Helicobacter pylori infection in uninvestigated dyspepsia T 
224 Helicobacter pylori eradication for non-ulcer dyspepsia T 
 Kidney disease (Indigenous)  
275 Screen and drug: ACE inhibitor (remote, non-diabetics) P 
276 Screen and drug: ACE inhibitor (non-remote, non-diabetics) P 
277 Screen and drug: ACE inhibitor (remote, diabetics) P 
278 Screen and drug: ACE inhibitor (non-remote, diabetics) P 
280 Dialysis only T 
281 Current renal replacement therapy versus dialysis T 
 Diabetes (Indigenous)  
268 Screen and dietary advice P 
269 Screen and exercise physiologist P 
270 Screen and dietary advice and exercise physiologist P 
271 Screen and drug: rosiglitazone P 
272 Screen and drug: metformin P 
273 Screen and drug: acarbose P 
274 Screen and drug: orlistat P 
 Blood pressure and cholesterol (Indigenous)  
232 Looma healthy lifestyle: community-based intervention for remote Indigenous, ages 20+ P 
236 Statins; ACCHSs, ages 35+ P 
240 ACE inhibitors; ACCHSs, ages 35+ P 
244 Diuretics; ACCHSs, ages 35+ P 
260 Polypill $200; ACCHSs, ages 35+ P 
 Other prevention (Indigenous)   
265 Universal infant hepatitis B vaccination P 
266 Selective hepatitis B vaccination and immunoglobulin for infants born to carrier mothers P 
267 Universal hepatitis B vaccination and additional immunoglobulin for infants born to carrier 
mothers 
P 
ACCHS, Aboriginal community controlled health service; ACE, angiotensin-converting enzyme; CBT, cognitive behavioural 
therapy; HIV, human immunodeficiency virus; HPV, human papillomavirus; P, prevention; PSA, prostate-specific antigen; T, 
treatment; TCA, tricyclic antidepressant; SSRI, selective serotonin re-uptake inhibitor  
* See Appendix 2 for further details of intervention numbers. 
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1. Introduction 
 
Making difficult decisions in health care is not a new task. Decisions about what services to provide and 
what opportunities to let go, about who receives health care and who misses out, are made continually 
in a multitude of healthcare settings. What is new, however, is the increasing attention that decision-
makers are giving to how they make these difficult decisions. Governments, clinicians and academics 
are now paying increasing attention to explicit methods for setting priorities. Four key reasons are 
discussed in the international literature: 
• growing evidence that the deployment of current resources is far from optimal [7–13] ; 
• concerns about the continued growth in healthcare expenditure, fuelled by ageing populations 
and technology growth [14, 15]; 
• social justice concerns about leaving access to essential healthcare services to the ‘free market’ 
based on willingness and ability to pay rather than need [16]; and 
• the desire to bring growing community aspirations and limited health budgets closer [17–21].  
 
Figure 1.1 Breakdown by cost driver of projected change in total health and residential aged care expenditure,  
2012–13 to 2032–33. 
In Australia, for example, recent projections by the Australian Institute of Health and Welfare [14] have 
total health and residential aged care expenditure growing by 189% over the 2003 to 2033 period; 
increasing from $85 billion to $246 billion (an increase of $161 billion). This growth would increase 
health expenditure as a proportion of GDP from 9.3% to 12.4%. These estimates, whilst challenging in 
their own right, are lower than earlier estimates from the federal Treasury [22]. The projected increase 
of $161 billion (Table 1.1) in health expenditure is driven by an increase in the ‘volume of services per 
case’ ($81.3 billion; largely because of introduction of new technologies and changes in treatment 
practices and is expected to continue); an ageing population ($37.8 billion) and population growth 
($34.4 billion) (Figure 1.1). These projections, however, and the underlying demographic, burden of 
disease and treatment practice assumptions, all reflect a ‘business as usual’ scenario. There is a 
growing appreciation amongst governments and their advisors that informed purchasing is central to 
efforts to harness this expenditure growth and use available budgets more efficiently. In short, 
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governments desperately need reliable information on the costs and health outcomes of current 
practice and of options for change that will enable them to: 
• direct available resources towards best-practice cost-effective services; 
• provide best-practice cost-effective services that address unmet need in the Australian 
community; 
• modify not cost-effective services to improve their cost-effectiveness; 
• discontinue not cost-effective services that cannot be made more cost-effective or cannot be 
justified on other compelling grounds; 
• target services to those in need rather than to people with low-risk profiles who are unlikely to 
benefit in a cost-effective manner; and 
• bundle services together into cost-effective strategies. 
 
Table 1.1 Projected change in total health and residential aged care expenditure by disease category, 2002–03 to 2032–33 
      Expenditure by year (A$ billion*) Change (%) 
Disease category 2002–03 2032–33 2003–33 
Cardiovascular 9.3 22.6 143 
Respiratory 7.2 22.0 206 
Injuries 6.7 14.4 115 
Dental 5.9 14.9 153 
Mental 5.2 12.1 133 
Digestive 4.9 16.5 237 
Neurological 4.7 21.5 357 
Musculoskeletal 4.4 14.2 223 
Genitourinary 3.7 10.9 195 
Cancer 3.5 10.1 189 
Diabetes 1.6 8.6 438 
Other† 28 78.3 180 
Total 85.1 246.1 189 
* 2006–07 dollars 
† Includes other diseases and expenditure that cannot be assigned by disease 
 
ACE–Prevention is a National Health and Medical Research Council-funded Health Services Research 
Grant designed to provide information for the prevention of non-communicable disease. We evaluate 
with rigorous epidemiological and health economic methods approximately 150 interventions for the 
general community, with adaptation to suit the Indigenous population of as many of these 
interventions as possible.  
The goal of ACE–Prevention is thus to inform policy-makers about the most cost-effective bundle of 
preventive interventions given available resources and to illustrate the significance of an ongoing 
commitment to facilitating informed purchasing. But the provision of cost-effectiveness information is 
only part of the story. Governments need this information in a form that they can readily utilise in their 
decision-making. Policy relevance is greatly improved if this cost-effectiveness information is combined 
with information on broader issues that routinely impinge on healthcare decisions, such as 
affordability, equity of access, feasibility of implementation, reach and size of impact and quality of the 
evidence base. ACE methods have been designed to have regard to these broader policy issues through 
what we call our ‘second-stage filter’ analysis. Over a series of ACE studies, this element of our research 
has been highly regarded by stakeholders on our working groups [23–26]. 
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Two aspects of the ACE approach to this task of priority-setting should be reassuring to decision-
makers and the broader community: 
• that it is underpinned by an explicit and detailed attempt to define what constitutes an ‘ideal’ 
approach to priority-setting, culminating in a published checklist and assessment of alternative 
approaches to priority-setting [26]; and 
• that, as evidenced by the funding of a series of successful ACE studies [23–26], the resulting ACE 
approach has appealed to both academic peers (competitive grant funding) and to governments 
(commissioned work) in both Australia and overseas. 
 
The Priority-Setting Checklist (Appendix 1), which identifies the ideal characteristics of priority-setting 
models, is based not only on guidance from economic theory, but also on ethics and social justice, 
lessons from empirical experience and the needs of decision-makers. The checklist is important 
because for the first time, to our knowledge, criteria from such a broad range of considerations have 
been brought together in a framework for priority-setting that endeavours to be both realistic and 
theoretically sound. Using resources wisely to optimise health outcomes is important, but respecting 
community values such as ethics, social justice and equity in the ways decisions are taken is also vital, 
particularly if decisions are to have legitimacy for patients, providers and the general public. 
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2. Methods  
 
2.1 Background 
The Priority-Setting Checklist (Appendix 1) underlying the ACE approach places importance on rigour in 
the economic appraisals, sound epidemiological modelling approaches and the use of best available 
evidence, but places this technical analysis within a broader setting that has regard for the concerns of 
decision-makers. The ACE approach, summarised here, reflects our wish to strike a balance between 
technical rigour (that matters to academics), relevance (that matters to policy-makers) and due process 
(that matters to stakeholders and the general community). In this section we cover: 
• the ACE approach to priority-setting; 
• key assumptions underlying the economic analysis; 
• second-stage filter analysis; and 
• presentation of results. 
 
2.2 The ACE approach to priority-setting 
The ACE approach to priority setting is summarised here, and more detail is available in an economic 
evaluation protocol document on our website (www.sph.uq.edu.au/bodce-ace-prevention).  
A comprehensive article has been published [26] that covers the origins, methods and application of 
the ACE approach. The decision context for ACE work is the possible Australia-wide adoption of options 
to improve the efficiency of current health services. Also, ACE results will inform policy-makers about 
the best bundle of interventions, given different levels of budget availability, to assist them to 
formulate strategies to address specific risk factors and/or diseases that are amenable to prevention 
and early intervention. 
On the technical side, the ACE approach applies the key economic concepts of opportunity cost, 
marginal analysis and clear concept-of-benefit, using standardised evaluation methods clearly 
documented in the economic protocol. Undertaking the economic analysis as part of the priority-
setting exercise addresses the reservations expressed by many economists about the simplistic use of 
league tables, where economic studies are assembled from the literature with little regard to 
differences in methods, context and setting. The key methodological characteristics of our ACE–
Prevention study are: 
• The rationale for the selection of interventions is discussed and clearly specified. 
• The evaluation methods are standardised, documented and open to scrutiny, with special 
consideration given to methods appropriate for services utilised by Indigenous Australians. 
• The setting, context and comparator (i.e. current practice) are common to all interventions for the 
general population, with careful thought given to modifications necessary for the Indigenous 
context. 
• Australian data are used, wherever possible, for health system costs and demographic and 
epidemiological disease parameters.  
• Cost–utility analysis is used to develop incremental cost-effectiveness ratios (ICERs) based on 
economic/epidemiological modelling techniques that utilise best available data on 
efficacy/effectiveness of interventions (usually based on systematic reviews). 
• All costs and health outcome measures are reported as a range (around point estimates), 
reflecting explicitly the uncertainty of cost, process, outcome and value estimates. 
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• Data needs are made tractable by utilising the Australian Burden of Disease Study as the primary 
source of epidemiological parameters of diseases and risk factors [6], together with the Australian 
Disease Costs and Impacts Study [27] to assist with estimates of disease treatment costs that can 
be avoided by prevention. 
• ICERs are placed within a broader decision-making framework that includes considerations about 
equity, strength of evidence, feasibility of implementation, acceptability to stakeholders and other 
study-specific considerations (such as cultural security for Indigenous Australians). We refer to 
these as the second-stage filter criteria.  
• Information is assembled by a multidisciplinary research team, preparing briefing papers to a 
standardised format agreed by a steering committee of stakeholders who are involved throughout 
the study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 The ACE approach to priority-setting. 
 
ACE Steering Committees generally consist of topic experts, clinicians and practitioners, representatives 
of relevant community organisations and policy-makers. The Steering Committee in ACE studies has an 
important role in selecting the interventions for evaluation, as well as achieving balance between the 
technical analyses and due process. Members contribute in areas of their expertise and discuss issues 
of method and evidence. Also, they ensure stakeholder interests and views are articulated; facilitate 
sensible interpretation of the technical analysis; assist with value judgement aspects of the second-
stage filter analysis; help ensure transparency throughout the project; and assist in the promulgation of 
the results to policy-makers (Figure 2.1). In ACE–Prevention, because of the size and complexity of the 
task, there were two Steering Committees: one to guide overall project management and focus on 
interventions evaluated for the general population; and another to guide the Indigenous research and 
focus on interventions evaluated for Indigenous Australians. In addition, a series of Technical Advisory 
Research question 
• Researcher initiated 
• Decision-maker initiated 
 
Create Working Group of stakeholders 
 
Confirm evaluation methods 
• Technical analysis ($ cost per DALY) 
• 2nd stage filters (equity, acceptability, etc) 
 
Select interventions 
• Agree selection criteria 
• Apply to get agreed work program 
 
Agree findings and disseminate 
 
Undertake technical analysis and 2nd stage filters 
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Panels were constituted to guide researchers in specific topic areas. Membership of these Steering 
Committees and Technical Advisory Panels is set out in the acknowledgements of this report. We are 
indebted to the members of these committees and panels for their enthusiasm and contributions to 
the research effort. However, the authors of the report take full responsibility for the results and their 
interpretation. 
 
2.3 Key assumptions underlying the economic analysis 
The purpose of this section is to make explicit the key assumptions associated with the application of 
economic evaluation methods in ACE–Prevention, so that potential users of the results can judge the 
suitability of these assumptions for their decision context and use, or adjust the results accordingly.  
In the economic literature these key assumptions are often divided into those concerning the study 
frame and others pertaining to the study design [28]. Taken together, study frame and study design 
define and describe the economic evaluation undertaken, including the approach to data collection and 
analysis.  
Details are available in a protocol document on our website (www.sph.uq.edu.au/bodce-ace-
prevention) [29]. 
2.3.1 Study frame 
The decision context and objectives of ACE–Prevention are described in Section 1. Other key elements 
of the study frame are given here.  
Study perspective: A ‘health sector perspective’ is adopted, with costs to government (both 
Commonwealth and State/Territory) and the private sector clearly identified. When non-health sector 
impacts are important to an intervention (either on the cost or outcome side), we flag the impact and 
undertake sensitivity analysis to assess the significance of adopting a broader perspective.  
Reference year:  We chose 2003 as the reference year because most of our disease and mortality rates 
are derived from the 2003 Australian Burden of Disease study [6]. 
Target group: The target group is the Australian population in 2003, who are potential recipients of the 
intervention. This can be either: 
• the whole population, such as for population-wide health promotion campaigns; or  
• a subpopulation, based on characteristics such as age, sex, risk factor profile or disease.  
Study boundaries: Spill-over effects ripple out from every intervention and the question is how far to 
follow them. Key exclusions from the primary analysis are: 
• production gains and losses in the wider economy and other non-health-sector impacts;  
• health-related quality of life impacts other than those on intervention participants (e.g. family and 
carers); and  
• all-of-life effects (i.e. unrelated ongoing healthcare costs of people who are alive because of the 
intervention).  
Time horizon: The time horizon for modelling the implementation of interventions is based on how the 
interventions would be applied in real life. For instance, the duration of nicotine replacement for 
smoking cessation (recommended for up to three months of use) is very different from that of anti-
retroviral drugs in the treatment of HIV/AIDS, which need to be taken over a lifetime to continue to 
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reap benefits. The time horizon for tracking the associated costs/cost savings and health consequences 
extends over the lifetime of the target population through to death or 100 years of age.  
Defining the intervention: In modelling interventions we fully specify all activities (i.e. who does what, 
to whom, when and where?), and assume that all interventions are fully implemented (i.e. in ‘steady-
state’ operation). Our focus question is: ‘What is the cost-effectiveness of interventions when they 
achieve their full potential as per the evidence on effectiveness?’ 
Defining the comparator: We usually specify both ‘current practice’ and ‘do nothing’ as the 
comparator. With ‘current practice’ as the comparator, we address the research question: ‘What is the 
cost-effectiveness of replacing existing practice for dealing with the health problem with the new 
intervention(s)?’ This relates most closely to short-term policy decision-making: with ‘do nothing’ as 
the comparator, the research question relates more to long-term policy decision-making; that is, ‘What 
is the most efficient approach to dealing with this health problem?’ and ‘How far removed from this 
ideal is current practice?’ We use the ‘do nothing’ comparator when we develop intervention pathways 
(see Section 3.4) to address issues associated with putting interventions together into strategies. A ‘do 
nothing’ comparator also allows explicit quantification of the inefficiency of current practice. 
2.3.2 Study design 
Models: We use mathematical models to predict the costs and benefits that are relevant to an 
intervention by combining available information, often from disparate sources, on disease 
epidemiology, effectiveness and costs. In predicting population-level costs and consequences of health 
interventions, a variety of modelling techniques are available. Analyses in this project rely on the 
principles of Markov models, multi-state life tables and micro-simulation [30]. The first two types of 
models predict in discrete steps over time the difference in health risks, costs and outcomes for the 
average individual in the target population between the comparator scenario and an intervention 
scenario. When the data allow it, we use micro-simulation methods if there is considerable variation in 
the target populations in terms of response to the intervention and/or when the response to the 
intervention is strongly dependent on time. 
Uncertainty and sensitivity analysis: We quantify uncertainty in our estimates in two ways. We use 
multivariate Monte Carlo simulation for the model variables that are based on sampled data, the effect 
size of the intervention being a prime example. This technique allows uncertainty to be expressed as a 
95% interval around our point estimates. Sensitivity analysis is used for variables not based on sampled 
data, with the discount rate as an important example. We recalculate and present results for a number 
of possible values for this kind of variable.  
Measurement of costs: To help identify relevant costs, interventions and their comparators are 
described in concrete and well-defined steps that generally include: 
• an ‘event pathway’; and 
• a ‘patient flowchart’. 
The ‘event pathway’ will generally include the following elements: 
• ongoing recruitment (+/– training of providers);  
• key intervention elements (such as advice, consultations, care, change in legislation or 
regulations);  
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• monitoring, evaluation and support elements; and  
• downstream effects such as the costs of treatment for long-term disabilities or side effects.  
The ‘patient flowchart’ describes how we get from the target population to those who actually 
participate in the activities.  
Costs included: Our choice of a ‘health sector perspective’ means we take into account costs to the 
health system, patients and families involved in the delivery of the intervention. This includes the costs 
associated with each step of the intervention pathway. We present results both with and without time 
and travel costs. 
Costs excluded: As interventions are assessed in ‘steady state’ operation, we assume that trained 
personnel are available to deliver the intervention and that all necessary infrastructure is available. 
Given this, we exclude:  
• costs associated with the research, development and maintenance of materials to be used in the 
intervention;  
• costs associated with training the trainer;  
• costs associated with the development and education of an adequate provider workforce;  
• production gains and losses other than time cost of participation;  
• time costs of children; and  
• monitoring and evaluation above a routine level. 
Valuation of costs: Unit cost data for all resources associated with an intervention are collated where 
possible based on the Pharmaceutical Benefits Advisory Committee Manual of Resource Items and 
Their Associated Costs and the Medicare Schedule, measured in real prices for the reference year 
(2003). In costing staff employed by an intervention, a factor of 1.6 is applied to the base salary to 
cover salary on-costs and a loading for administrative assistance, office space and utility services. We 
cost staff that are already employed by an organisation and have access to office space, equipment, 
etc. as part of that position with a factor of 1.3 to cover the salary oncost component only. If a unit cost 
for a particular resource is not available from the cited unit cost sources we endeavour to use national 
pricing as far as is practical (e.g. national pay scales). 
Time costs: Time costs can be: 
• an integral part of providing the health service itself (such as travelling time, waiting time, 
treatment time); or 
• a consequence of providing the intervention (such as time of parents in taking children to an 
intervention activity).  
There is no set method of valuing time. We adopt the simplest method using the hourly wage rate as a 
proxy for the value of time, combined with a common convention [31] of valuing leisure time at 25% of 
the wage rate. Our approach adopts a weighting for workforce participation and age/sex composition, 
which yields an average hourly time cost of $17.44, which we apply to all time costs in adults. 
Travel costs: Travel costs refer to the costs of travelling to and from the intervention and associated 
intervention activities (such as petrol and car costs). We use a weighted average of travel to and from 
primary care in rural and urban settings as an indicative cost of travel ($7.04 per trip). 
Cost of non-adherence: We assume that any non-adherers incur intervention costs but receive no 
benefit. 
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Cost offsets: If an intervention prevents future disease or treats current disease so that future 
complications are avoided, the projected healthcare costs in the eligible population are likely to be 
lower following the intervention. The difference in projected healthcare costs between the 
intervention and comparator situation are identified as cost offsets. We use disease-specific health 
expenditure estimates from the Australian Institute of Health and Welfare [27]. 
Discounting: We apply a 3% discount rate to both costs and benefits. In sensitivity analysis we test the 
impact of other discount rates.  
Measurement of benefits: We measure the size of the health gain associated with each intervention in 
‘health-adjusted life years’ where we value the loss of health due to non-fatal health states with the 
appropriate disability weight(s) used to estimate disability-adjusted life years (DALYs) in burden of 
disease studies. When we present our results we equate these health-adjusted life years gained to 
DALYs averted by the intervention. However, there are important differences between DALYs 
calculated in burden of disease studies and ACE–Prevention DALYs averted. First, in a burden of disease 
study, the health status of a population is estimated in a particular year. It is therefore, a cross-
sectional measure. Economic evaluation methods always have a time dimension. Health gain is 
calculated as the difference in mortality and morbidity outcomes between a comparator and the 
intervention option over a defined period of time (the ‘time horizon’).  
Second, in burden of disease studies the DALY is constructed as a health gap measure, i.e. an ideal is set 
(everyone ought to live into old age free of disease) and contrasted with the current health status of a 
population. Thus, years of life lost, the mortality component of the DALY, are calculated as the 
difference between age at death and a standard life expectancy at that age for each death. In economic 
analyses, we do not use the standard life table to give a value to loss of life. Instead, we keep track of a 
target population over time and count the health-adjusted years of life lived in intervention and 
comparator scenarios assuming realistic mortality risks as people age. This includes an adjustment for 
expected levels of disability by age and sex for conditions not immediately affected by the intervention 
of interest. In other words, extra years of life gained from a preventive intervention are counted as less 
than full years taking into account the probability that the person would suffer from osteoarthritis, 
dementia, hip fracture or any other condition as they age. We do this in order to measure realistic 
health gains, rather than hypothetical health gains assessed against perfect health.  
Effectiveness and safety of interventions in ACE–Prevention: We seek data on the effectiveness and 
potential side effects of interventions by systematic review of relevant intervention trials and 
subsequent follow-up studies. We synthesise the outcome measure by meta-analysis. Trials of risk-
factor-modifying interventions often only report an impact on exposure to the risk factor. That means 
we need to extrapolate to disease outcomes using available data on the relationship between risk 
factor and disease outcomes from observational studies. We identify potential effect modification of 
the intervention under routine health service conditions in Australia, often by assuming a lower 
adherence to an intervention than was observed under trial conditions.  
Extrapolating treatment effects over time: In modelling health outcomes, ACE researchers have to 
confront the issue that trials measure outcomes over a limited time period while our interest is in the 
true impact on disease outcomes and costs. One option is to limit the modelling to the duration of the 
trial, but this does not adequately reflect reality. The alternative is to make assumptions about the 
impact beyond the duration of the available trials (i.e. to assume either a continued impact over time, a 
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lessening of the impact over a period beyond the known impact time from trials or the abrupt 
disappearance of the impact). The assumption we take depends on:  
• the intervention in question;  
• discussions with our technical experts; and  
• the most plausible way of modelling.  
Often, however, there is no clear choice and the solution we adopt is to present results as discrete 
scenarios using different choices as a sensitivity analysis. For instance, we assume an annual decay of 
the impact of GP-mediated physical activity interventions of 50% and vary this between 0% and 100% 
in sensitivity analyses.  
 
2.4 Second-stage filter analysis  
The ACE studies consciously adopt an explicit approach to priority-setting where visibility of the cost-
effectiveness estimates, of judgements about broader issues that impact on decision-making, and of 
the evaluation processes employed, are all emphasised (Figure 2.2).  
Consideration of broader issues in addition to cost-effectiveness results acts as a second stage by which 
each of the interventions is judged before recommendations are made concerning allocation of 
resources. In the first stage of the ACE analysis, options are ranked by those criteria directly related to 
determining the resources consumed or released by the option, together with the size of the 
anticipated health gain (based on the ICERs). The first stage is characterised by aspects that lend 
themselves to logical decision rules, drawn essentially from the health economics discipline. The 
second stage incorporates aspects for which it is very difficult to develop decision rules and decisions 
will rest heavily on judgement and due process.  
A common set of filters have been used in all ACE studies, which reflect government generic policy 
objectives and facilitate comparability of ACE results. ACE methods provide for additional filters to be 
added where the study context warrants their selection. The core filters used in all ACE studies are: 
• capacity of the intervention to reduce inequity; 
• acceptability to stakeholders; 
• feasibility of implementation; and 
• strength of the evidence base. 
The additional filters adopted by the Project Steering Committee in ACE–Prevention are: 
• sustainability; and 
• potential for other consequences (side effects). 
The additional filters adopted by the Indigenous Steering Committee in ACE–Prevention are: 
• cultural security; and 
• community health gain. 
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Overview of ‘due process’ 
Evaluation process 
 
Key mechanism for due process    
 
 
 
Due process requirements 
 
 
 
 
 
 
Figure 2.2 Overview of due process in ACE approach to priority-setting. 
 
The filters applied to interventions for the general population are defined below. The main outcome of 
the second-stage filter analysis is a table for each intervention in which these broader issues are 
flagged and a qualitative judgement made explicit about each of the criteria and their impact (Table 
2.1). Issues raised under the ‘equity filter’ or the ‘acceptability to stakeholders’ filter, for example, are 
briefly described and then a summary entry made (such as ‘not a key issue’; ‘possible concerns, needs 
attention’) under a ‘decision point’ heading; these are then brought together under ‘policy 
considerations’, combining both the cost-effectiveness and second-stage filter information. The 
second-stage filter analysis can lead to recommendations about the need for pilots prior to widespread 
implementation; about the need for intervention re-design to address equity concerns; and/or the 
need for ongoing evaluation/research to improve the evidence base. 
2.4.1. Capacity of the intervention to reduce inequity 
This filter was defined as ‘the impact of the intervention on inequity in the distribution of disease and 
health status and access to, or utilisation of, specific intervention(s)’. Particular attention is given to 
instances where an intervention or option for change may aggravate or worsen existing inequities. The 
equity filter may include an analytical component (e.g. numerical evidence of inequalities in current 
health status and/or access to or utilisation of services); but the judgement by the Project Steering 
Committee is still inherently qualitative. Various possible methods can be used to combine cost-
effectiveness ratios and equity considerations in a numerical way. These include weighting the DALY 
measure in accordance with who gains the DALY reduction, using decision theory to create a new index 
score [31] and cost value analysis developed by Nord [32]. The Project Steering Committee preferred to 
keep equity considerations separate as an explicit filter and not attempt to internalise equity within the 
cost-effectiveness ratios. The Indigenous Steering Committee decided likewise, but, importantly, 
endorsed the development of an additional Indigenous concept-of-benefit instrument (see Section 4.3). 
Working Group of stakeholders 
+/- Steering Committee 
 +/- Technical Advisory Panels 
Transparency 
Accountability 
Chance to express views 
Involvement from beginning to end 
Clear roles 
Explicitness of data, analysis, findings 
Review process 
Ownership 
Intervention selection 
• Agree selection criteria 
• Agree work program 
Technical analysis 
• Confirm methods 
• Input to research 
• Review briefing papers 
2nd Stage filters 
• Agree filters 
• Apply filters 
• Agree impact of filters 
Findings and their 
dissemination 
24 
 
Table 2.1 Summary of incremental cost-effectiveness ratios and second-stage filter analysis 
Intervention Cost per 
DALY 
summary 
Strength of 
evidence  
Equity  Acceptability 
to 
stakeholders  
Feasibility and 
sustainability  
Potential 
for side 
effects  
Brief 
description of 
intervention 
Summary of 
central ICER 
information 
Summary of key issues for each filter 
Decision point: 
Assessment of 
impact of filter 
Conclusion 
about ICER 
credentials 
Evidence base 
strong enough to 
support 
implementation or 
more cautious 
approach required? 
For each filter, whether there is or is not a problem. If 
so, nature of problem? If not, supportive or neutral to 
adoption? 
 
Policy considerations: 
Overall review of ICERs, plus the impact of filters for non-Indigenous Australians; for example, ICERs are 
favourable, but caution is required due to impact of second-stage filter issues or uncertainty requires a more 
cautious approach (e.g. pilot before widespread implementation)  
DALY, disability-adjusted life year; ICER, incremental cost-effectiveness ratio 
2.4.2 Acceptability to stakeholders 
This criterion refers to the anticipated acceptability of proposed interventions to the various 
stakeholders affected by the intervention (participants/patients, parents and carers, the general 
community, third-party funders, health service providers, government and the non-government 
sector). By its very nature, acceptability is a difficult criterion on which to find empirical data. 
Judgements must thus be made by the Project Steering Committee, the Indigenous Steering Committee 
and the various Technical Advisory Committees.  
2.4.3 Feasibility of implementation 
This criterion is concerned with the ease of implementing the intervention, considering factors such as 
the availability of appropriate expertise to implement the intervention on a national scale (particularly 
in rural and/or remote areas), the potential size of the financial commitment, and the time scale for 
implementation.  
As with equity, feasibility is a criterion that may be informed by quantitative data, but essentially 
involves judgement rather than the application of technical decision rules. For this criterion, the Project 
Steering Committee largely restricted itself to flagging issues that required attention and to presenting 
descriptive information to assist policy-makers. 
2.4.4 Strength of the evidence base 
Evidence is a fundamental consideration in the ACE approach and impacts on the ACE–Prevention 
study through (i) the selection of the options for change for which evidence of effectiveness is 
available; (ii) the sensitivity and uncertainty analysis around the ICERs; and (iii) the confidence that 
policy-makers can have in the cost-effectiveness results.  
A view is emerging of a single framework within which evidence on clinical, public health and 
behavioural interventions can be assessed. While the nature of the evidence for different kinds of 
health interventions inevitably varies, and the evidence for public health and social science 
interventions often is weaker than that for clinical interventions, the logic used to assess the evidence 
is the same for all of them. Following work on alternative classifications, the Project Steering 
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Committee resolved at its March 2005 meeting to accept a classification system that sought to combine 
the traditional classification of evidence based on epidemiologic study design with indirect and parallel 
forms of evidence that would not ordinarily be captured. This classification is based on the 
classifications used for the ACE-Obesity study [33] and draws on the work of Hawe and Shiell [34], 
Swinburn and Kumanyika [35] and also reflects aspects of other evidence frameworks [36–38].  
The approach of the ACE–Prevention study is set out in Table 2.2. 
To some extent, this strength of evidence criterion is presented quantitatively in the sensitivity and 
uncertainty analyses. In other words, if the evidence on effectiveness is weak, large uncertainty around 
the size of the impact measure was used during the simulation modelling of uncertainty. However, for 
some interventions evidence is so limited that the Project Steering Committee would not want to make 
a firm recommendation to increase funding for the intervention even if the uncertainty analysis 
showed a favourable cost-effectiveness ratio. In such cases, a recommendation is made to implement 
the intervention as a pilot project and to monitor the impact before recommending wider 
implementation.  
2.4.5 Sustainability  
This criterion refers to the durability of the intervention considering such factors as: (i) the level of 
ongoing funding support required; (ii) the community empowerment and capacity building likely to be 
achieved; (iii) the level of policy support likely to be achieved; and (iv) the likelihood of required 
changes in behaviours, practices and attitudes being achieved on an ongoing basis. 
2.4.6 Potential for other consequences  
This criterion refers to the potential for both positive and negative side effects arising from an 
intervention. These might be impacts such as: (i) other health consequences (such as 
anxiety/depression stemming from stigmatisation); (ii) environmental consequences (for example due 
to air quality); (iii) social capital (for example, from empowered communities or improved social 
networks); (iv) increased household costs; and (v) other economic consequences (such as impact on 
industry). We took care to ensure that any consequences noted under this filter are not already 
captured in the cost-effectiveness ratio, either on the cost side (cost impacts on families) or on the 
outcome side (in the DALY measure).  
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Table 2.2 Classification of the strength of the evidence approach adopted in ACE–Prevention 
Conventional approach based on epidemiological 
study design  
Evidence from level I–III study designs  
Additional categories utilised in the ACE–Prevention 
study 
Evidence from level IV studies, indirect or parallel evidence 
and/or from epidemiological modelling using a mixture of study 
designs 
‘Sufficient evidence of effectiveness’ 
Effectiveness is demonstrated by sufficient evidence from 
well-designed research that the effect: 
• is unlikely to be due to chance (e.g. p<0.05); and 
• is unlikely to be due to bias, e.g. evidence* from: 
- a level I study design; 
- several good quality level II studies; or 
- several high quality level III-1 or III-2 studies from which 
effects of bias and confounding can be reasonably 
excluded on the basis of the design and analysis). 
‘Likely to be effective’  
Effectiveness results are based on: 
• sound theoretical rationale and program logic; and 
• level IV studies, indirect† or parallel‡ evidence for outcomes; 
or 
• epidemiological modelling to the desired outcome using a 
mix of evidence types or levels. 
The effect is unlikely
Implementation of this intervention should be accompanied by 
an appropriate evaluation budget. 
 to be due to chance (the final uncertainty 
interval does not include zero and there is no evidence of 
systematic bias in the supporting studies).  
‘Limited evidence of effectiveness’ 
Effectiveness is demonstrated by limited evidence from 
studies of varying quality that: 
• the effect is probably not due to chance (e.g. p<0.10); but 
• bias, while not certainly an explanation for the effect, 
cannot be excluded as a possible explanation (e.g., 
evidence* from: 
- one level II study of uncertain or indifferent quality; 
- one level III or III study of high quality; 
- several level III or III studies of insufficiently high quality 
to rule out bias as a possible explanation; or 
- a sizeable number of level III studies of good quality and 
consistent in suggesting an effect). 
‘May be effective’  
Effectiveness results are based on: 
• sound theoretical rationale and program logic; or 
• level IV studies, indirect† or parallel‡ evidence for outcomes; 
or 
• epidemiological modelling to the desired outcome using a 
mix of evidence types or levels. 
The effect is probably not
 
 due to chance but bias, while not 
certainly an explanation for the effect, cannot be excluded as a 
possible explanation.  
Would benefit from further research and/or pilot studies 
before implementation. 
‘Inconclusive evidence of effectiveness’ 
Inadequate evidence due to insufficient or inadequate 
quality research. 
No position could be reached on the presence or absence of 
an effect of the intervention (e.g. no evidence from level I 
or level II studies and level III studies are available, but they 
are few and of poor quality.) 
‘No evidence of effectiveness’ 
No position could be reached on the likely credentials of this 
intervention. Further research may be warranted. 
 
 
*Evidence classifications based on those of the National Health and Medical Research Council [39]: 
I  Evidence obtained from a systematic review of all relevant randomised controlled trials. 
II  Evidence obtained from at least one properly designed randomised controlled trial. 
III-1 Evidence obtained from well-designed pseudo-randomised controlled trials (alternate allocation or some other method). 
III-2 Evidence obtained from comparative studies with concurrent controls and allocation not randomised (cohort studies), 
case-control studies, or interrupted time series with a control group. 
III-3 Evidence obtained from comparative studies with historical control, two or more single-arm studies, or interrupted time 
series without a parallel control group. 
IV Evidence obtained from case series, either pre-test and post-test. 
† Information that strongly suggests that the evidence exists (e.g. a high and continued investment in food advertising is 
indirect evidence that there is positive (but propriety) evidence that food advertisement increases sales of those products) 
[35].  
‡Evidence of intervention effectiveness for another public health issue using similar strategies (e.g. the role of social 
marketing, regulation or behavioural change initiatives in tobacco control, sun exposure, speeding) [35] 
Source: Haby MM, et al. [33]. 
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2.5 Presentation of results  
Concisely presenting a large number of results, each with many aspects, is challenging. Inevitably, it 
requires making choices. This section explains the choices we have made, and how to read the tables in 
the Results section below. Readers should realise that this report only gives a ‘helicopter’ view: details 
of the interventions are available in pamphlets, briefing papers and/or journal articles. These are 
available at our website (www.sph.uq.edu.au/bodce-ace-prevention). 
Table 2.3 Categories used to classify interventions according to various aspects  
Aspect Categories 
Cost-effectiveness ratio • Dominant: interventions that improve health and saves money; 
• Very cost-effective: interventions that improve health at a cost of less than $10,000 per 
DALY; 
• Cost-effective: interventions that improve health at a cost of between $10,000 and $50,000 
per DALY; 
• Not cost-effective: interventions that improve health at a cost of more than $50,000 per 
DALY; and 
• Dominated: interventions with worse health outcomes at a cost; or more cost-effective 
alternatives are available that ‘replace’ the dominated intervention. 
Health impact  
(lifetime) 
 
Small 
0–10,000 DALYs  
 
Medium 
10,000–100,000 DALYs 
 
Large 
>100,000 DALYs 
Intervention cost  
(annual) Small 
<$10 million 
Medium 
$10–100 million 
 
Large 
>$100 million  
Strength of evidence  
(Table 2.2) 
Comparative evidence: 
• sufficient;  
• limited; or 
• inconclusive;  
No comparative evidence:  
• likely;  
• maybe; or 
• no evidence 
Other issues No pre-defined categories 
One of the main characteristics of the ACE methodology is that economic evaluation is not just about 
calculating cost-effectiveness ratios. While the cost-effectiveness ratio is pivotal, other important 
aspects of the intervention concern its health impact, the cost when implemented, the strength of the 
evidence, and any other issues that are deemed important, such as acceptability, feasibility and equity. 
In order to simplify the body of this report, we treat all these aspects as categorical variables. Table 2.3 
lists the aspects and the categories we use. We then proceed to discuss them. Appendix 2 provides a 
complete list of all interventions and more details of each. 
An example: Table 2.4 is part of a results table. The first thing to notice is which of the five cost-
effectiveness classes this concerns: very cost-effective ($0–10,000 per DALY). Then there is an entry for 
topic area (physical activity) and one or more interventions (two in this case).  
The GP prescription intervention has a medium-sized health impact (between 100 and 10,000 DALYs, 
denoted by yellow colour and two plus signs), high intervention costs (more than $100 million, denoted 
by red colour and three plus signs), the evidence is sufficient, but there are issues with feasibility and 
equity. 
+ ++ +++
+ ++ +++
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The internet intervention also has a medium-sized health impact, but low cost (less than $10 million, 
green colour and one plus sign), sufficient evidence and an equity issue. 
Table 2.4 Example of presentation of interventions 
Topic area Intervention Lifetime  
health impact 
Annual 
intervention 
cost 
Strength of 
evidence 
Other issues 
Very cost-effective ($0–10,000/DALY) 
Physical 
activity 
GP prescription + +++ Sufficient Feasibility/equity: limited 
capacity GPs, esp. in 
rural areas 
Internet intervention + + Sufficient Equity: requires 
computer literacy and 
internet access 
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3. Results, total population 
3.1 Interventions 
We set out to perform cost-effectiveness analyses of 100 preventive interventions addressing non- 
communicable disease and to benchmark these against a further 50 interventions of treatment or 
infectious disease control. We strived to be comprehensive in our evaluation of prevention of non-
communicable disease and its main risk factors. Eventually, we selected and analysed 121 preventive 
interventions, of which six concerned prevention of infectious disease but with no impact on non-
communicable disease. Interventions addressing an infectious cause of non-communicable disease 
(such as human papillomavirus and cervical cancer; hepatitis B and liver cirrhosis and cancer; and 
Helicobacter pylori and peptic ulcer disease) were classified as prevention of non-communicable 
disease. We also completed analyses for 24 treatment interventions. There was one Indigenous-specific 
intervention addressing lifestyle risk factors in a remote community. We adapted our total population 
models to estimate the cost-effectiveness of 16 prevention interventions and two treatment 
interventions for Indigenous Australians.  
We have addressed a broad spread of interventions across risk factors and disease areas (Table 3.1). It 
should be noted that the risk factors affect multiple diseases. For instance, cardiovascular disease is 
affected by seven of the risk factors included in the table. For each intervention we chose the most 
appropriate category with a preference for listing interventions under risk factors rather than disease 
groups. Interventions that were modelled in several scenarios (such as 15% and 30% tax increase on 
excise duty of tobacco and alcohol) were counted only once. Full details of all interventions evaluated 
are presented in Appendix 2. 
Table 3.1 Number of preventive and treatment interventions by topic area, ACE–Prevention 
Topic area               Total population             Indigenous population 
  Prevention  Treatment Prevention  Treatment 
Alcohol 9 2   
Tobacco 8    
Physical activity 6    
Nutrition 26    
Body mass 9    
Blood pressure/cholesterol 12  5  
Bone mineral density 3    
Illicit drugs 2 1   
Cancer 9 1   
Diabetes 7  7  
Kidney disease 2 2 4 2 
Mental disorders 11 10   
Cardiovascular disease 1 5   
Other prevention 11  3  
Infectious disease 7    
Other treatment  6   
Total 123 27 19 2 
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A few topics have been given no or little attention. We decided not to include prevention of air 
pollution due to the complexity of the modelling required (with a lot of benefits outside the health 
sector) and an inadequate evidence base for attributing non-fatal outcomes to air pollution. Similarly, 
we have not included analyses of prevention of age-related hearing loss, as the evidence base for 
prevention is thin.  
In terms of the benchmarks (i.e. treatment or infectious disease control options), we have largely been 
opportunistic rather than systematic in choosing interventions, being guided by preferences of project 
researchers and students/researchers wishing to have a short-term association with the project. We 
deliberately included a number of common high-cost treatment interventions such as stenting of 
coronary arteries, kidney dialysis and transplant, and hip and knee joint replacement. 
Eight interventions on our list have not made it past the scoping phase for lack of evidence on 
effectiveness (Table 3.2). These have, nonetheless, involved research effort and are therefore counted 
in Table 3.1, and more detailed documentation on these is available electronically.  
Table 3.2 ACE–Prevention interventions not modelled through to cost-effectiveness due to lack of evidence on effectiveness 
Topic area Intervention Comments 
Obesity ‘Traffic light’ labelling of food Scenario analysis based on what was 
deemed a plausible effect  
Vision Screen by regular vision testing No evidence of effectiveness 
Oral health Subsidisation of annual dental check at ages 12–17: No evidence of effectiveness 
 • check-up only 
• + radiography 
• + cleaning/scaling/sealants 
 
Mental health Emergency contact cards for the reduction of deliberate  
self-harm/suicide 
Not effective 
Other 
 
Helicobacter pylori eradication therapy for:  
• non-ulcer dyspepsia; and 
• uninvestigated dyspepsia 
No evidence of effectiveness but 
likely to be cheaper than 
symptomatic treatment 
 
3.2 Cost-effectiveness: introduction 
We start by presenting the cost-effectiveness results for each of the individual interventions in what is 
often called a league table format. This is a first sifting of interventions into those that are and are not 
good value for money. We also indicate the relative size of the annual intervention costs and the 
amount of health gain projected over the lifetime of the 2003 Australian population receiving the 
interventions. If other important policy considerations might facilitate or hinder the implementation, 
these are raised. 
This approach is not fully informative for two reasons. First, some interventions appear cost-effective 
when analysed in isolation but have more efficient alternatives. For instance, the cost-effectiveness 
ratio of beta blockers for prevention of cardiovascular disease appears favourable when analysed as a 
single intervention option. However, because three other classes of blood-pressure-lowering drugs are 
more cost-effective, beta blockers are not recommended. When treating individual patients a GP may, 
for important other reasons, have a preference for prescribing beta blockers over the alternatives. 
Second, the one-by-one analyses do not take into account that many interventions are not 
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implemented in isolation. When combinations of interventions are analysed, care must be taken not to 
double-count shared costs and benefits. The latter tends to be the more important consideration: 
other interventions in the chosen package reduce disease rates and any additional intervention cannot 
claim the same reduction. Therefore, in topic areas with many alternative intervention options (such as 
blood pressure and cholesterol-lowering, alcohol, physical inactivity, body mass and kidney disease) we 
have analysed the most cost-effective ‘optimal’ mix. These ‘intervention pathways’ are presented in a 
separate section following the league table. It demonstrates the inefficiency of current practice and 
marks as undesirable some interventions that had reasonable cost-effectiveness credentials when 
analysed in isolation, but are ‘crowded out’ or ‘dominated’ by more efficient options.  
Lastly, we present the results of an intervention pathway that combines the impact of many 
interventions across different topic areas. This allows us to quantify the overall intervention costs, 
downstream disease treatment costs averted and health gain for packages of interventions. In 
particular, we show this for the group of interventions that in the league table section are labelled as 
‘dominant’ (i.e. cost-saving) or very cost-effective (costing less than $10,000 per disability-adjusted life 
year (DALY)). 
 
3.3 Cost-effectiveness: league table 
Acknowledging the uncertainty around the cost-effectiveness results we present the league table of 
our results in five categories in an order from most to least favourable. 
3.3.1 Dominant (cost-saving) interventions 
Twelve of the 23 dominant prevention interventions have a population-wide focus aiming to reduce 
exposure to harmful risk factors and behaviours by taxation (of alcohol, tobacco and unhealthy food) or 
regulation (alcohol advertising bans, raising minimum age of drinking, limiting salt in processed food 
and fluoridation of drinking water). Four others are health promotion interventions that advocate 
physical activity and fruit and vegetable consumption or address cardiovascular health in general. The 
remaining seven are screening interventions targeting treatment to those at high risk (Table 3.3). These 
seven interventions address cardiovascular disease, chronic kidney disease, suicide, psychosis and liver 
cirrhosis or liver cancer as long-term consequences of hepatitis B.  
The polypill combines three blood-pressure-lowering drugs in low dose and a statin in a single pill. The 
polypill is not yet available in Australia but early results from a trial in Australia and New Zealand 
indicate that it is as effective as was estimated from the effect sizes of the individual drugs. Using 
generic drugs it can be produced very cheaply and the expectation is that it would be possible to 
market the polypill at an annual cost of around $200 per person treated (personal communication, 
Anthony Rodgers). The polypill has been developed based on the principles of ‘absolute risk’, an 
assessment of an individual’s cardiovascular risk profile determined by age, sex, diabetes, smoking, 
body mass index, blood pressure and cholesterol. We have classified the Australian population based 
on their risk of a cardiovascular event (stroke, heart attack or serious angina) over the next five years: 
>15%, 10–14%, 5–9% and a low-risk category of <5%. This absolute risk determines the need for 
treatment regardless of the values of the individual risk factors. Thus, if someone has a high risk of 
cardiovascular disease (CVD) (e.g. because of being a smoker and a diabetic with high cholesterol) 
treatment with a blood-pressure-lowering drug may be the first line treatment even if blood pressure is 
within a normal range. For people at greater than 5% absolute CVD risk the polypill is a cost-saving 
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intervention with a large impact on population health. The polypill (assuming a yearly cost of $200 per 
person treated), given to all people at greater than 5% absolute CVD risk, would cost $260 million per 
year and lead to 340,000 DALYs averted over the lifetime of the 2003 population. 
Table 3.3 Dominant (cost-saving) preventive interventions for non-communicable disease, ACE–Prevention 
Topic area Intervention Lifetime 
health 
impact* 
Annual 
intervention 
cost* 
Strength of 
evidence 
Alcohol Volumetric tax ++ + Likely 
 Tax increase 30% +++ + Likely 
 Advertising bans + + Limited 
 Raise minimum legal drinking age to 21 + + Limited 
Tobacco Tax increase 30% (with or without indexation) +++ + Likely 
Physical activity Pedometers ++ ++ Sufficient 
Mass media ++ ++ Inconclusive 
Nutrition Community fruit and vegetable intake promotion + ++ May be effective 
 Voluntary salt limits + + Likely 
 Mandatory salt limits +++ + Likely 
Body mass 10% tax on unhealthy food +++ + May be effective 
Blood pressure and 
cholesterol 
Community heart health program ++ + May be effective 
Polypill $200 for >5% CVD risk +++ +++ Likely 
Osteoporosis  Screen women aged 70+ and alendronate ++ ++ Sufficient 
Hepatitis B Vaccine and immunoglobulin to infants born to 
carrier or high-risk mothers 
+ + Sufficient 
 High-risk infant vaccination + + Sufficient 
 Selective vaccination of infants with mothers from 
highly endemic countries 
+ + Sufficient 
Kidney disease Proteinuria screen and ACE inhibitors for diabetics ++ + Sufficient 
Mental disorders Problem-solving post-suicide attempt + + Sufficient 
Treatment for individuals at ultra-high risk for 
psychosis 
+ + Likely 
Oral health Fluoridation drinking water, non-remote  + + Limited 
ACE, angiotensin-converting enzyme; CVD, cardiovascular disease 
* See Section 2.5 for an explanation of table symbols and colour-coding. 
The regulatory and taxation interventions are the least costly interventions from a health sector 
perspective. The taxation interventions and the mandatory limits in the salt content of processed food 
can lead to substantial health gain in the population. From a public health point of view there are no 
hesitations to advocate the implementation of these interventions. Their implementation requires 
political will. The recent debate around the introduction of a higher tax on ‘alcopop’ drinks has shown 
that such new measures require a substantial effort and the right political environment to be adopted. 
It is therefore unlikely that any government would be willing to adopt many of these interventions at 
the same time. We would argue that the expected health impact ought to be an important argument to 
select interventions that are worth the effort of guiding it through the long process of decision-making. 
The regulatory and taxation interventions for alcohol in Table 3.3 (with greater detail in Appendix 2) 
illustrate this point. The health impact of raising the legal drinking age to 21 is very modest compared 
to the large health gain expected from alcohol tax increases and taxation reform. 
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It is noteworthy that two physical activity interventions fall in this very favourable category but it 
includes none for obesity prevention, apart from the somewhat speculative analysis of taxing 
unhealthy food (non-core foods that are high in saturated fat, sugar and/or salt) that used ‘parallel’ 
rather than observed evidence on its effectiveness. The evidence for the effectiveness of a mass media 
campaign to promote physical activity is from a lack of decline in physical activity in NSW compared to 
other states. That is not considered a very robust level of evidence. We classified the evidence for 
pedometers as sufficient because it came from a meta-analysis of eight randomised trials, but we have 
reservations about the sustainability of their effect. Only five of these dominant interventions were 
judged to have strong evidence for effectiveness: screen and alendronate for osteoporosis; ACE 
inhibitors for chronic kidney disease, problem-solving for people who have attempted suicide and the 
two hepatitis B vaccination strategies. An important reason is that population-wide interventions are 
more difficult to evaluate than clinical interventions. Our analysis does indicate, however, that there is 
an important research agenda for more frequent and better evaluation of such population-wide 
interventions.  
The benefits of a community heart health program were modelled against a ‘do nothing’ comparator. 
We assume that most of the benefits that could be achieved by such health promotional activities 
around a diet that protects against cardiovascular disease have already been made.  
We made a conscious effort to include a range of preventive interventions for mental disorders. The 
two dominant mental health interventions address suicide and psychosis; two outcomes that only 
more recently have become a focus of prevention. The suicide intervention, which targets people who 
have attempted suicide with a problem-solving intervention, is very cost-effective as it is quite effective 
at preventing further attempts. The psychosis intervention addresses adolescents with early warning 
signs. The program mainly delays the onset of psychosis and is associated with lower costs than usual 
care in this high-risk group. 
3.3.2 Very cost-effective interventions ($0–10,000 per DALY) 
Fifteen of the 20 very cost-effective preventive interventions (with a cost-effectiveness ratio less than 
$10,000 per DALY) are interventions that involve screening people, either in primary care or in schools, 
for severe obesity, physical inactivity, hazardous or harmful alcohol use or increased risk of 
cardiovascular disease or symptoms of mental disorders. The screen is followed by a drug, 
psychological, health promotional or surgical intervention. Two more interventions in this category are 
of a regulatory nature (licensing controls of alcohol outlets and responsible media reporting of 
suicides). A further two interventions are in health education (for physical activity and fruit and 
vegetable intake), and a universal infant vaccination intervention is also in this category (Table 3.4). 
Gastric banding for severe obesity and the four interventions that address blood pressure and 
cholesterol are estimated to have the largest health impact. We assumed that 25% of people who have 
a BMI greater than 35 (severely obese) would take up gastric banding. This would lead to considerable 
health gain (140,000 DALYs) at large cost to the health sector ($3.7 billion), though compensated by 
large cost offsets from averting future disease ($2.9 billion). 
If the polypill were provided to every person over the age of 55, regardless of their absolute CVD risk 
profile, 640,000 DALYs could be averted over their lifetime at a cost of $520 million per year. This raises 
a question about the desirability of putting a large proportion of the population on daily medication for 
the rest of their lives. On the other hand, we have seen a very large decrease of 70% in cardiovascular 
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mortality over the last 40 years. Our modelling indicates that greater decreases are still possible and 
can be achieved by very cost-effective means, but that the overall cost is considerable. 
Table 3.4 Very cost-effective preventive interventions ($0–10,000 per DALY) for non-communicable disease, ACE–
Prevention 
Topic area Intervention Lifetime 
health 
impact* 
Annual 
intervention 
cost* 
Strength of 
evidence 
Alcohol Brief alcohol intervention GP with or without 
telemarketing and support 
+ + Sufficient 
 Licensing controls + + Likely 
Tobacco Cessation aid: varenicline ++ +++ Sufficient 
 Cessation aid: bupropion ++ +++ Sufficient 
 Cessation aid: nicotine replacement therapy ++ ++ Sufficient 
Physical activity GP Green Prescription + +++ Limited 
 Internet intervention + ++ Sufficient 
Nutrition Information mail-out, multiple re-tailored to promote 
fruit and vegetable intake 
+ + Limited 
Body mass Gastric banding for severe obesity +++ +++ Sufficient 
Blood pressure and 
cholesterol 
Low-dose diuretics >5% CVD risk +++ +++ Sufficient 
Polypill $200 to ages 55+ +++ +++ Likely 
 CCBs >10% CVD risk ++ ++ Sufficient 
 ACE inhibitors >15% CVD risk ++ ++ Sufficient 
Mental disorders 
drugs/suicide 
Screen and bibliotherapy to prevent adult depression  + ++ Likely 
 Screen and psychologist to prevent 
childhood/adolescent depression 
+ ++ Sufficient 
 Screen and bibliotherapy to prevent 
childhood/adolescent depression 
+ + Limited 
 Responsible media reporting for the reduction of 
suicide 
+ + Likely 
 Parenting intervention for the prevention of childhood 
anxiety disorders 
+ + Sufficient 
Other Universal infant hepatitis B vaccination + ++ Sufficient 
ACE, angiotensin-converting enzyme; CCB, calcium channel blocker; CVD, cardiovascular disease 
* See Section 2.5 for an explanation of table symbols and colour-coding. 
 
Individual blood-pressure-lowering drugs and dietary counselling also fall in this category of very cost-
effective interventions. Diuretics are the cheapest option and are very cost-effective if given to people 
at a five-year CVD risk greater than 5%. The more expensive calcium channel blockers (CCBs) and ACE 
inhibitors and dietary counselling are indicated for higher risk categories only, at a cost below $10,000 
per DALY prevented. In Section 3.4.1 we look at combinations of interventions addressing cholesterol 
and blood pressure as risk factors for CVD. 
The four screening and psychological treatments for mental disorders in this category would cost 
around $90 million annually and avert 15,000 DALYs. The main limiting factor to implement these 
interventions is the availability of skilled staff (mainly psychologists) to provide the diagnosis and 
therapies. Moreover, unlike the case for treatment of adult depression and anxiety, there are no 
provisions yet in Medicare to subsidise the cost of psychologists for these indications. 
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Brief alcohol interventions by a GP have very modest costs and health outcomes because only a small 
proportion of GPs are recruited and choose to implement the intervention, even if additional 
telemarketing and support are provided. The GP Green Prescription of physical activity is rather costly 
($230 million) but leads to a healthy 7000 DALYs, even if we assume a relatively rapid decay in the 
intervention effect (a yearly halving of the remaining effect).  
Most of these very cost-effective interventions have sufficient or likely evidence for effectiveness. The 
fruit and vegetable intervention was deemed to have limited evidence as it is based on a single study 
and only five out of 23 fruit and vegetable interventions were cost-effective. We had to model each of 
these separately, as they used a wide range of methods with different costs and target population 
groups. The fruit and vegetable intervention with better cost-effectiveness credentials had some 
distinguishing features: focusing on the general population rather than targeting those at high risk or in 
the workplace and keeping costs low by relying on mail-outs and tailored information. Nevertheless, 
the impact of this type of intervention is very modest. Overall, with so few of the counselling and 
health information interventions to improve fruit and vegetable intake proving cost-effective in our 
analyses, we have little confidence that these few interventions can be replicated cost-effectively in 
practice. 
Universal vaccination of all infants for hepatitis B plus screening of mothers for carrier status and 
providing hepatitis B immunoglobulin to their infants as is currently implemented is a cost-effective 
intervention, despite health gain being achieved after several decades only. However, a more selective 
approach – vaccinating and providing hepatitis B immunoglobulin to infants of carrier mothers only – 
has better cost-effectiveness credentials, as indicated by their inclusion in the group of dominant 
interventions. As universal vaccination has become accepted it is unlikely that a more targeted 
approach would be adopted.  
3.3.3 Cost-effective interventions ($10,000–50,000 per DALY) 
Among the 28 cost-effective interventions with a cost-effectiveness ratio between $10,000 and 
$50,000 per DALY, one is of a regulatory nature (enforcement of laws on driving under the influence of 
alcohol) and four concern health education (addressing drink driving, fruit and vegetable intake, 
physical activity and skin cancer). The remaining 23 are targeted interventions following a screen to 
identify those with high levels of lifestyle-related diseases, cervical cancer or symptoms of mental 
disorders (Table 3.5). The level of evidence for the health promotional interventions was judged to be 
limited while all the targeted interventions in this category had sufficient or likely evidence to support 
effectiveness.  
36 
 
Table 3.5 Cost-effective preventive interventions ($10,000–50,000 per DALY) for non-communicable disease,  
ACE–Prevention 
Topic area Intervention Lifetime 
health 
impact* 
Annual 
intervention 
cost* 
Strength of 
evidence 
Alcohol Drink drive mass media + ++ Limited 
 Roadside breath testing + ++ Likely 
Physical activity TravelSmart + +++ May be effective 
 GP referral + +++ Limited 
Nutrition Multiple tailored mailed fruit and vegetable 
promotion 
+ + Limited 
Obesity Diet and exercise for overweight + +++ Sufficient 
 Low-fat diet for overweight + ++ Sufficient 
Blood pressure and 
cholesterol 
Dietary counselling >5% CVD risk by dietitian ++ ++ Sufficient 
 Dietary counselling >5% CVD risk by GP ++ ++ Sufficient 
 Phytosterol supplementation >5% CVD risk ++ +++ Sufficient 
 Statins >5% CVD risk +++ +++ Sufficient 
 Statins and ezitimibe >5% CVD risk +++ +++ Sufficient 
 Beta blockers >5% CVD risk ++ +++ Sufficient 
 CCBs >5% CVD risk +++ +++ Sufficient 
 ACE inhibitors >5% CVD risk +++ +++ Sufficient 
Cancer Pap screen (current practice) + ++ Sufficient 
 HPV DNA test screen 3-yearly from age 18 + + Likely 
 HPV vaccination and Pap screen  + ++ Likely 
 HPV vaccination and HPV DNA test screen 3-yearly 
from age 18 
+ ++ Likely 
 SunSmart +++ +++ Limited 
Pre-diabetes Screen and dietary advice + ++ Sufficient 
 Screen and exercise physiologist ++ ++ Sufficient 
 Screen and dietary advice and exercise 
physiologist 
++ ++ Sufficient 
 Screen and metformin ++ ++ Sufficient 
 Screen and acarbose ++ ++ Sufficient 
Kidney disease Chronic kidney disease screen and ACE inhibitors 
for non-diabetics age >25  
++ ++ Sufficient 
Mental disorders Screen and group CBT to prevent adult depression + ++ Likely 
Screen and CBT to prevent post-partum 
depression 
+ + Limited 
ACE, angiotensin-converting enzyme; CBT, cognitive behaviour therapy; CCB, calcium channel blocker; CVD, cardiovascular 
disease; HPV, human papillomavirus 
* See Section 2.5 for an explanation of table symbols and colour-coding. 
 
The largest impact on population health outcomes can be expected from an increase in national 
investment for a SunSmart program at the average level achieved by Victoria in the 1990s, blood 
pressure and cholesterol control, drugs for smoking cessation and treating people identified with pre-
diabetes or chronic kidney disease. These interventions tend to be more costly. A large proportion of 
the costs of the SunSmart intervention are borne by individuals purchasing sunscreen lotion. The 
evidence for effectiveness was imputed from a reduction in the increase in skin cancer cases seen in 
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Victoria as compared to other states and assuming the extra investment in SunSmart activities in 
Victoria was responsible. As there was no control population, this is a rather uncertain result. 
3.3.4 Not cost-effective interventions (>$50,000 per DALY) 
Not cost-effective preventive interventions include the majority of fruit and vegetable interventions, 
dietary advice on salt and a multiple-component intervention addressing diet, weight and exercise 
(Table 3.6). Each of these has poor effectiveness and some have high cost. The commercial Weight 
Watchers program is not cost-effective as there is poor maintenance of weight loss. The high cost of 
orlistat and sibutramine makes them not cost-effective. 
Table 3.6 Not cost-effective preventive interventions (>$50,000 per DALY) for non-communicable disease, ACE–Prevention 
Topic area Intervention Comments 
Diet Fruit and vegetable interventions targeting individuals 
(except tailored mailings) 
Poor effectiveness 
  Fruit and vegetable interventions at workplace Poor effectiveness 
  Dietary advice on salt Poor effectiveness and high cost 
  Weight Watchers Poor maintenance of weight loss 
  Multi-component diet/physical activity/weight 
intervention 
Poor effectiveness 
  Orlistat, sibutramine Too expensive 
Osteoporosis Raloxifene No effect on hip fractures and too 
expensive 
Cancer Combined Pap and HPV DNA test screen 3-yearly from age 
18 
No benefit from start at age 18 instead 
of 25 
 HPV vaccination and combined Pap and HPV DNA test 
screen 3-yearly from age 18 
No benefit from start at age 18 instead 
of 25 
 Anal cytology for MSM Expensive screen for rare cancer 
Pre-diabetes Screen and orlistat Too expensive 
 Screen and rosiglitazone Too expensive 
CVD Aspirin Risk of bleeding and ambiguous evidence 
for effect in primary prevention 
Vision loss Ranibizumab for age-related macular degeneration Too expensive 
Mental 
health/drugs 
  
School-based drug intervention Poor effectiveness 
Gun buy-back and legislation changes to reduce suicides Only ecological evidence for reduction in 
suicide; high cost 
Shingles Varicella zoster vaccination at age 50 Low frequency of shingles; expensive 
CVD, cardiovascular disease; HPV, human papillomavirus; MSM, males who have sex with males 
Raloxifene has not been shown to prevent hip fractures and is too expensive a drug to be considered 
for prevention of osteoporosis. Aspirin has been considered for a long time to be an effective drug for 
preventing cardiovascular disease. As it is so cheap, it would become one of the most efficient options 
for CVD prevention. However, recently two studies showed no beneficial effect of aspirin [40, 41]. As 
aspirin also carries a risk of bleeding in the stomach and brain, particularly in the elderly [24], not using 
it in primary prevention may be wiser.  
A school-based drug intervention had poor effectiveness. The gun buy-back scheme introduced after 
the 1996 Port Arthur massacre in Tasmania was very expensive. The drop in suicide that followed 
cannot be unequivocally attributed to the scheme. 
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3.3.5 Dominated interventions (‘do more harm than good’ or ‘better options available’) 
Three interventions fall in the category of dominated interventions (Table 3.7). The first is prostate-
specific antigen (PSA) testing to screen for prostate cancer. A large proportion of false positive test 
results means a greater number of expensive and unpleasant follow-up diagnostic procedures and, in 
some cases, unnecessarily aggressive treatments for a disease that may never have given symptoms 
during an individual’s lifetime. These harmful effects are greater than the modest population health 
gain from detecting true cases of prostate cancer. While there is no official PSA screening program, 
there is an extensive level of de facto screening.  
The second dominated intervention is rosiglitazone for people identified with pre-diabetes. It is 
associated with an increased risk of cardiovascular disease. Third, beta blockers, while effective in 
preventing cardiovascular disease, compete with three more cost-effective blood-pressure-lowering 
drugs. Combining more than three such drugs is contrary to clinical practice. Lastly, dietary advice by a 
GP is dominated by dietary advice provided by a dietitian. 
Table 3.7 Dominated interventions, ACE–Prevention 
Topic area Intervention Comments 
Cancer Prostate cancer screen by PSA More harm than benefit 
Diabetes Screen and rosiglitazone Adverse effect on cardiovascular disease 
Blood pressure and 
cholesterol 
Beta blockers Three more efficient drugs in class 
Dietary advice by a GP Less expensive option 
PSA, prostate-specific antigen 
3.3.6 Treatment interventions  
Four benchmark interventions were dominant (Table 3.8). Australia’s needle exchange program is very 
good value for money with a sizeable impact. The rates of HIV and hepatitis C infection in intravenous 
drug users would have been closer to the high levels observed in western countries, rather than the 
very low levels in Australia, if this successful program had not been in place [42]. The early psychosis 
intervention has modest impact on health outcomes but saves costs compared to usual treatment. 
Probiotics to prevent antibiotic-associated diarrhoea in hospitalised elderly patients and eradication 
therapy for H. pylori in people with peptic ulcer disease are associated with modest health gain at a 
population level and are not very costly to implement.  
Kidney transplant is a cost-effective intervention compared to chronic dialysis but availability of donor 
organs is the limiting factor. A nine-week short course of trastuzumab for early breast cancer appears 
to be cost-effective although the trial demonstrating its effectiveness was underpowered. A full-year 
course of trastuzumab, the current practice in Australia, is not good value for money despite multiple 
previous cost-effectiveness studies indicating the opposite [43]. These studies used inappropriate 
modelling methods in assuming all women with breast cancer have the same experience as a woman of 
average age with breast cancer. 
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Table 3.8 ‘Benchmark’ treatment or infectious disease control interventions, ACE–Prevention 
Topic area Intervention Lifetime 
 health 
 impact* 
Annual 
intervention  
cost* 
Strength of 
evidence 
Dominant   (net cost savers) 
Psychosis Early psychosis prevention and intervention centre + + Likely 
HIV Needle exchange program +++ ++ Likely 
Diarrhoea Probiotic Lactobacillus to prevent antibiotic-related 
diarrhoea in hospitalised elderly 
+ + Limited 
Peptic ulcer 
disease 
Eradication with triple therapy in Helicobacter pylori 
and patients with peptic ulcer 
+ + Sufficient 
Very cost-effective    ($0–10,000/DALY)  
Illicit drugs Individual CBT for cannabis dependence + + Sufficient 
Depression Individual CBT treatment major depressive episodes 
by psychologist  
++ +++ Sufficient 
 Group CBT treatment major depressive episodes by 
psychologist  
++ ++ Sufficient 
 Bibliotherapy for major depression + + Sufficient 
 Maintenance group CBT by psychologist  ++ ++ Sufficient 
CVD Rehabilitation after myocardial infarction + ++ Sufficient 
HIV Intermittent pre-exposure drug prophylaxis  ++ +++ Sufficient 
 Circumcision all MSM + ++ Sufficient 
Osteoarthritis Hip replacement for osteoarthritis +++ +++ Sufficient 
 Knee replacement for osteoarthritis +++ +++ Sufficient 
Cost-effective ($10,000–50,000/DALY)  
Breast cancer Trastuzumab for early breast cancer, 9-week course + ++ Limited 
Depression TCAs for major depressive episodes plus 6 months 
continuation  
+ ++ Sufficient 
 SSRIs for major depressive episodes plus 6 months 
continuation  
+ +++ Sufficient 
 Maintenance TCAs following major depressive 
episode 
++ +++ Sufficient 
 Maintenance SSRIs following major depressive 
episode 
++ +++ Sufficient 
 Maintenance individual CBT by psychologist ++ +++ Sufficient 
CVD Early stenting for myocardial infarction + +++ Sufficient 
 Angioplasty coated stents in diabetics + ++ Sufficient 
Asthma Asthma clinic; generous interpretation of benefits + +++ Limited 
Not cost-effective    (>$50,000/DALY) 
Breast cancer Trastuzumab for early breast cancer, 1-year course + +++ Limited 
Alcohol Residential treatment and naltrexone + ++ Sufficient 
 Residential treatment + ++ Sufficient 
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Topic area Intervention Lifetime 
 health 
 impact* 
Annual 
intervention  
cost* 
Strength of 
evidence 
Kidney disease Current dialysis and transplant ++ +++ Sufficient 
Dialysis only + +++ Sufficient 
CVD Angioplasty coated stents non-diabetics + ++ Sufficient 
 Elective bypass surgery and stents versus optimal 
medical treatment 
+ +++ Sufficient 
Influenza Universal influenza vaccination for adults age 50–64 
assuming Australian influenza-like illness incidence 
rate 1.79% 
+ ++ Limited 
Varicella Herpes zoster vaccine + +++ Sufficient 
HIV Early antiretrovirals ++ ++ Sufficient 
 Post-exposure prophylaxis for HIV + + Sufficient 
ACE, angiotensin-converting enzyme; CBT, cognitive behaviour therapy; CVD, cardiovascular disease; HIV, human 
immunodeficiency virus; MSM, males who have sex with males; TCA, tricyclic antidepressant; SSRI, selective serotonin re-
uptake inhibitor 
* See Section 2.5 for an explanation of table symbols and colour-coding. 
Coronary bypass surgery and stenting have no impact on survival compared to optimal medical 
treatment (Table 3.8). The impact on reducing the pain symptoms of angina do not weigh up against 
the high cost. Nevertheless, this intervention is used widely at considerable cost to government. 
Assuming 10% bypass surgery at $25,000 and 90% stenting at $6500, and 18,551 cases in Australia in 
2003, the cost would be $150 million. 
Early treatment with antiretroviral drugs for HIV is expensive. Giving the drugs as prophylaxis after 
males who have sex with males (MSM) have been exposed has uncertain efficacy and is cost-effective 
as too many people at low-risk exposures are currently receiving prophylaxis. Residential treatment, 
with or without naltrexone pharmacotherapy, for alcohol dependence has low effectiveness but 
imperatives other than health concerns may justify residential treatment.  
The intervention with the highest total expenditure in this list is kidney dialysis ($0.6 billion in 2003). 
The cost per individual is estimated at $70,000 per year. As there is considerable disability associated 
with dialysis, at such a high annual cost it obviously cannot have a cost-effectiveness ratio below our 
threshold of $50,000 per DALY, even though a person would die quickly without intervention. 
Economists invoke the ‘rule of rescue’ to justify spending a large amount on a small number of 
individuals who stand to benefit greatly, e.g. averting imminent death in end-stage kidney failure. 
Anal cytology in MSM to detect anal cancer is not cost-effective compared to the much cheaper digital 
rectal examination screening method. The evidence for the effectiveness of asthma clinics is 
ambivalent. A Cochrane review shows a reduction in emergency department visits but the indicators on 
hospitalisations and days out of role are ambiguous [44]. 
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3.4 Optimal intervention mix for selected risk factors and health problems 
We have completed ‘intervention pathways’ in the areas of physical activity, obesity, alcohol, blood 
pressure- and cholesterol-lowering and kidney disease. A pathway for tobacco is still outstanding as 
some cost-effectiveness analyses are yet to be completed. A pathway for the pre-diabetes screening 
interventions could not be made as the two cost-effective options (metformin and lifestyle intervention 
on diet and exercise) were not a cost-effective option when combined. In the pathways we combine 
intervention options that address the same health problem (disease or risk factor) and determine the 
most cost-effective package of interventions. 
3.4.1 Intervention pathway of blood pressure- and cholesterol-lowering interventions 
The intervention pathway for blood pressure- and cholesterol-lowering combines the largest number of 
interventions for a single topic area and is the only example of a pathway with a significant level of 
current practice interventions analysed within ACE–Prevention. The pathway includes all drug and non-
drug interventions that primarily aim to reduce blood pressure and/or cholesterol. The range of other 
interventions that affect cardiovascular disease (e.g. interventions that address tobacco, physical 
activity, diet or body mass) has been included not in this pathway but in the larger pathway in the next 
section. We had to use current practice estimates from the Australian Diabetes, Obesity and Lifestyle 
Study [45] in the year 2000, in which respondents reported use of blood pressure- or cholesterol-
lowering drugs in general, because we needed to have estimates for each absolute CVD risk category. 
We extrapolated that the mix of cholesterol- and blood-pressure-lowering drugs prescribed in Australia 
in 2003, based on Pharmaceutical Benefits Scheme (PBS) data, would be the same for their use in 
primary prevention. While we are unable to verify these assumptions, it is clear that current drug 
treatments are inefficient (Figure 3.1). Current practice averts 380,000 DALYs over the lifetime of the 
2003 Australian population, at a lifetime cost of $12 billion.  
 
Figure 3.1 Intervention pathway of the most cost-effective interventions for blood pressure- and cholesterol-lowering 
interventions compared to current practice. ACEi, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; 
CHHP, community heart health program; DALY, disability-adjusted life year 
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A more cost-effective mix of interventions consisting of a community heart health program, three 
blood-pressure-lowering agents, dietary advice and use of phytosterols in margarine would achieve a 
30% increase in health gain at a third of the cost of continuing current practice. Figure 3.1 indicates 
that the greatest inefficiency is due to the cost of the current intervention mix. Current practice already 
has a significant impact on health outcomes and is one of the more important contributors to the 
decline in cardiovascular disease since the 1970s. The main reasons for the inefficiency of current 
practice are the choice of prescribing expensive rather than cheaper drugs even if they are as effective; 
and the prescription of expensive drugs to people who may have elevated levels on one risk factor 
while at low levels of absolute risk. 
Introduction of the polypill at a feasible price of $200 is a more efficient option. With the non-drug 
interventions it can achieve as much health gain as current practice at a net cost saving (Figure 3.2). 
The combination of three separate blood-pressure-lowering drugs achieves greater health gain than 
can be achieved with the polypill, even if no cholesterol-lowering drug is added. The difference lies in 
the strength of the blood-pressure-lowering component agents in the polypill, which were assumed to 
be half the strength of the usual dose, to reduce side effects. The incremental cost-effectiveness ratio 
of adding cholesterol-lowering drugs to the pathway is greater than our threshold of $50,000 per DALY 
in both scenarios (Figures 3.1 and 3.2). Note that the combination of statins and ezetimibe is 
considered a more cost-effective option than use of statins only. The reason that cholesterol-lowering 
drugs become not cost-effective, if the most efficient mix of interventions is put in place first, is due to 
the high price of these drugs. 
 
Figure 3.2  Intervention pathway of the most cost-effective interventions for blood pressure- and cholesterol-lowering 
interventions, including the polypill, compared to current practice. ACEi, angiotensin-converting enzyme inhibitor; CCB, 
calcium channel blocker; CHHP, community heart health program; DALY, disability-adjusted life year 
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3.4.2 Intervention pathway of alcohol interventions 
The intervention pathway for alcohol combines seven interventions to prevent alcohol-related disease 
and injury and one intervention to treat alcohol dependence (Figure 3.3). Of the seven prevention 
interventions, random breath testing is considered the only intervention with more than negligible 
level of implementation in current practice. The vast majority of the health gain is achieved by the 30% 
tax on alcohol. The 30% tax alone could achieve 21% of the population health improvements that 
would be achieved if all drinkers reduced their daily alcohol consumption to fewer than four standard 
drinks for men and two standard drinks for women (the limits that the international literature and 
National Health and Medical Research Council until recently used to describe moderate alcohol 
intake). A volumetric tax that is revenue-neutral would have a far lower impact on health than the 
general tax increase. Further combinations of volumetric and increased taxation on alcohol are 
provided in Appendix 2 and in a separate report [46]. 
Taxation, advertising bans and an increase in minimum legal drinking age to 21 are cost-saving 
(dominant) interventions as indicated by the downward slope in the pathway in Figure 3.3. Brief 
intervention by a GP, licensing controls, drink driving mass media and the current practice of random 
breath testing are cost-effective additions to the pathway. The slope of the line towards residential 
treatment (with or without naltrexone pharmacotherapy) is very steep. Its inclusion in the pathway is 
not cost-effective. 
The total package of alcohol interventions could avert 110,000 DALYs. However, there is only modest 
evidence around the preventive alcohol interventions and we have limited understanding of their 
effects on long-term drinking behaviour. 
 
 
Figure 3.3  Intervention pathway for the alcohol interventions. DALY, disability-adjusted life year;  
RBT, random breath testing 
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3.4.3 Intervention pathway of physical activity interventions 
The pathway combines six interventions that we evaluated for promoting physical activity (Figure 3.4). 
Overall, the evidence of effectiveness of physical activity interventions is quite weak. We excluded 
interventions that had not been evaluated for at least three months or studies that did not include 
measurement in a ‘do nothing’ comparator group. We chose interventions studies that were most 
generalisable to the Australian population. 
Currently, in Australia, GPs are relied upon to deliver physical activity interventions (when time 
permits). In addition, governments provide some encouragement to change physical activity behaviour 
through local mass media and transport campaigns, but investment is minimal. In our review, we found 
that while some of the interventions were being implemented in the baseline year of 2003 all were 
operating at less than 5% of the estimated full capacity. 
When evaluated incrementally in the pathway, the pedometer and mass media-based community 
campaigns and GP referral interventions are cost-saving to the health sector. These would be best 
followed up with the internet-based intervention program, the GP physical activity prescription 
program, and the TravelSmart program to encourage more active transport, which are all under the 
$50,000 per DALY threshold of cost-effectiveness. 
The total package of physical activity interventions would cost $850 million to deliver, but would avert 
61,000 DALYs, which is 34% of the population health improvements that could be achieved if everyone 
increased their physical activity to recommended levels. 
 
Figure 3.4  Intervention pathway for the physical activity interventions. 
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league table: a 10% tax on unhealthy food (modelled for non-core foods that are high in saturated fat, 
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diet and exercise intervention targeted at overweight and obese people in primary care settings  
(Figure 3.5). The tax intervention has the greatest potential health impact but the evidence base is 
rather weak using data from the UK on elasticities, i.e. the reduction in consumption per unit increase 
in price. There is much stronger evidence that gastric banding for people with severe obesity can have 
a considerable impact on health outcomes. The large upfront costs are countered by considerable cost 
savings from not having to treat the diseases associated with obesity. The diet and exercise 
interventions in primary care offered to overweight and obese people, while cost-effective, have only a 
minor impact on population health outcomes as the weight lost is regained within a few years on 
average. 
 
 
Figure 3.5  Intervention pathway for the weight loss interventions. 
 
3.4.5 Intervention pathway of chronic kidney disease interventions 
Guidelines are available for the screening of people with diabetes but not yet for the general 
population. The screening test is simple and cheap. The treatment with ACE-inhibitor drugs for those 
identified with chronic kidney disease is very effective and has the added benefit of preventing 
cardiovascular disease. Screening in diabetics leads to a net cost saving. Adding non-diabetics to the 
screening guidelines is very cost-effective for ages 50 to 79 and inclusion of younger people is also cost-
effective but with some uncertainty. In contrast, the costs and health outcomes of not screening and 
having to provide dialysis and transplant services are not favourable. However, it has become accepted 
practice to invest in the high treatment costs of people with end-stage kidney failure as the alternative 
is imminent death. Due to ageing of the population and the increase in diabetes, demand for dialysis is 
increasing and kidney donor organs are in short supply. For these reasons, we consider screening for 
chronic kidney disease one of the missed opportunities in prevention (Figure 3.6). 
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Figure 3.6  Intervention pathway for the chronic kidney disease interventions. DALY, disability-adjusted life year;  
DM, diabetes mellitus 
 
3.5 Cost-effectiveness of combined intervention packages 
We have evaluated the total intervention costs, cost offsets and health gain associated with 
implementing the package of interventions that are dominant (cost-saving) and the package of 
interventions that are dominant or very cost-effective (all interventions with cost-effectiveness less 
than $10,000 per DALY).  
The different risk factor and disease interventions in Table 3.3 (dominant) and Table 3.4 (very cost-
effective) have been modelled independently, but many have common disease outcomes (e.g. 
ischaemic heart disease or bowel cancer). In particular, these include the ‘lifestyle’ interventions that 
target blood pressure- and cholesterol-control, physical activity, nutrition (salt intake), alcohol intake 
and use of tobacco. Therefore, to determine the combined effect of these interventions on the total 
costs and health outcomes of the intervention packages, the interventions have been re-evaluated in a 
large combined model that integrates all relevant risk factors and disease parameters.  
The packages of interventions are evaluated in the combined model in comparison to a partial null (‘no 
intervention’) scenario. For comparison, we also simulate current practice, which largely reflects the 
current use and prescribing practices for the primary preventive use of cardiovascular disease drugs. 
Results are presented over time from the baseline year of 2003 to illustrate the timing of investment in 
intervention packages and return in the form of population health improvements and disease and 
injury cost offsets. 
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3.5.1 Dominant (cost-saving) interventions 
The package of dominant interventions could avert one million DALYs over the lifetime of the 2003 
Australian population. Eighty per cent of this health gain could be achieved with the taxation and 
regulation interventions on salt, alcohol and tobacco, and the polypill for cardiovascular disease 
prevention. 
The package of dominant interventions would cost the health sector $4.6 billion, but could avert $11 
billion in healthcare costs. Fourteen per cent of the investment would be required in the first year, with 
lower annual costs thereafter for the ongoing delivery of drugs for cardiovascular disease prevention  
(Figure3.7).   
 
 
 
 
Figure 3.7 Intervention costs, cost offsets and health gain with the package of dominant (cost-saving) preventive 
interventions. DALY, disability-adjusted life year 
 
The healthcare costs saved would reach a peak around 12 years after intervention. The extension of life 
due to implementation of this set of interventions would lead to a small net additional disease 
treatment cost from 2059 onwards. 
In Figure 3.8 we overlay the costs, health impact and disease treatment costs saved by current practice 
in prevention on the previous graph. The costs of implementing the dominant package of interventions 
are substantially less than is currently spent on blood pressure- and cholesterol-lowering drugs and 
lifestyle management for preventing cardiovascular disease. Current assessment and management 
practices lead to far less health gain and less treatment costs averted than could be achieved with the 
dominant intervention package. In part, this is because of the inefficiency of current practice in blood 
pressure- and cholesterol-lowering due to a preference for expensive drugs and the inadequate 
targeting of people at risk based on individual risk factor levels rather than absolute cardiovascular risk. 
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Also, the taxation and regulation interventions in the dominant intervention package reduce the need 
for preventive cardiovascular disease drugs, which remain expensive even if prescribed most efficiently. 
  
 
Figure 3.8 Intervention costs, cost offsets and health gain with the package of dominant (cost-saving) preventive 
interventions and current practice. 
 
3.5.2 Very cost-effective interventions ($0–10,000 per DALY) 
Adding interventions with cost-effectiveness less than $10,000 per DALY prevented to the package of 
dominant interventions leads to substantially greater upfront costs of intervention (Figure 3.9). Total 
cost of the package of dominant and very cost-effective interventions would be $13 billion, but this 
would be more than matched over time by $14 billion in reduced costs of health care.  
A total of 1.4 million DALYs would be averted by the package of dominant and very cost-effective 
interventions, which is 400,000 DALYS more than the dominant package alone. A large proportion of 
the additional health gain is attributable to the polypill interventions, which include delivery to people 
at more than 5% absolute risk or at least 55 years in age, or the individual cardiovascular disease drugs 
if the polypill is not implemented (compare Graphs a and b in Figure 3.9).  
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(a)  
(b)  
 
Figure 3.9 Intervention costs, cost offsets and health gain with the package of very cost-effective ($0–10,000/DALY) 
preventive interventions: (a) including the polypill; (b) including individual blood pressure- and cholesterol-lowering drugs 
instead of the polypill. 
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4. Indigenous research in ACE–Prevention 
 
4.1 Background and rationale for providing separate analyses 
If Indigenous Australians experienced the same level of mortality and disability as the total Australian 
population, their total burden of disease in 2003 would have been 59% lower [47]. While considerable 
efforts are being made to reduce this health gap, there is a critical lack of information to guide policy-
makers on what works and what represents good ‘value for money’. It is our experience that the target 
disease burden, the prevalence and distribution of harmful exposures, the effectiveness of intervention 
strategies, the type of health service models, the acceptability to stakeholders and the cost of 
implementing effective interventions are all substantially different for Indigenous and non-Indigenous 
Australians. It is vital for effective policy, therefore, that health services are evaluated separately for 
the Indigenous and non-Indigenous populations, but undertaken in a way that enables meaningful 
analysis across and within these two populations. What makes this task more challenging is that 
conventional cost-effectiveness information may not provide sufficient economic guidance in 
Indigenous health. This is because: (i) the lip service given to equity within applied economic evaluation 
gives insufficient weight to increasing concerns about the health gap; and (ii) Indigenous Australians 
define ‘good health’ quite differently to non-Indigenous Australians. Indigenous Australians incorporate 
broader concepts of benefit, such as ‘community health gain’ and ‘cultural security’ not picked up in 
current quality-of-life metrics used by economists. 
To meet this challenge, we need: 
• sensible application and adaptation of existing knowledge on cost-effective interventions in the 
general population to the Indigenous population. The large size of the Indigenous health gap 
strongly suggests that this research effort has the potential to make a substantial difference; 
• evaluation of interventions for health promotion and illness prevention that have been designed 
for and/or by Indigenous Australians and that reflect Indigenous knowledge systems; and 
• development of innovative decision tools that are sensitive to Indigenous concepts of ‘value’, both 
in terms of health outcomes and in the way in which health services are delivered. 
In ACE–Prevention we made important progress in meeting these needs, but are very conscious that 
much more remains to be done. In Section 4.4 we report the technical and second-stage filter analysis 
for 21 interventions that were adapted from analyses undertaken for the general population. These 
results cover interventions targeting blood pressure and cholesterol, pre-diabetes, kidney disease and 
hepatitis B. We also present results for the Looma Healthy Lifestyle Community-based intervention, an 
Indigenous-designed initiative for Indigenous Australians living in remote areas.  
We adapted our analyses for the general population with one of two approaches. Either interventions 
were assumed to operate from mainstream health services, with model parameters adjusted for target 
population, participation and adherence rates or from ACCHSs, with model parameters adjusted using 
our Indigenous Health Service Delivery (IHSD) template. The template adjusted cost parameters as well 
as participation and adherence assumptions. More detail is given in Section 4.2.  
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4.2 Indigenous Health Service Delivery template 
This section draws on the PhD work of Katherine Ong, who developed the IHSD template, and is 
reproduced from a pamphlet that describes this work (available from our website; see Appendix 3). 
4.2.1 Background 
Qualitative evidence suggests that a ‘best-practice’ model of primary healthcare delivery for Indigenous 
populations is based on self-determination and community control, epitomised by the ACCHS model of 
comprehensive primary health care [48, 49]. Therefore, the ACE–Prevention project has set out to 
evaluate the impact of delivering interventions to the Indigenous population using this health service 
type. However, there is a lack of quantitative evidence of the costs and effectiveness for interventions 
delivered from ACCHSs on which to base economic evaluations. To overcome this issue, the IHSD 
template was developed. 
4.2.2 Overview  
The IHSD template includes components that describe the additional activities provided by ACCHSs 
compared to mainstream GP practices, together with their impacts on the cost of delivering 
interventions and their health benefits for the Indigenous population. These can be described in terms 
of the differences between the two service types and are detailed in Box 4.1. The template transforms 
mainstream effectiveness data so that economic evaluations can be performed on interventions as if 
they were delivered from an ACCHS. Information used to construct the template has been obtained 
from the public literature and from interviews with people working within the ACCHS sector. 
 
Table 4.1 The additional costs of IHSD Template components 
IHSD template component category Additional cost per ACCHS patient encounter 
Basic health intervention delivery components $16.67–31.57 (depending on consultation length) 
Population health, social and community activities $9.28 
Management and governance $3.87 
Patient transport services $47.01 
Services to remote regions $5.50 
ACCHS, Aboriginal community controlled health service; IHDS, Indigenous Health Service Delivery 
 
For the relevant IHSD template components in Box 4.1, values have been determined for both the 
additional costs involved each time a patient visits an ACCHS compared to a mainstream GP practice, 
and also for the differences in rates of Indigenous utilisation and adherence for the health service types 
(see Tables 4.1 and 4.2). A ratio of the differences in future cost offsets for the Indigenous compared to 
the non-Indigenous population has also been established, and these are also shown in the table. 
Additional costs have been attributed to a single encounter with a health service practitioner, as this 
then allows the intervention costs to be adjusted according to the number of health practitioner visits 
that are involved in the event pathway for an intervention. Calculated costs exclude services not 
directly related to healthcare delivery that may be provided by ACCHSs such as legal services. 
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The IHSD Template values shown in Table 4.1 reveal that the costs of providing consultations via 
ACCHSs are higher than in mainstream GP practices, primarily due to the comprehensive nature of 
these services. In particular, the provision of patient transport contributes approximately 50% of the 
additional cost. In addition, improved access to health services for the Indigenous population is 
illustrated by higher rates of Indigenous utilisation of ACCHSs and adherence to treatments compared 
to mainstream GP services, thereby increasing the intervention’s effectiveness when delivered from 
ACCHSs (see Table 4.2). Cost offsets are greater for the Indigenous population, irrespective of health 
service type, as disease treatment costs for Indigenous patients are higher due to greater co-
morbidities and severity of disease, which leads to higher potential cost savings as a result of 
preventive interventions. 
Table 4.2 IHSD template values (average across all services) 
 Mainstream GP services ACCHS 
Short consultation cost $30.85 $113.18 
Indigenous utilisation rate (cf. non-Indigenous) 60.0% 73.2% 
Indigenous adherence rate (cf. non-Indigenous) 77.8% 95.7% 
Cost offsets ratio (Indigenous : non-Indigenous) 1.19 1.19 
ACCHS, Aboriginal community controlled health service 
Box 4.1 The Indigenous Health Service Delivery (IHSD) template components 
Differences in health intervention delivery between ACCHSs and mainstream GP services, classified by key 
service characteristics, are shown. 
• Basic health intervention delivery components: 
- role substitution: a patient may be seen by an Aboriginal health worker or a nurse in addition to, or 
instead of, a doctor; 
- compliance management, e.g. medication dosing and appointment recalls; 
- staff training activities, e.g. cultural in addition to professional training for non-Indigenous staff; 
- emphasis on home visits; 
- time spent on paperwork, case conferencing and the management of complex medical conditions; 
and 
- seeing of other family members as part of routine consultations. 
• Population health, social and community activities: 
- provision of other services, e.g. social work and counselling; 
- provision of services usually provided by outside agencies, e.g. financial and housing assistance; 
- health promotion and community development activities; and 
- provision of a community space. 
• Management and governance structures: 
- presence of a community management board and the associated need for community capacity-
building in management; and 
- additional management resources required for overseeing larger staff numbers and multiple 
projects. 
• Patient transport services: 
- provision of transport for patients to and from appointments. 
• Provision of services to a large remote population: 
- out-of-hours emergency care; 
- outreach services; 
- housing and relocation costs for staff; and 
- additional costs associated with pharmaceutical and pathology services. 
• Rates of Indigenous utilisation of services and adherence to treatments  
• Future cost offsets (cost savings)  
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4.2.3 Using the Indigenous Health Service Delivery template 
It should be noted that the IHSD template remains a prototype at the completion of the ACE–
Prevention project and requires further refinement and validation. It has been trialled in a number of 
ACE–Prevention evaluations involving the prevention of cardiovascular disease, diabetes and kidney 
disease; and these results are reported in Section 4.4. The data for these interventions taken from 
mainstream GP services modelling is adapted to the ACCHS setting using the IHSD template values prior 
to economic evaluation. For example, if an intervention entails one short GP consultation, the cost of 
$30.85 for mainstream GP services is substituted by $113.18 in the event pathway when delivered from 
ACCHSs. Similarly, the utilisation of health services by the Indigenous population is taken to be 60.0% 
for mainstream GP services, increasing to 73.2% for ACCHSs.  
The IHSD template thus allows the resulting cost-effectiveness ratios to take these differences in 
treatment costs, utilisation and adherence rates into account when economic evaluations are 
performed. This is in addition to differences in Indigenous population demographics and disease risk, 
which are adjusted for separately in the modelling of health outcomes. As a result, the ACE–Prevention 
economic evaluations are made more relevant to the Indigenous population for use in priority-setting 
within the Indigenous context. 
 
4.3 Work on Indigenous concept-of-benefit instrument 
An important element of research design for Indigenous health services is capturing the Indigenous 
concept of health and wellbeing [50]. Over the course of three workshops with the ACE–Prevention 
Indigenous Steering Committee, agreement was reached on benefit dimensions/sub-dimensions and 
on how to define them. The dimensions of health benefit from an Indigenous perspective were 
identified as: 
• individual health gain, with both DALY and non-DALY sub-dimensions (with the non-DALY 
dimension defined to cover empowerment, emotional wellbeing and spiritual wellbeing); 
• community health gain, defined to cover internal relationships (development of bonding, social 
capital and Indigenous governance/control of interventions and involvement in decision-making), 
external links to social policies and institutions affecting health and wellbeing and sustainability of 
interventions;  
• equity, with both disease status differentials (between Indigenous and non-Indigenous 
populations and also within Indigenous populations) and access attributes (covering physical 
availability and user charges); and 
• cultural security, judging whether interventions had a design informed by Indigenous knowledge, 
were an appropriate response to cultural differences and values; whether they facilitated strong 
partnerships between providers and the Indigenous community; and the extent of employment of 
Indigenous workers. 
One of the challenges in developing the Indigenous concept-of-benefit instrument is balancing the 
need for clear measurement properties that health economics demands (such as orthogonal 
dimensions, clear simple language, interval properties) with the richness of language and nuances of 
meaning the more sociological/behavioural science approaches favour. While this task is feasible, it is 
time consuming and cannot be rushed. The next steps in developing the instrument involve:  
(i) calibration of each dimension on a measurement scale; (ii) agreement on weights to combine the 
dimensions into an index score; (iii) piloting of the new benefit metric; and (iv) application to all the 
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interventions evaluated using the cost per DALY approach. In the meantime, the second-stage filter 
analysis will be utilised to capture the key dimensions of cultural security and community health gain. 
 
4.4 Cost-effectiveness results for Indigenous population 
Our analyses for the Indigenous population focus on interventions that address cardiovascular disease, 
diabetes and kidney disease. Indigenous Australians suffer much higher rates of these three diseases 
and the three diseases are closely linked by common risk factors. The vaccination strategies for 
hepatitis B are part of a PhD student’s project and available in time for inclusion in this report. 
4.4.1 League table for Indigenous population 
The evidence base for the only Indigenous-specific intervention (the community-based health lifestyle 
intervention in Looma) was limited as it was based on a before-and-after comparison of risk factor 
levels without a control group. All other interventions included have sufficient evidence for efficacy, 
although not specific for Indigenous Australians. However, for the drug and medical interventions 
chosen we assumed the same effect size applies while allowing for differences in outcomes by 
adherence levels. 
As we did for the total population, we classify the lifetime health impact and annual intervention costs 
into three categories. To reflect the great disparities in disease burden between Indigenous and total 
population we set the thresholds at twice the level for the total population proportionate to population 
size (Tables 4.3 and 4.4). Greater numerical detail for each intervention is available in Appendix 2. 
The polypill (at an assumed annual cost of $200 per person) is a cost-saving intervention if delivered by 
mainstream services to all Indigenous Australians over the age of 35. Delivery of the polypill by ACCHSs 
is no longer cost-saving due to the higher costs of health service visits but would lead to greater health 
gain because of an improved Indigenous access to health services (increased utilisation of services and 
adherence to treatment). Note that the blood pressure- and cholesterol-lowering interventions in the 
Indigenous population are modelled by age and not by absolute risk as was done in the total 
population. This is partly because there are no representative health measurement data for Indigenous 
Australians but is also based on the argument that the high cardiovascular disease rates might warrant 
treatment of the whole population rather than those at high risk only. Of the individual drugs, diuretics 
and ACE inhibitors delivered by mainstream services are cost-effective but the addition of statins or the 
delivery of ACE inhibitors by ACCHs have a cost between one and three times the threshold for the 
total population of $50,000 per DALY. We deliberately created this extra category as equity concerns 
could be expressed as a greater willingness to pay for the same amount of health gain. The lifetime 
health impact of any of these interventions delivered to the Indigenous population by ACCHSs is 50% 
greater than if these same interventions were delivered by mainstream health services, due to 
improved Indigenous access. This is important to consider in addition to cost-effectiveness ratios if an 
objective is to close the Indigenous health gap. 
Table 4.3 Key to Indigenous results 
Key to results    
Lifetime health impact (DALYs) >$5000 $500–5000 <$500 
Annual intervention costs <$0.5 million $0.5–5 million >$5 million 
DALY, disability-adjusted life year 
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Table 4.4 League table of 19 interventions for the Indigenous population 
Topic area Intervention Lifetime health 
impact 
Annual 
intervention cost 
Strength of 
evidence 
Dominant (net cost savers)       
Blood pressure and 
cholesterol  
Polypill $200; mainstream, ages 35+ ++ +++ Sufficient 
Hepatitis B Universal infant hepatitis B vaccination ++ ++ Sufficient 
Hepatitis B vaccination and 
immunoglobulin for infants born to 
carrier mothers 
++ + Sufficient 
Universal hepatitis B vaccination and 
immunoglobulin for infants born to 
carrier mothers 
++ ++ Sufficient 
Kidney disease  
  
Screening and ACE inhibitors for chronic 
kidney disease, ages 25+ 
++ ++ Sufficient 
Very cost-effective ($0–10,000/DALY ) 
Blood pressure and 
cholesterol 
Polypill $200; ACCHS, ages 35+ +++ +++ Sufficient 
Cost-effective ($10,000–50,000/DALY) 
Blood pressure and 
cholesterol 
ACE inhibitors; mainstream, ages 35+ ++ +++ Sufficient 
Diuretics; mainstream, ages 35+ ++ +++ Sufficient 
Diuretics; ACCHS, ages 35+ ++ +++ Sufficient 
Pre-diabetes  Screen and dietary advice +++ +++ Sufficient 
Screen and exercise physiologist +++ +++ Sufficient 
Screen and dietary advice and exercise 
physiologist 
+++ +++ Sufficient 
Screen and metformin +++ +++ Sufficient 
Screen and acarbose +++ +++ Sufficient 
$50,000 –150,000/DALY 
Blood pressure and 
cholesterol 
Statins; Mainstream, ages 35+ ++ +++ Sufficient 
Statins; ACCHS, ages 35+ ++ +++ Sufficient 
ACE inhibitors; ACCHS, ages 35+ ++ +++ Sufficient 
Pre-diabetes Screening and orlistat +++ +++ Sufficient 
Kidney disease Dialysis and transplant ++ ++ Sufficient 
Dialysis only + ++ Sufficient 
Not cost-effective (>$150,000/DALY) 
Blood pressure and 
cholesterol 
Looma healthy lifestyle: community-
based intervention for remote 
Indigenous, ages 20+ 
++ +++ Limited 
Pre-diabetes Screen and rosiglitazone + +++ Sufficient 
ACCHS, Aboriginal community controlled health service; ACE, angiotensin-converting enzyme; HPV, human papillomavirus  
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Vaccination for hepatitis B and screening for chronic kidney disease are cost-saving interventions 
because of the high rates of disease in the Indigenous population. Screening for pre-diabetes followed 
by drug (metformin or acarbose) and lifestyle interventions is cost-effective. As in the total population 
the cost for dialysis and transplant is higher than $50,000 per DALY but the same rule of rescue 
argument holds, it is established practice and unlikely to change. 
While the Looma lifestyle intervention would rate highly on the proposed dimension of cultural security 
for an extended Indigenous concept-of-benefit, the effectiveness measured during the study as a 
change in risk factor levels was so small that it has a very unfavourable cost-effectiveness measured as 
a ‘traditional’ cost per DALY. Further evaluation of this intervention would be warranted once the 
Indigenous concept-of-benefit instrument has been developed (see Section 4.3). 
4.4.2 Intervention pathways for the Indigenous population 
Screening for chronic kidney disease in Indigenous Australians from as early an age as 25 with or 
without diabetes, in remote and non-remote areas, is a very attractive preventive option. It is cost-
saving due to the very high costs of treatment once end-stage kidney failure has been reached  
(Figure 4.1). 
 
 
 
 
 
Figure 4.1 Intervention pathway for kidney disease interventions in the Indigenous population. DM, diabetes mellitus 
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5. Discussion and recommendations for policy-makers  
 
5.1 Summary of results 
Large impact on population health through prevention can be achieved by a limited number of 
interventions: taxation of tobacco, alcohol and unhealthy foods; a mandatory limit on salt in just three 
basic food items (bread, cereals and margarine); improving the efficiency of blood pressure- and 
cholesterol-lowering drugs using an absolute risk approach and choosing the most cost-effective 
generic drugs (or potentially introducing a low-cost polypill); gastric banding for severe obesity; and an 
intensive SunSmart campaign (Table 5.1). The evidence is strong for the treatment interventions, and 
‘likely’ for the tax and regulation interventions. The SunSmart analysis is based on a rather weak 
comparison of skin cancer rates between states with low and high investment in SunSmart programs. 
The taxation and regulation interventions have low implementation costs but the ‘political cost’ of 
implementing these may be much higher. In 2009, the National Preventative Health Task Force had 
recommended tax increases for tobacco and alcohol [51]. In May 2010, the federal government 
announced a 25% increase in excise on tobacco, indicating that the 30% tax increase we modelled as 
our main tobacco tax scenario is feasible. No increase in the tax on alcohol was announced. The 
protracted political decision-making around the introduction of a tax increase on alcopop drinks may 
have made government reluctant to contemplate another alcohol tax change. We have modelled a 
wide range of alcohol taxation options. As with tobacco we present a 30% tax increase as our main 
scenario. However, it would be advisable for Australia to move to a volumetric tax on alcohol. This 
would differentially increase taxation on cheap wines as these currently have a low tax relative to their 
alcohol content. Setting a volumetric tax at a level 10% above that currently imposed on spirits would 
achieve the same amount of health gain as the 30% tax increase of the current taxation levels for each 
type of drink. The impact of a tax on unhealthy foods is more speculative as we had to use UK data on 
the reduction in consumption of these foods in the absence of Australian data. We estimate that just a 
10% tax on unhealthy non-core foods would lead to substantial health gain and considerable future 
cost savings by averting treatment of obesity-related diseases. 
A mandatory limit on the salt content in processed foods is another cheap intervention with 
considerable health gains and cost savings from avoided cardiovascular disease events. It would also 
meant that less people would need to take preventive drug treatment. 
The preventive treatments for cardiovascular disease by blood pressure- and cholesterol-lowering 
drugs are very effective and have contributed in part to the more than 70% decline in cardiovascular 
mortality over the last four decades. However, they are an expensive and recurrent cost. A shift 
towards cheaper generic drugs and guided by absolute risk rather than individual risk factor threshold 
levels could increase health gain by a third over what currently is being achieved, at very large 
immediate and ongoing cost savings. The cost savings would become even greater if Australia were to 
adopt a generic polypill containing three blood-pressure-lowering drugs and one cholesterol-lowering 
drug. Issuing new guidelines based on absolute risk and with strong recommendations for using the 
most efficient drugs is an important first step to persuade practitioners to prescribe more efficiently. A 
further set of incentives to promote desired practitioner behaviour and disincentives for continuing old 
habits may need to be put in place.  
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We estimate large health gain for laparoscopic gastric banding as a preventive surgical treatment. This 
estimate assumes a quarter of severely obese people would opt for surgery. The upfront costs would 
be enormous but would in large part be compensated by large cost savings from averting diseases like 
diabetes and cardiovascular disease. This may seem like a radical approach to prevention for a large 
number of people. However, apart from the suggestion that a tax on unhealthy food may deal with the 
growing obesity problem, our analyses show that there is no evidence for other viable alternatives 
currently available that can make significant inroads into the very large increase in obesity-related 
disease. Weight loss interventions through diet and exercise have little impact as, on average, weight is 
regained within a few years.  
A national SunSmart program at the level of intensity in Victoria is a rather costly intervention when we 
include the cost of sunscreen purchase by individuals. The cost to government is a rather modest 5% of 
the total cost listed in Table 5.1. Introduction of greater investment in other states should be 
accompanied by a well-designed evaluation study to improve the evidence base of its effectiveness. 
 
Table 5.1 Lifetime health outcomes, intervention costs and cost offsets for the most cost-effective preventive interventions 
with largest population health impact 
 
(Lifetime, discounted)  
Intervention DALYs Intervention costs 
(A$ billion) 
Cost offsets 
(A$ billion) 
Taxation    
Tobacco tax 30% 270,000 0.02 0.7 
Alcohol tax 30% 100,000 0.02 0.5 
Alcohol volumetric tax 10% above current excise on 
spirits 
110,000 0.02 0.7 
Unhealthy foods tax 10% 170,000 0.02 3.5 
Regulation    
Mandatory salt limits processed food 110,000 0.07 1.5 
Preventive treatments    
Three blood-pressure-lowering drugs to replace current 
practice of preventive drug treatments* 
20,000 –1.9 0.3 
Polypill to replace current practice  60,000 –7.0 0.8 
Laparoscopic gastric banding BMI>35 140,000 3.7 2.9 
Health Promotion    
Intensive SunSmart  120,000 2.0 0.3 
BMI, body mass index; DALY, disability-adjusted life year 
*We estimate a lifetime health benefit of 230,000 DALYs from current practice. The polypill or a combination of blood-
pressure-lowering drugs targeting by absolute cardiovascular risk and ‘realistic’ assumptions on uptake and adherence would 
lead to some additional health gain but large cost savings. 
Apart from these few high-impact preventive measures we have identified a large range of preventive 
interventions with more modest impact at a population level. In our results tables (Tables 3.2–3.8; 
Table 4.4; Appendix 2 for details), we have marked interventions with a lifetime impact of between 
10,000 and 100,000 DALYs as having a moderate impact. The main missed opportunities among these 
are screening programs for pre-diabetes, chronic kidney disease and low bone mineral density in 
elderly women. Evidence is good for the effectiveness of the drug and lifestyle treatments that are 
recommended for the high-risk individuals identified by screening. 
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Smoking cessation aids, pedometers and mass media for physical activity are other approaches with 
moderate population health impact. We note that a considerable health impact of physical activity can 
be achieved without necessarily reducing body weight.  
Of the cost-effective interventions with smaller population health impact, the growing list of potential 
preventive measures for mental disorders deserves mentioning. Until recently, the focus was solely on 
treatment of mental disorders. While it is encouraging to see an emerging literature on effective means 
of prevention, our analyses indicate that treatment will continue to be the mainstay of mental health 
services as the health gain from prevention is still modest. Hepatitis B and human papillomavirus 
vaccination are cost-effective measures of preventing largely what tend to be called non-
communicable disease outcomes: cancers and cirrhosis. 
We have also identified a range of not cost-effective forms of prevention (Table 3.6). A considerable 
investment in prevention is currently made for some of these, e.g. weight loss interventions and most 
of the approaches in the literature to promote the intake of fruit and vegetables. We would argue for a 
redirection of those resources towards more favourable interventions. The worst example of a not 
cost-effective intervention is screening by prostate-specific antigen test to detect prostate cancer. The 
properties of the test are so poor that it leads to many unnecessary invasive follow-up examinations 
and treatments that have serious long-term consequences. These harms are greater than the benefits 
of early detection of new cases that could lead to death. The strong recommendation is to stop using 
the test in asymptomatic men altogether. 
For comparison, we also analysed the cost-effectiveness of a smaller number of treatment and 
infectious disease control interventions. These were intended as ‘benchmarks’ for our preventive 
interventions. A number of results are worth noting. Australia’s needle exchange program is cost-saving 
and has contributed to the low HIV-seroprevalence in injecting drug users in Australia. Well 
established, high-cost treatments that are not considered cost-effective include kidney dialysis, 
stenting or bypass surgery for coronary heart disease and a one-year course of trastuzumab for early 
breast cancer. Providing a kidney transplant instead of ongoing dialysis is cost-effective but limited by 
the number of available donor organs. The alternative of imminent death in people with end-stage 
kidney disease justifies continued investment in current practice of dialysis and transplant services 
despite the not-so-favourable cost of $70,000 per DALY. Recent evidence shows that elective stenting 
or bypass surgery has no benefit on survival in people with coronary heart disease. Therefore, the cost 
is high in comparison to the limited benefits of symptom relief of angina only. The high drug cost makes 
trastuzumab in a full one-year course not cost-effective. Weak evidence from an underpowered study 
indicated that a similar effect can be achieved with just nine weeks of treatment. 
 
5.2 Comparison with other cost-effectiveness studies of prevention 
ACE–Prevention is an important achievement, more than doubling the published economic appraisal 
research on health promotion/illness prevention in Australia. During a search in 2005, Dalziel and Segal 
[52] found published cost-effectiveness results for 245 interventions in Australia. They classified 78 of 
these as prevention. At a recount excluding infectious disease control interventions and variations on 
the same intervention (e.g. different age cut-offs for a screening program) the review included 56 
preventive interventions for non-communicable disease. Half of these were from Segal’s group 
concerning prevention of diabetes, obesity and nutrition-related interventions [53, 54]. Where the 
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same interventions were modelled our results tend to be less favourable. Important differences in 
approach are that Segal and colleagues (i) assume no decay of intervention effect over time unless 
explicitly measured in a trial; (ii) base analyses on single trial information rather than meta-analysis of 
all available trial data; (iii) present results without uncertainty analysis; and (iv) do not estimate the 
effects and costs at a population level. 
Internationally comparable economic evaluation studies that have addressed prevention include the 
WHO CHOICE (CHOosing Interventions based on Cost-Effectiveness) project [55, 56], modelling by the 
Dutch Centre for Public Health and the Environment (RIVM) and the National Institute for Clinical 
Excellence (NICE) in the UK. The focus of WHO CHOICE is on developing countries. An important 
difference in approach is their choice to model interventions based on efficacy rather than 
effectiveness while we have endeavoured to use realistic estimates of coverage, effectiveness and 
adherence under routine health service conditions. WHO CHOICE findings on cardiovascular disease 
prevention [57] and alcohol [58] lead to similar conclusions as our results although results are not so 
easy to compare as they are presented for large world regions. 
RIVM has built up a complex chronic disease model. They run analyses mainly to inform Dutch national 
policies. The model has its epidemiologic input data from a continuous burden of disease-like exercise 
performed by another department at the same RIVM, which systematically collects, analyses and 
interprets all available national study data. Recent publications by this group are on alcohol taxes [59], 
brief GP interventions for alcohol abuse [60], lifestyle modification in diabetic patients [61], weight 
reduction with low-calorie diet alone or diet and orlistat [62], smoking cessation [63], tobacco taxes 
[63] and smoking prevention and cessation among students [64]. While the work of the RIVM has 
similarities to the ACE–Prevention project, it seems to be functioning at a smaller scale and does not 
cover anywhere near the number of interventions, although it could accumulate more over the years, it 
being a continuing program. In recent work the RIVM expressly includes the total healthcare costs in 
life years gained by interventions, which ACE–Prevention does not.  
In the UK, NICE produces health technology assessments and cost-effectiveness studies across a wide 
range of topics. To 2010, NICE produced guidance on 24 prevention topics, including alcohol, tobacco 
and physical activity. It is not so clear how comparable their results are across different topic areas as 
segments of work were commissioned separately but we have not found a set of economic evaluation 
guidelines that is nearly as detailed as ours.  
 
5.3 Strengths and limitations 
The greatest strength of this body of work is the sheer number of comparisons of cost-effectiveness 
results. Economic evaluation is all about comparisons and the value of the information increases with 
the number of alternatives examined. We aimed to be comprehensive in our analysis of prevention 
options for non-communicable disease in Australia. We have managed to cover the most important 
strategies for the main diseases and risk factors. While greater detail is possible within topic areas, we 
are confident that we provide a comprehensive overview of the evidence base of prevention and how 
it applies to the context of Australian health services.  
Another important strength is that ACE–Prevention couples volume of work with technical rigour. 
There are six key factors that we addressed in achieving technical rigour. 
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First, we carefully evaluated all evidence of efficacy for each intervention. Where we could, we applied 
effect sizes from meta-analyses. For each intervention we endeavoured to find data to determine the 
effectiveness under routine health service conditions in Australia. If no data were available, we made 
assumptions on coverage and adherence that were similar to those made for interventions with data 
available.  
Second, we build our analyses on a comprehensive and consistent set of disease and risk factor 
parameters pertaining to the Australian population from the Australian Burden of Disease study. That 
allowed us to address idiosyncrasies of ill-defined deaths and disease codes in routine databases, which 
tend to be ignored in most disease-specific epidemiological and economic studies. It also enabled us to 
estimate the probability of health loss by age and, thus, to adjust the health gain from averted deaths 
in our economic models to reflect that a year gained at older ages is a less healthy year than that 
gained by a younger person.  
Third, we estimated costs of interventions and future disease treatment costs based on Australian data 
and in a consistent manner across all interventions following a detailed protocol.  
Fourth, we used a consistent approach to economic evaluation across all our analyses. Such a 
consistent approach allows valid comparisons of cost-effectiveness results in a league table. This is in 
contrast to league tables that haphazardly combine estimates from different studies in different 
contexts and using different methods and that are rightly criticised in the literature [65].  
Fifth, we present our results with uncertainty and examine variations in important assumptions in 
sensitivity analyses. Apart from capturing uncertainty numerically in our results, separately, we also 
provide a more qualitative assessment of the strength of the evidence underlying each of the individual 
analyses.  
Sixth, we present results for the ideal package of interventions for major topic areas and can contrast 
this with current practice to identify its degree of inefficiency. We also present results for a large 
combination of recommended prevention strategies across many different topic areas. This is 
important as decisions are not taken in isolation and the implementation of one intervention can 
influence the cost-effectiveness credentials of another. For instance, implementation of a 30% increase 
in tobacco tax will have a major impact on cardiovascular disease rates and we have been able to 
evaluate by how much this would reduce the amount of health gain from other cardiovascular 
preventive interventions. We have also been able to address synergies between costs, for example 
when a second intervention can be provided during the same health service contact. The combined 
analysis also gives a good indication of the magnitude of the aggregate health gains that are possible 
with optimal policy. 
While most of the research endeavour focused on ensuring the technical rigour of the cost-
effectiveness analyses in ACE–Prevention, we also put emphasis on ‘due process’ involving 
stakeholders from governments, health non-government organisations, academics and service 
providers. Represented in a project steering committee and technical advisory groups they have 
provided advice on the selection of interventions, the modelling methods, interpretation of the results, 
formulation of policy-relevant recommendations and a dissemination strategy. It has not always been 
easy to maintain stakeholders’ interest over the five-year period and there has been a rather rapid 
turnover of representatives from some of the organisations. Nevertheless, particularly the 
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representatives of government have expressed their satisfaction with the emphasis on collaboration 
and consultation in this project. This means that as researchers we are more likely to reach our aim of 
influencing decision-making on resource allocation to prevention. 
Despite our efforts to provide valid comparisons by using consistent methods or the highest technical 
rigour, we recognise a number of weaknesses in our study design.  
First, we could not include a number of prevention strategies for which there was no evidence of 
effectiveness. For instance, there has been no long-term, independent, well-funded, sustained media 
campaign on alcohol and therefore also no evidence on effectiveness. However, there is evidence that 
such media campaigns on tobacco have been effective. The least this suggests is that there is promise 
in applying the same approach for other health problems. We did include a cost-effectiveness analysis 
of a media campaign on physical activity, albeit based on limited evidence of effectiveness.  
Second, we chose to model all interventions targeting the Australian population of 2003 who would be 
eligible depending on the focus of each intervention. We then modelled everyone to 100 years of age 
or death. That means that after the baseline year of 2003, our models deal with a dwindling cohort 
rather than the Australian population over time. We made that decision because the alternative is to 
make rather difficult assumptions about the time horizon over which interventions are implemented 
and consequences are being measured. WHO CHOICE, for instance, makes an assumption that 
interventions are implemented for 10 years and then stopped altogether while continuing to count the 
costs and benefits that would occur afterwards. That is a decision that is rather removed from reality. A 
decision on what time horizons to use for implementation and for health impacts is necessary to be 
able to capture all costs and benefits associated with an intervention. An alternative solution may be to 
extend the period of intervention for a period that is long enough that discounting no longer changes 
the results. At 3% discounting, that would be a period of at least 50 years.  
Third, it was not easy to set rules about the duration of interventions. Some interventions are clearly 
implemented as ‘one-off’ (taxation and regulation interventions), others clearly intended to extend for 
life, but a large number of interventions fall in between. For many of these interventions there is little 
or no information in the literature on the design of interventions that would sustain longer term 
impacts. This is particularly the case for health promotional interventions (such as mass media 
campaigns) and behaviour change interventions targeted at individuals (such as dietary counselling or 
physical activity interventions by exercise physiologists). We decided to model these interventions with 
a one-year horizon and we applied a decay function of the effect after that. For some behaviour change 
interventions we found evidence for a dwindling effect in longer term follow-up studies but for most of 
these interventions we had to postulate the degree of decaying effect. It is a vital assumption in our 
models and is one of the reasons why we tend to measure higher cost-effectiveness ratios than other 
studies.  
Fourth, we used a number of modelling approaches. The standard approach was to use a multi-state 
life table modelling approach applying average costs and effect sizes to the eligible cohort and 
modelling these in five-year age groups to death or 100 years of age. For some diseases we resorted to 
a micro-simulation approach when we had enough data and there were important variations between 
individuals. Examples of these are the model for cervical cancer screening that needed to take into 
account variation in the growth of tumours and the model for screening for pre-diabetes that needed 
to take into account a history of having been screened in the past. However, when we took the data 
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inputs from each of the risk factor life table models and constructed our large combined model using a 
micro-simulation approach we found a systematic difference with the combined estimates showing 
lower health gain by up to 25%. Part of the reason is that a micro-simulation approach allows a more 
accurate estimation of the intervention impact across the whole distribution of risk factor exposure. 
Another reason is that the ‘null’ (the hypothetical back calculation to a ‘no intervention’ scenario) is 
different in the combined model as it takes currently implemented interventions across multiple topic 
areas into account. We will explore this further in future and contribute to the literature on ‘model 
uncertainty’ an aspect of uncertainty in economic modelling that is not often quantified [66]. 
Fifth, while the inclusion of our second-stage filter criteria has been welcomed and embraced by policy-
makers, there are opportunities to add more empirical evidence to these considerations. An example is 
the work we have started developing with the Indigenous Steering Committee on how to incorporate 
aspects of health benefits that are important to Indigenous Australians such as community health gain 
and cultural security. Also, there remains a gap in the literature regarding how to incorporate equity 
concerns into measures of efficiency (i.e. cost-effectiveness). 
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Glossary of terms 
 
ACCHS Aboriginal community-controlled health service 
AIDS acquired immunodeficiency syndrome 
BMI body mass index 
CBT cognitive behaviour therapy 
CCB calcium channel blocker 
CHHP community heart health program 
CVD cardiovascular disease 
DALY disability-adjusted life year 
DWL deadweight loss 
GP general practitioner 
HIV human immunodeficiency virus 
HPV human papillomavirus 
ICER incremental cost-effectiveness ratio 
IHDS Template Indigenous Health Delivery Service Template 
MSM males who have sex with males 
PSA prostate-specific antigen 
SSRI selective serotonin re-uptake inhibitor 
TCA tricyclic antidepressant 
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Appendix 1  Priority-setting checklist 
 
For each criterion the letters in square brackets indicate the relevant rationale, viz. economic theory (T); ethical rationale (E); pragmatic rationale (P); and user 
considerations (U). 
 
1. Is there a well-defined research question? (T; P; U) 
Does the model specify a well-defined research question in answerable form? Is the model adaptable to variations in decision context and setting? If not, are the 
general settings and purposes for which the model is appropriate specified? Is the model appropriate to the specific research question of the decision-maker(s) and 
the context in which it occurs?  
2. Is there a clear concept of benefit? (T; E; U) 
Does the model have a mechanism or process to define benefit in a way that captures the perspective and objectives of the decision-maker? Does the model 
establish a clear logical connection between the concept of benefit, the research question and the priority-setting objectives? Are the ethical values underlying the 
concept of benefit made explicit? 
3. Is there an acceptable process for generating the options for change? (T; U; P) 
Does the model have an explicit mechanism for generating options for change? Do the options generated pay specific regard to the choice problem of the decision-
maker(s) and the legitimate interests of stakeholders? Do the options for change meet the following criteria: comprehensiveness (important alternatives are not 
omitted; inclusion of both increments and decrements); relevance (to choice problem and decision-maker needs); evidence-based (including a process for 
establishing and dealing with the evidence base of options for change); defined in concrete terms so that the pathway of activities can be clearly determined; and 
manageable (the evaluation task is tractable in the time available))?   
4. Is marginal analysis an integral component? (T)  
Does the model utilise incremental analysis in comparing the options for change? Does it operationalise the measurement and analysis of costs and benefits 
associated with the options for change through marginal analysis? Does the marginal analysis cover the scale and scope of the interventions, the target/user groups 
or mode of service delivery? 
5. Are the decision rules clearly specified? (T, E) 
Does the model clearly articulate the decision rules by which the options for change are ranked (maximisation through equating marginal cost and marginal benefit; 
maximisation with equity weights; maximisation subject to constraints; two-stage decision process, etc.)? Does the model specify how any multiple dimensions of 
benefit are weighted and aggregated? If outcomes are weighted for equity, are the equity principles, data sources and methods clearly specified? 
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For each criterion the letters in square brackets indicate the relevant rationale, viz. economic theory (T); ethical rationale (E); pragmatic rationale (P); and user 
considerations (U). 
 
6. Is the role of judgement recognised? (E; P; U) 
Does the model check the need for judgement in the specification, application and interpretation of the technical analysis, particularly in relation to underlying 
assumptions and values? Does the model make explicit the basis on which judgement impacts on the technical results?  
7. Are the data needs tractable? (P; U) 
Does the model have a mechanism for making the data needs of the evaluation process tractable?  
8. Is the need for due process recognised? (E; P; U; T) 
Does the model check the need to place the technical analysis within a process for decision-making that contributes to the legitimacy of the decisions and their 
acceptability to stakeholders? Is this process characterised by transparency and openness; accountability; fairness and reasonableness (unbiased; consideration 
given to all relevant factors; disregarding of irrelevant factors; accessing of relevant information); involvement of key stakeholders; consistency in decision-making; 
with an appeal or review mechanism? 
9. Do the measurement methods demonstrate appropriate rigour? (T; P; U, E) 
Does the model involve a clearly specified evaluation protocol and standardised evaluation methods appropriate to the research question? Does the measurement 
of costs and benefits strike a reasonable balance between expense, difficulty and timeliness? Is there sensitivity analysis of key design parameters and evaluation 
assumptions? Is there rigour in the implementation of both efficiency and equity objectives; recognition that the choice of outcome measures has important ethical 
implications? 
10. Reporting/implementation? (U; P; E) 
Does the reporting address issues of likely concern to decision-makers, including ethical implications, feasibility of implementation, acceptability to stakeholders, 
importance of the problem addressed, financial implications? Is the reporting format designed to assist with judgements on what weight might be placed on the 
results, including generalisability to other settings and contexts; consultation processes adopted; strengths and weaknesses of the technical analysis, including 
comparison with similar evaluation studies in the literature?  
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Appendix 2  Interventions, cost-effectiveness ratios, health outcomes, intervention costs, cost offsets, strength of evidence and second-stage filter considerations, 
ACE–Prevention*,† 
The table presents incremental cost-effectiveness ratio, number of disability-adjusted life years averted, intervention costs and 
healthcare cost savings over the lifetime of Australians alive in 2003, estimated annual intervention costs, strength of evidence and 
major issues identified in the second-stage filter analysis. 
 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
Prevention: risk factors 
1 Alcohol Volumetric tax (revenue-neutral) Dominant Dominant Dominant 11,000 0.58 0.03 –57 Likely Political will 
2 Alcohol Volumetric tax (DWL-neutral) Dominant Dominant Dominant 13,000 0.58 0.03 –69 Likely Political will 
3 Alcohol Volumetric tax (level: current excise 
high-strength beer; duty-free 
threshold: 1.15% all beverages 
except spirits) 
Dominant Dominant 3600 4700 18 0.9 –19 Likely Political will 
4 Alcohol Volumetric tax (level: current excise 
spirits; duty-free threshold 1.15% all 
beverages except spirits) 
Dominant Dominant Dominant 75,000 18 0.9 –460 Likely Political will 
5 Alcohol Two volumetric alcohol tax tiers: 
• high-strength beer and wine at rate 
of current excise high-strength beer 
• alcopops and spirits at rate current 
excise spirits. 
Duty-free threshold 1.15% all 
beverages except spirits 
Dominant Dominant Dominant 23,000 18 0.9 –140 Likely Political will 
6 Alcohol Volumetric tax (level: 10% increase in 
current excise spirits; duty-free 
threshold 1.15% all beverages except 
spirits) 
Dominant Dominant Dominant 110,000 18 0.9 –650 Likely Political will 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
7 Alcohol Volumetric tiered tax (level: 
increasing exponentially by 1% for 
every per cent of alcohol content; 
duty-free threshold 1.15% all 
beverages except spirits; discount 
70.4% and 42.6% on high and low 
strength beer sold onsite) 
Dominant Dominant Dominant 13,000 18 0.9 –72 Likely Political will 
8 Alcohol Volumetric tiered tax (level: 
increasing exponentially by 2% for 
every per cent of alcohol content; 
duty-free threshold of 1.15% all 
beverages except spirits; discount 
70.4% and 42.6% on high and low 
strength beer sold onsite) 
Dominant Dominant Dominant 28,000 18 0.9 –170 Likely Political will 
9 Alcohol Volumetric tiered tax (level: 
increasing exponentially by 3% for 
every per cent of alcohol content; 
duty-free threshold of 1.15% all 
beverages except spirits; discount 
70.4% and 42.6% on high and low 
strength beer sold onsite) 
Dominant Dominant Dominant 46,000 18 0.9 –290 Likely Political will 
10 Alcohol General tax 30% Dominant Dominant Dominant 100,000 0.58 0.030 –530 Likely Political will 
11 Alcohol General tax 15% Dominant Dominant Dominant 64,000 0.58 0.030 –530 Likely Political will 
12 Alcohol General tax 15% (DWL-neutral) Dominant Dominant Dominant 64,000 100 5 –330 Likely Political will 
13 Alcohol General tax 30% (DWL-neutral) Dominant Dominant 3000 100,000 400 19 –330 Likely Political will 
14 Alcohol Advertising bans Dominant Dominant 1000 7800 20 1.0 –31 Limited Political will 
15 Alcohol Minimum legal drinking age to 21  Dominant Dominant 3700 150 1 0.2 –0.8 Limited Political will 
16 Alcohol Brief intervention via GPs 3800 Dominant 14,000 160 2 1.9 –1.2 Sufficient Feasibility/equ
ity: limited GP 
capacity, esp. 
in rural areas 
17 Alcohol Licensing controls 3200 Dominant 8300 2700 20 1.0 –11 Likely Political will 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
18 Alcohol Drink drive mass media 14,000 7100 450,000 1500 39 39 –11 Limited – 
19 Alcohol Random breath testing 23,000 10,000 75,000 2300 71 71 –17 Likely – 
20 Alcohol Brief intervention and telemarketing 
and support 
7500 290 19,000 340 5 5 –3 Sufficient Feasibility/equ
ity: limited GP 
capacity, esp. 
in rural areas 
21 Tobacco Cessation aid: varenicline 5800 3500 9400 33,000 260 130 –76 Sufficient – 
22 Tobacco Cessation aid: bupropion 7700 5300 11,000  23,000 230 120 –54 Sufficient – 
23 Tobacco Cessation aid: nicotine replacement 
therapy 
8900 6700 11,000 14,000 160 80 –34 Sufficient – 
24 Tobacco Taxation +10% with indexation in line 
with inflation 
Dominant Dominant Dominant 48,000 18 0.87 –130 Likely Political will 
25 Tobacco Taxation +10% Dominant Dominant Dominant 17,000 18 0.86 –140 Likely Political will 
26 Tobacco Taxation +15% with indexation in line 
with inflation 
Dominant Dominant Dominant 120,000 18 0.86 –320 Likely Political will 
27 Tobacco Taxation +15% Dominant Dominant Dominant 48,000 18 0.86 –320 Likely Political will 
28 Tobacco Taxation +30% with indexation in line 
with inflation 
Dominant Dominant Dominant 270,000 18 0.86 –690 Likely Political will 
29 Tobacco Taxation +30% Dominant Dominant Dominant 110,000 18 0.86 –690 Likely Political will 
30 Tobacco Taxation +50% with indexation in line 
with inflation 
Dominant Dominant Dominant 340,000 18 0.86 –860 Likely Political will 
31 Tobacco Taxation +50% Dominant Dominant Dominant 140,000 18 0.86 –870 Likely Political will 
32 Tobacco Taxation +60% with indexation in Iine 
with inflation 
Dominant Dominant Dominant 640,000 18 0.87 –1600 Likely Political will 
33 Tobacco Taxation +60% Dominant Dominant Dominant 270,000 18 0.87 –1600 Likely Political will 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
34 Tobacco Package of current population-wide 
strategies of tobacco control (restrict 
advertising; legislation to restrict 
smoking in public places; minimum 
age for sale of tobacco; mass media; 
pack warnings)‡ 
In 
preparation 
– – – – – – – – 
35 Tobacco Brief interventions via GPs‡ In 
preparation 
– – – – – – – – 
36 Tobacco QUIT line versus extended QUIT line‡  In 
preparation 
– – – – – – – – 
37 Physical activity Pedometers Dominant Dominant Dominant 20,000 54 54 –480 Sufficient Sustainability 
of effect? 
38 Physical activity Mass media Dominant Dominant Dominant 23,000 13 13 –440 Inconclusive – 
39 Physical activity TravelSmart 21,000 Dominant Dominated 9300 410 410 –220 May be 
effective 
– 
40 Physical activity GP prescription 9500 Dominant 210,000 7100 240 240 –170 Limited – 
41 Physical activity GP referral to exercise physiologist 21,000 Dominant 140,000 1900 110 110 –54 Limited – 
42 Physical activity Internet intervention 2400 Dominant 210,000 740 21 21 –17 Sufficient – 
43 Nutrition Fruit and vegetable intake: dietary 
counselling, telephone follow-up) [67] 
140,000 62,000 350,000 17 2.7 2.7 –0.2 Limited – 
44 Nutrition Fruit and vegetable intake: dietary 
counselling, information mail-out [68] 
390,000 95,000 Dominated 96 37 37 –0.9 Sufficient – 
45 Nutrition Fruit and vegetable intake: telephone 
counselling, information mail-out [69] 
10,000,000 1,900,000 Dominated 0.2 2.1 2.1 – Limited – 
46 Nutrition Fruit and vegetable intake: peer 
counselling, telephone counselling, 
promotional materials [70] 
3,700,000 1,400,000 68,000,000 35 130 130 –0 Limited – 
47 Nutrition Fruit and vegetable intake: telephone 
counselling, information mail-out [71] 
74,000 30,000 290,000 0 0 0 – Limited – 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
48 Nutrition Fruit and vegetable intake: telephone 
counselling, information mail-out [72] 
410,000 140,000 2,300,000 760 330 330 –8 Limited – 
49 Nutrition Fruit and vegetable intake: telephone 
counselling, information mail-out [73] 
880,000 290,000 7,200,000 21 14 14 –0 Limited – 
50 Nutrition Fruit and vegetable intake: individual 
dietary counselling [74] 
520,000 250,000 1,300,000 33 18 18 –0 Limited – 
51 Nutrition Fruit and vegetable intake: individual 
and group dietary counselling [75] 
75,000 30,000 180,000 85 7 7 –1 Limited – 
52 Nutrition Fruit and vegetable intake: 
information mail-out, tailored [76] 
27,000 2900 Dominated 0 – – – Limited – 
53 Nutrition Fruit and vegetable intake: 
information mail-out, multiple tailored 
[76] 
12,000 130 85,000 0 0 0 – Limited – 
54 Nutrition Fruit and vegetable intake: 
information mail-out, multiple re-
tailored [76] 
8600 Dominant 45,000 0 0 0 – Limited – 
55 Nutrition Fruit and vegetable intake: 
community-based events, 
sponsorship, promotion [77] 
Dominant Dominant Dominant 5200 47 47 –54 May be 
effective  
– 
56 Nutrition Fruit and vegetable intake: 
Supermarket displays, flyers,  
discount coupons [78] 
2,500,000 86,000 Dominated 100 150 150 –1 Limited  – 
57 Nutrition Fruit and vegetable intake: 
information seminars, promotional 
materials [79] 
77,000 35,000 230,000 100 9 9 –1 Limited  – 
58 Nutrition Fruit and vegetable intake: 
information seminars, promotional 
materials, cafeteria changes [80] 
3,400,000 930,000 35,000,000 230 630 630 –2 Limited  – 
59 Nutrition Fruit and vegetable intake: 
information seminars and promotional 
materials and cafeteria changes [81] 
650,000 230,000 2,800,000 180 100 100 –2 Inconclusive  – 
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60 Nutrition Fruit and vegetable intake: 
information seminars and promotional 
materials and cafeteria changes [82] 
270,000 97,000 1,200,000 540 140 140 –5 Inconclusive  – 
61 Nutrition Fruit and vegetable intake: 
information seminars, promotional 
materials, cafeteria changes [83] 
1,000,000 260,000 10,000,000 130 100 100 –1 Inconclusive  – 
62 Nutrition Fruit and vegetable intake: 
information seminars, promotional 
materials, cafeteria changes [84] 
380,000 99,000 Dominated 280 89 89 –3 Limited  – 
63 Nutrition Fruit and vegetable intake: 
promotional materials, cafeteria 
changes [85] 
47,000 Dominant Dominated 1200 60 60 –12 Inconclusive  – 
64 Nutrition Fruit and vegetable intake: farmers’ 
market vouchers [86] 
270,000 130,000 860,000 32 9 9 –0 Inconclusive – 
65 Nutrition Fruit and vegetable intake: 
supermarket vouchers [86] 
660,000 220,000 Dominated 13 9 9 –0 Inconclusive – 
66 Salt Dietary advice on salt (>140 mmHg) 160,000 99,000 270,000 1700 290 290 –22 Sufficient Access to 
dietitians 
limited outside 
major cities 
67 Salt Dietary advice on salt (>115 mmHg) 260,000 160,000 440,000 2600 720 720 –34 Sufficient Access to 
dietitians 
limited outside 
major cities 
68 Salt ‘Tick’ program to reduce salt intake 
from processed food 
Dominant Dominant Dominant 5300 5 0 –77 Likely – 
69 Salt Mandatory salt limits for processed 
food 
Dominant Dominant Dominant 110,000 69 3 1500 Likely – 
70 Multi-
component 
‘Lighten Up’: Weight loss, fruit and 
vegetable intake, physical activity 
94,000 6500 Dominated 38 4 4 –0 May be 
effective 
– 
71 Body mass Diet and exercise for BMI>25 28,000 1800 62,000 3000 140 140 –63 Sufficient – 
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72 Body mass Low-fat diet for BMI>25 37,000 Dominant 290,000 1900 94 94 –40 Sufficient – 
73 Body mass Sibutramine for BMI>30 230,000 170,000 330,000 5900 1500 1500 –88 Sufficient – 
74 Body mass Orlistat for BMI>30 700,000 500,000 1,000,000 2100 1500 1500 –45 Sufficient – 
75 Body mass Front-of-pack traffic light nutrition 
labelling 
Dominant Dominant Dominant 32,000 77 4 –710 No evidence  
76 Body mass Unhealthy food tax 10% with 
indexation in line with inflation 
Dominant Dominant Dominant 170,000 18 1 –3500 May be 
effective 
Political will 
and public; 
regressive tax 
77 Body mass Laparoscopic adjustable gastric 
banding for BMI>35 
5800 Dominant 14,000 140,000 3700 120 –12,000 Sufficient Only 
acceptable 
when all else 
failed. Side 
effects not 
modelled 
78 Body mass Weight Watchers 84,000 1000 Dominated 54 5 5 –0.8 Sufficient – 
79 Blood pressure 
and cholesterol§ 
Current practice 29,000 22,000 40,000 380,000 15,000 1300 –4100 – – 
80 Blood pressure 
and cholesterol§ 
Community heart health program Dominant Dominant Dominant 80,000 47 3 –1100 May be 
effective 
Mostly 
realised 
already in 
current 
practice 
81 Blood pressure 
and cholesterol§ 
Dietary counselling by a dietitian  
>5% CVD risk 
16,000 3100 55,000 41,000 1100 81 –490 Sufficient – 
82 Blood pressure 
and cholesterol§ 
Dietary counselling by a dietitian 
>10% CVD risk 
11,000 710 41,000 21,000 470 39 –240 Sufficient – 
83 Blood pressure 
and cholesterol§ 
Dietary counselling by a dietitian 
>15% CVD risk 
8600 Dominant 35,000 12,000 230 23 –130 Sufficient – 
84 Blood pressure 
and cholesterol§ 
Dietary counselling by a GP  
>5% CVD risk 
35,000 15,000 130,000 17,000 770 55 –200 Sufficient – 
  
 
81 
 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
85 Blood pressure 
and cholesterol§ 
Dietary counselling by a GP  
>10% CVD risk 
25,000 9900 98,000 8700 320 26 –97 Sufficient – 
86 Blood pressure 
and cholesterol§ 
Dietary counselling by a GP  
>15% CVD risk 
21,000 7500 84,000 4800 150 15 –52 Sufficient – 
87 Blood pressure 
and cholesterol§ 
Phytosterol supplementation  
>5% CVD risk 
24,000 9900 65,000 43,000 1500 110 –510 Sufficient – 
88 Blood pressure 
and cholesterol§ 
Phytosterol supplementation  
>10% CVD risk 
18,000 6000 50,000 22,000 630 53 –250 Sufficient – 
89 Blood pressure 
and cholesterol§ 
Phytosterol supplementation  
>15% CVD risk 
14,000 4100 42,000 12,000 310 31 –130 Sufficient – 
90 Blood pressure 
and cholesterol§ 
Statins >5% CVD risk 34,000 26,000 44,000 100,000 4700 340 –1200 Sufficient – 
91 Blood pressure 
and cholesterol§ 
Statins >10% CVD risk 25,000 19,000 34,000 54,000 2000 160 –610 Sufficient – 
92 Blood pressure 
and cholesterol§ 
Statins >15% CVD risk 21,000 15,000 28,000 30,000 950 95 –330 Sufficient – 
93 Blood pressure 
and cholesterol§ 
Statins and ezitimibe  
>5% CVD risk 
34,000 30,000 39,000 230,000 11,000 770 –2800 Sufficient – 
94 Blood pressure 
and cholesterol§ 
Statins and ezitimibe  
>10% CVD risk 
25,000 21,000 29,000 120,000 4500 370 –1400 Sufficient – 
95 Blood pressure 
and cholesterol§ 
Statins and ezitimibe  
>15% CVD risk 
21,000 17,000 25,000 69,000 2200 220 –750 Sufficient – 
96 Blood pressure 
and cholesterol§ 
Low-dose diuretics  
>5% CVD risk 
4200 Dominant 13,000 120,000 1800 130 –1300 Sufficient – 
97 Blood pressure 
and cholesterol§ 
Low-dose diuretics  
>10% CVD risk 
1,800 Dominant 8600 66,000 760 64 –660 Sufficient – 
98 Blood pressure 
and cholesterol§ 
Low-dose diuretics  
>15% CVD risk 
600 Dominant 6600 37,000 370 37 –360 Sufficient – 
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99 Blood pressure 
and cholesterol§ 
Beta blockers >5% CVD risk 24,000 10,000 78,000 86,000 2700 190 –690 Sufficient – 
100 Blood pressure 
and cholesterol§ 
Beta blockers >10% CVD risk 17,000 6300 58,000 46,000 1100 94 –360 Sufficient – 
101 Blood pressure 
and cholesterol§ 
Beta blockers >15% CVD risk 14,000 4,300 50,000 26,000 550 55 –200 Sufficient – 
102 Blood pressure 
and cholesterol§ 
CCBs >5% CVD risk 12,000 3200 44,000 150,000 3300 230 –1400 Sufficient – 
103 Blood pressure 
and cholesterol§ 
CCBs >10% CVD risk 8200 770 33,000 78,000 1400 110 –730 Sufficient – 
104 Blood pressure 
and cholesterol§ 
CCBs >15% CVD risk 6200 Dominant 28,000 44,000 670 67 –400 Sufficient – 
105 Blood pressure 
and cholesterol§ 
ACE inhibitors >5% CVD risk 17,000 9100 32,000 130,000 3400 250 –1300 Sufficient – 
106 Blood pressure 
and cholesterol§ 
ACE inhibitors >10% CVD risk 11,000 5400 23,000 68,000 1400 120 –650 Sufficient – 
107 Blood pressure 
and cholesterol§ 
ACE inhibitors >15% CVD risk 9100 3600 19,000 38,000 700 70 –360 Sufficient – 
108 Blood pressure 
and cholesterol§ 
Aspirin >5% CVD risk Dominant Dominant Dominant 80,000 710 51 –1200 Inconclusive Increased 
bleeding; not 
proven 
effective for 
primary 
prevention 
109 Blood pressure 
and cholesterol§ 
Aspirin >10% CVD risk Dominant Dominant Dominant 43,000 300 25 –570 Inconclusive 
110 Blood pressure 
and cholesterol§ 
Aspirin >15% CVD risk Dominant Dominant Dominant 24,000 140 14 –310 Inconclusive 
111 Blood pressure 
and cholesterol§ 
Polypill $200 >5% CVD risk 730 Dominant 4600 270,000 3000 250 –3700 Likely – 
112 Blood pressure 
and cholesterol§ 
Polypill $50 >15% CVD risk Dominant Dominant Dominant 82,000 360 36 –1000 Likely – 
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113 Blood pressure 
and cholesterol§ 
Polypill $50 >10% CVD risk Dominant Dominant Dominant 150,000 730 61 –1800 Likely – 
114 Blood pressure 
and cholesterol§ 
Polypill $50 >5% CVD risk Dominant Dominant Dominant 270,000 1700 120 –3700 Likely – 
115 Blood pressure 
and cholesterol§ 
Polypill $100 >15% CVD risk Dominant Dominant Dominant 82,000 450 45 –1000 Likely – 
116 Blood pressure 
and cholesterol§ 
Polypill $100 >10% CVD risk Dominant Dominant Dominant 150,000 910 76 –1800 Likely – 
117 Blood pressure 
and cholesterol§ 
Polypill $100 >5% CVD risk Dominant Dominant 830 270,000 2200 150 –3700 Likely – 
118 Blood pressure 
and cholesterol§ 
Polypill $150 >15% CVD risk Dominant Dominant Dominant 82,000 540 54 –1000 Likely – 
119 Blood pressure 
and cholesterol§ 
Polypill $150 >10% CVD risk Dominant Dominant 780 150,000 1100 92 –1800 Likely – 
120 Blood pressure 
and cholesterol§ 
Polypill $150 >5% CVD risk Dominant Dominant 2700 270,000 2600 190 –3700 Likely – 
121 Blood pressure 
and cholesterol§ 
Polypill $200 >15% CVD risk Dominant Dominant 1200 82,000 630 63 –1000 Likely – 
122 Blood pressure 
and cholesterol§ 
Polypill $200 >10% CVD risk Dominant Dominant 2300 150,000 1300 92 –1800 Likely – 
123 Blood pressure 
and cholesterol§ 
Polypill $500 >15% CVD risk 4900 1400 9000 82,000 1200 120 –1000 Likely – 
124 Blood pressure 
and cholesterol§ 
Polypill $500 >10% CVD risk 6700 3000 11,000 150,000 2400 200 –1800 Likely – 
125 Blood pressure 
and cholesterol§ 
Polypill $500 >5% CVD risk 11,000 6200 16,000 270,000 5800 410 –3700 Likely – 
126 Blood pressure 
and cholesterol§ 
Polypill $2500 >15% CVD risk 50,000 41,000 64,000 82,000 4900 490 –1000 Likely – 
  
 
84 
 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
127 Blood pressure 
and cholesterol§ 
Polypill $2500 >10% CVD risk 58,000 48,000 74,000 150,000 9900 830 –1800 Likely – 
128 Blood pressure 
and cholesterol§ 
Polypill $2500 >5% CVD risk  77,000 63,000 96,000 270,000 24,000 1700 –3700 Likely – 
129 Blood pressure 
and cholesterol§ 
Polypill $5000 >15% CVD risk 110,000 89,000 130,000 82,000 9500 950 –1000 Likely – 
130 Blood pressure 
and cholesterol§ 
Polypill $5000 >10% CVD risk 120,000 100,000 150,000 150,000 19,000 1600 –1800 Likely – 
131 Blood pressure 
and cholesterol§ 
Polypill $5000 >5% CVD risk 160,000 130,000 200,000 270,000 46,000 3,300 –3700 Likely – 
132 Blood pressure 
and cholesterol§ 
Polypill $200 to ages 55+ 2500 Dominant 6500 530,000 6800 510 –6900 Likely – 
133 Blood pressure 
and cholesterol§ 
Polypill $50 to ages 55+ Dominant Dominant Dominant 530,000 3400 260 –6900 Likely – 
134 Blood pressure 
and cholesterol§ 
Polypill $100 to ages 55+ Dominant Dominant 1600 530,000 4500 340 –6900 Likely – 
135 Blood pressure 
and cholesterol§ 
Polypill $150 to ages 55+ 310 Dominant 4000 530,000 5600 420 –6900 Likely – 
136 Blood pressure 
and cholesterol§ 
Polypill $500 to ages 55+ 15,000 10,000 22,000 530,000 14,000 390 –6900 Likely – 
137 Osteoporosis  Osteoporosis screening and 
alendronate for women aged 70–89  
Dominant Dominant 21,000 14,000 420 42 –530 Sufficient – 
138 Osteoporosis  Osteoporosis screening and 
raloxifene for women aged 70–89  
170,000 140,000 230,000 1500 260 26 –7.3 Sufficient – 
139 Osteoporosis  Mass media campaign physical 
activity targeting women aged 25–60 
58,000 Dominant 600,000 130 13 1.3 –5.1 Likely – 
140 Illicit drugs School-based drug prevention: 
Gatehouse project 
59,000 31,000 180,000 1500 90 30 –4.8 Limited Feasibility of 
implement-
ation 
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141 Illicit drugs Random roadside drug testing 
program – scenario 2: achieving 10% 
deterrence 
43,000 38,000 50,000 56 2.8 2.8 –0.4 Limited Further 
evidence on 
deterrence 
needed 
142 Illicit drugs Random roadside drug testing 
program – scenario 3: achieving 15% 
deterrence 
28,000 23,000 32,000 81 2.8 2.8 –0.6 Limited Further 
evidence on 
deterrence 
needed 
143 Illicit drugs Random roadside drug testing 
program – scenario 1: achieving 5% 
deterrence 
84,000 73,000 96,000 31 2.8 2.8 –0.2 Limited Further 
evidence on 
deterrence 
needed 
Prevention: non-communicable diseases  
144 Cervical cancer Pap screen 2-yearly for women aged 
18+ (current practice)¶ 
41,000 – – 2100#  89# –5.5# Sufficient – 
145 Cervical cancer Pap screen 2-yearly for women aged 
25+** 
150,000 – – –100#  –15# 0.1# Sufficient – 
146 Cervical cancer Pap screen 3-yearly for women aged 
18+** 
74,000 – – –393#  –29# 0.9# Likely Acceptability: 
screening 
interval from 
2 to 3 years 
147 Cervical cancer HPV DNA test screening 3-yearly for 
women aged 18+  
11,000 – – 59#  0.65# –0.2# Likely Acceptability: 
screening 
interval from 
2 to 3 years 
148 Cervical cancer Combined Pap and HPV DNA test 
screen for women 3-yearly aged 18+ 
84,000 – – 190#  16# –0.5# Likely – 
149 Cervical cancer Pap screen for women aged 18–29 
and HPV DNA screen for women 
aged 30+, 3-yearly  
Dominant – – 84#  –1.5# –0.3# Likely – 
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150 Cervical cancer Combined Pap and HPV DNA test 
screen 3-yearly for women aged 25+ 
Dominant – – 160#  –1.9# –0.5# Likely Acceptability: 
screening 
interval from 
2 to 3 years. 
151 Cervical cancer HPV vaccination and Pap screen 2-
yearly for women aged 18+  
46,000 40,000 55,000 790#  36# –1.6# Likely – 
152 Cervical cancer HPV vaccination and Pap screen 2-
yearly for women aged 25+ 
27,000 23,000 34,000 770  21# –1.6# Likely – 
153 Cervical cancer HPV vaccination and Pap screen 3-
yearly for women aged 18+ 
12,000 9,900 18,000 680  8.5# –1.2# Likely Acceptability: 
screening 
interval from 
2 to 3 years 
154 Cervical cancer HPV vaccination and HPV DNA test 
screening 3-yearly for women aged 
18+ 
41,000 36,000 49,000 830#  34# –1.7# Likely – 
155 Cervical cancer HPV vaccination and combined Pap 
and HPV DNA test screening 3-yearly 
for women aged 18+ 
56,000 51,000 65,000 880#  49# –1.8# Likely – 
156 Cervical cancer HPV vaccination and Pap screen for 
women aged 18–29 and HPV DNA 
screen for women aged 30+, 3-yearly  
39,000 35,000 46,000 860  34# –1.7# Likely – 
157 Cervical cancer HPV vaccination and combined Pap 
and HPV DNA screen 3-yearly for 
women aged 25+ 
38,000 34,000 44,000 870  33# –1.8# Likely – 
158 Skin cancer SunSmart program (with optimal 
investment) 
16,000 12,000 22,000 120,000 2000 100 –270 Limited – 
159 Prostate cancer Screening with PSA test‡ Dominated – – – – – –  – 
160 Cancer Anal cytology for men having sex with 
men 
– – – – – – –  – 
161 Cancer and 
cirrhosis§ 
Universal infant Hepatitis B 
vaccination (HBV) 
600 Dominant 3000 1600††  21†† –20†† Sufficient – 
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162 Cancer and 
cirrhosis§ 
Universal infant vaccination and 
immunoglobulin to infants born to 
carrier mothers 
22 – 1500 2200††  25†† – Sufficient – 
163 Cancer and 
cirrhosis§ 
Vaccine and immunoglobulin for 
infants born to HBV carrier mothers 
Dominant Dominant Dominant 1900††  4.3†† –23†† Sufficient – 
164 Cancer and 
cirrhosis§ 
High-risk infant HBV vaccination Dominant Dominant Dominant 910††  2.1 †† –10†† Sufficient  
165 Cancer and 
cirrhosis§ 
High-risk infant vaccination and 
immunoglobulin to infants born to 
carrier mothers 
Dominant Dominant Dominant 1100††  2.5†† – Sufficient – 
166 Cancer and 
cirrhosis§ 
High-risk selective immunisation 
(vaccine and immunoglobulin) of 
infants born to carrier mothers (from 
high endemic countries) 
Dominant Dominant Dominant 1100††  0.6†† –12†† Sufficient – 
167 Pre-diabetes Screen and dietary advice 38,000 23,000 150,000 8200 310 26 –120 Sufficient – 
168 Pre-diabetes Screen and exercise physiologist 30,000 23,000 89,000 14,000 430 35 –180 Sufficient – 
169 Pre-diabetes Screen and dietary advice and 
exercise physiologist 
22,000 19,000 35,000 17,000 380 32 –210 Sufficient – 
170 Pre-diabetes Screen and drug: rosiglitazone Dominated Dominated 53,000 –20,060 2100 180 –49 Sufficient – 
171 Pre-diabetes Screen and drug: metformin 21,000 17,000 36,000 15,000 330 27 –250 Sufficient – 
172 Pre-diabetes Screen and drug: acarbose 37,000 25,000 130,000 20,000 760 63 –330 Sufficient – 
173 Pre-diabetes Screen and drug: orlistat 100,000 94,000 130,000 24,000 2500 200 –400 Sufficient – 
174 Kidney disease Screening and early treatment of 
chronic kidney disease (non-DM) 
13,000 Dominant 41,000 5900 290 24 –219 Sufficient – 
175 Kidney disease Screening and early treatment of 
chronic kidney disease (DM) 
Dominant Dominant 8000 4200 110 8.8 –172 Sufficient – 
176 Depression Screening and bibliotherapy to 
prevention of adult depression 
8,600 – – 2600 37 – –27 Likely – 
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177 Depression Screening and group psychological 
treatment for prevention of adult 
depression 
20,000 12,000 66,000 1700 38 – –11 Likely – 
178 Depression Screening and psychological 
treatment for prevention of post-
partum depression 
15,000 – – 370 6.9 – –6.0 Limited – 
179 Depression Screening and psychological 
intervention for prevention of 
childhood/adolescent depression 
5400 1400 32,000 5800 48 – –4.0 Sufficient Feasibility 
and 
acceptability 
in school 
setting and 
treatment of 
children 
without full-
blown 
disorder 
180 Depression Screening and bibliotherapy for the 
prevention of childhood/adolescent 
depression 
180 – – 5800 3.6 – –0.8 Limited Feasibility 
and 
acceptability 
in school 
setting and 
treatment of 
children 
without full-
blown 
disorder 
181 Self-
harm/suicide 
Problem-solving therapy for reduction 
of deliberate self-harm (suicide) 
Dominant Dominant Dominant 260 4.0 – –16 Sufficient – 
182 Self-
harm/suicide 
Emergency contact cards for the 
reduction deliberate self-harm 
(suicide) 
– – – – – – – No evidence 
of 
effectiveness 
– 
183 Self-
harm/suicide 
Gun ownership legislation and gun 
buy-back scheme) for reduction in 
suicide 
53,000 38,000 68,000 11,000 560 27 –5.5 May be 
effective 
– 
184 Self-
harm/suicide 
Responsible media reporting for 
reduction of suicide 
170 – – 1400 1.0 0.05 – Likely – 
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185 Psychosis Treatment for individuals at ultra-high 
risk for psychosis 
Dominant Dominant Dominant 180 8.4 – – Likely – 
186 Anxiety Parenting intervention for prevention 
of childhood anxiety disorders 
6900 2400 20,000 400 4.0 – –0.7 Sufficient – 
187 Vision loss Screening by regular vision testing  – – – – – – –14 No evidence – 
188 Vision loss Ranibizumab for age-related macular 
degeneration 
240,000 120,000 Dominated 3500 930 37 –1.3 Sufficient – 
189 Oral health Public water fluoridation for all towns 
>1000 people (89% coverage) 
Dominant Dominant Dominant 3700 13 1.1 – Limited Acceptability 
to public 
190 Oral health Public water fluoridation for all towns 
in Australia (100% coverage) 
92,000 34,000 180,000 5,900 680 58 – Limited Acceptability 
to public 
191 Oral health Annual dental check at ages 12–17: 
oral examination only 
54,000 – – 590 32 6.5 –95 No evidence – 
192 Oral health Annual dental check at ages 12–17: 
oral examination and X-ray and clean 
220,000 – – 590 130 27 –150 No evidence – 
193 Oral health Annual dental check at ages 12–17: 
oral examination and X-ray and clean 
and scale and sealant 
620,000 – – 590 370 73 – No evidence – 
Treatment: non-communicable diseases 
194 Alcohol Residential treatment and naltrexone 97,000 59,000 160,000 460 50 – –4.4 Sufficient Wider social 
concerns 
195 Alcohol Residential treatment 140,000 90,000 250,000 190 30 – –1.7 Sufficient  
196 Illicit drugs CBT for individuals with cannabis 
dependence 
5,400 Dominant 34,000 82 0.9 – –0.5 Sufficient Feasibility: 
workforce 
capacity 
197 Breast cancer§ Trastuzumab for early breast cancer, 
9-week course 
12,000 Dominated 90,000 1800 26 – – Sufficient – 
  
 
90 
 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
198 Breast cancer§ Trastuzumab for early breast cancer, 
1-year course 
96,000 73,000 140,000 1400 130 – – Sufficient Not more 
effective than 
short course 
199 Kidney disease Current renal replacement therapy 
versus do nothing 
70,000 65,000 76,000 10,000 730 730 – Sufficient Feasibility: 
shortage of 
donor kidneys 
200 Kidney disease Current renal replacement therapy 
versus dialysis only 
23,000 20,000 26,000 4300 100 100 – Sufficient Feasibility: 
shortage of 
donor kidneys 
201 Kidney disease Dialysis only 100,000 91,000 120,000 6100 630 630 – Sufficient – 
202 Depression TCAs for major depressive episodes 
plus 6 months continuation  
12,000 10,000 15,000 4900 70 – –9.5 Sufficient Acceptability: 
side effects 
203 Depression SSRIs for major depressive episodes 
plus 6 months continuation  
27,000 23,000 33,000 5000 150 – –10 Sufficient Acceptability: 
side effects 
204 Depression Individual CBT treatment of major 
depressive episodes by psychologist  
8600 6900 11,000 11,000 110 – –10 Sufficient – 
205 Depression Group CBT treatment of major 
depressive episodes by psychologist 
1300 870 1800 11,000 25 – –10 Sufficient – 
206 Depression Bibliotherapy for major depressive 
episodes 
620 380 950 3200 6.1 – –4.0 Sufficient – 
207 Depression 5-year maintenance therapy with 
TCAs following a major depressive 
episode 
11,000 9000 13,000 35,000 530 110 –160 Sufficient Acceptability: 
side effects 
208 Depression 5-year maintenance therapy with 
SSRIs following a major depressive 
episode 
35,000 30,000 42,000 36,000 1400 290 –160 Sufficient Acceptability: 
side effects 
209 Depression Individual maintenance CBT by a 
psychologist  
11,000 9500 13,000 49,000 700 140 –160 Sufficient – 
210 Depression Group maintenance CBT by a 
psychologist 
850 360 1200 49,000 200 40 –160 Sufficient – 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
211 Psychosis Early psychosis prevention and 
intervention centre 
Dominant Dominant Dominant – –0.05 – – Likely – 
212 Cardiovascular 
disease 
Early stenting for acute myocardial 
infarction 
16,000 11,000 29,000 6500‡‡ 110‡‡ – – Sufficient Feasibility/equ
ity/Indigenous
: only in larger 
hospitals, not 
rural/remote 
213 Cardiovascular 
disease 
Angioplasty coated stents: general 
population 
82,000 Dominant 890,000 160‡‡ 23‡‡ 23‡‡ – Sufficient – 
214 Cardiovascular 
disease 
Bypass surgery and stents versus 
optimal medical treatment 
2,134,000 1,468,000 3,527,000 – – – – Sufficient No impact on 
survival 
215 Cardiovascular 
disease 
Rehabilitation following acute 
myocardial infarction 
5400 500 18,000 4100 23 – – Sufficient No evidence 
that >6 weeks 
adds to effect 
216 Cardiovascular 
disease 
Angioplasty with coated stents: 
diabetic population 
25,000 Dominant 600,000 – – – – Sufficient – 
217 Asthma Asthma clinic, incl. benefits from 
emergency department visits and 
days off from work 
31,000 16,000 140,000 8000‡‡  260‡‡ – No evidence Ambivalent 
evidence 
218 Asthma Asthma clinic, incl. benefit from 
reduced emergency GP visits, 
emergency department visits, 
hospitalisation, and days off from 
work 
22,000 9000 91,000 8000‡‡  170‡‡ – No evidence Ambivalent 
evidence 
219 Asthma Asthma clinic, incl. benefit from 
reduced emergency department visits 
NA NA NA NA  260‡‡  No evidence Ambivalent 
evidence 
220 Osteoarthritis Hip replacement for osteoarthritis 3600 3200 4200 120,000 1600 160 –1200 Sufficient – 
221 Osteoarthritis Knee replacement for osteoarthritis 9900 8400 12,000 110,000 2800 280 –1700 Sufficient – 
222 Peptic ulcer 
disease§§ 
Eradication with triple therapy in 
Helicobacter pylori and patients with 
peptic ulcer 
Dominant – – – – – – Sufficient – 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
223 Peptic ulcer 
disease§§ 
Eradication therapy for Helicobacter 
pylori infection in uninvestigated 
dyspepsia 
– – – – – – – No evidence – 
224 Peptic ulcer 
disease§§ 
Helicobacter pylori eradication for 
non-ulcer dyspepsia 
– – – – – – – No evidence – 
225 Shingles¶¶ Varicella zoster vaccination age 50 140,000 NA NA 230¶¶ NA 32 NA Limited – 
Infectious disease control 
226 Influenza Universal influenza vaccination ages 
50–64 assuming influenza-like illness 
incidence 1.79% 
110,000 NA NA 390 43 43 – Limited – 
227 Influenza Universal influenza vaccination ages 
50–64 assuming influenza-like illness 
incidence of 5.37% (European rate) 
35,000 NA NA 1100 41 41 – Limited – 
228 HIV## Needle exchange program for 
prevention HIV and hepatitis 
Dominant Dominant Dominant         
370,000 
                                  
24 
                                       
24 
–  – 
229 HIV## Intermittent pre-exposure prophylaxis 
for HIV 
                    
5600 
Dominant                    
18,000 
          
95,000 
                                
210 
                                     
210 
– Sufficient – 
230 HIV## Circumcision: all men having sex with 
men  
                    
8900 
Dominant                    
45,000 
            
3400 
                                  
73 
                                       
73 
– Sufficient – 
231 HIV## Early antiretrovirals                    
73,000 
                  
3900 
                 
160,000 
          
12,000 
                                  
40 
                                       
40 
– Sufficient – 
232 HIV## Post-exposure prophylaxis                  
190,000 
              
170,000 
                 
210,000 
               
540 
                                    
4 
                                         
4 
– Sufficient Rule of 
rescue 
Indigenous interventions 
233 Blood pressure 
and cholesterol 
(Indigenous)§ 
Looma healthy lifestyle: community-
based intervention for remote 
Indigenous age 20+ 
390,000 380,000 400,000 1500 600 43 –25 Limited Enhances 
equity; non-
health 
benefits 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
234 Blood pressure 
and cholesterol 
(Indigenous)§ 
Statins – mainstream health services, 
ages 20+ 
82,000 69,000 97,000 3000 290 17 –47 Sufficient Enhances 
equity 
235 Blood pressure 
and cholesterol 
(Indigenous)§ 
Statins – mainstream health services, 
ages 35+ 
59,000 49,000 71,000 1500 – – – Sufficient Enhances 
equity 
236 Blood pressure 
and cholesterol 
(Indigenous)§ 
Statins – ACCHS, ages 20+ 110,000 91,000 130,000 4500 560 33 –70 Sufficient Enhances 
equity 
237 Blood pressure 
and cholesterol 
(Indigenous) § 
Statins – ACCHS, ages 35+ 80,000 66,000 97,000 2300 – – – Sufficient Enhances 
equity 
238 Blood pressure 
and cholesterol 
(Indigenous)§ 
ACE inhibitors – mainstream health 
services, ages 20+ 
44,000 30,000 77,000 3600 210 12 –48 Sufficient Enhances 
equity 
239 Blood pressure 
and cholesterol 
(Indigenous)§ 
ACE inhibitors – mainstream health 
services, ages 35+ 
31,000 19,000 57,000 1900 – – – Sufficient Enhances 
equity 
240 Blood pressure 
and cholesterol 
(Indigenous)§ 
ACE inhibitors – ACCHS, ages 20+ 69,000 47,000 120,000 5500 460 27 –72 Sufficient Enhances 
equity 
241 Blood pressure 
and cholesterol 
(Indigenous)§ 
ACE inhibitors – ACCHS, ages 35+ 51,000 33,000 89,000 2800 – – – Sufficient Enhances 
equity 
242 Blood pressure 
and cholesterol 
(Indigenous)§ 
Diuretics – mainstream health 
services, ages 20+ 
18,000 7900 36,000 3600 110 7 –49 Sufficient Enhances 
equity 
243 Blood pressure 
and cholesterol 
(Indigenous)§ 
Diuretics – mainstream health 
services, ages 35+ 
11,000 1600 25,000 1800 – – – Sufficient Enhances 
equity 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
244 Blood pressure 
and cholesterol 
(Indigenous)§ 
Diuretics – ACCHS, ages 20+ 43,000 27,000 76,000 5400 310 18 –73 Sufficient Enhances 
equity 
245 Blood pressure 
and cholesterol 
(Indigenous)§ 
Diuretics – ACCHS, ages 35+ 30,000 17,000 57,000 2700 – – – Sufficient Enhances 
equity 
246 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $50 – mainstream health 
services, ages 20+ 
Dominant Dominant Dominant 9200 83 5 –130 Sufficient Enhances 
equity 
247 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $50 – mainstream health 
services, ages 35+ 
Dominant Dominant Dominant 4700 – – – Sufficient Enhances 
equity 
248 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $50 – ACCHS, ages 20+ 5500 Dominant 12,000 14,000 270 16 –190 Sufficient Enhances 
equity 
249 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $50 – ACCHS, ages 35+ 750 Dominant 6600 7100 – – – Sufficient Enhances 
equity 
250 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $100 – mainstream health 
services, ages 20+ 
Dominant Dominant 2900 9200 110 6 –130 Sufficient Enhances 
equity 
251 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $100 – mainstream health 
services, ages 35+ 
Dominant Dominant Dominant 4700 – – – Sufficient Enhances 
equity 
252 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $100 – ACCHS, ages 20+ 8,300 1800 15,000 14,000 310 18 –190 Sufficient Enhances 
equity 
253 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $100 – ACCHS, ages 35+ 3000 Dominant 9000 7100 – – – Sufficient Enhances 
equity 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
254 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $150 – mainstream health 
services, ages 20+ 
1100 Dominant 6000 9200 140 8 –130 Sufficient Enhances 
equity 
255 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $150 – mainstream health 
services, ages 35+ 
Dominant Dominant 2100 4700 – – – Sufficient Enhances 
equity 
256 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $150 – ACCHS, ages 20+ 11,000 4500 18,000 14,000 350 20 –190 Sufficient Enhances 
equity 
257 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $150 – ACCHS, ages 35+ 5300 Dominant 11,000 7100 – – – Sufficient Enhances 
equity 
258 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $200 – mainstream health 
services, ages 20+ 
3900 Dominant 9200 9200 160 10 –130 Sufficient Enhances 
equity 
259 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $200 – mainstream health 
services, ages 35+ 
Dominant Dominant 4600 4700 – – – Sufficient Enhances 
equity 
260 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $200 – ACCHS, ages 20+ 14,000 7200 22,000 14,000 390 23 –190 Sufficient Enhances 
equity 
261 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $200 – ACCHS, ages 35+ 7500 1000 14,000 7100 – – – Sufficient Enhances 
equity 
262 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $500 – mainstream health 
services, ages 20+ 
21,000 15,000 29,000 9200 320 19 –130 Sufficient Enhances 
equity 
263 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $500 – mainstream health 
services, ages 35+ 
13,000 6800 20,000 4700 – – – Sufficient Enhances 
equity 
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DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
264 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $500 – ACCHS, ages 20+ 31,000 23,000 41,000 14,000 630 36 –190 Sufficient Enhances 
equity 
265 Blood pressure 
and cholesterol 
(Indigenous)§ 
Polypill $500 – ACCHS, ages 35+ 21,000 14,000 29,000 7100 – – – Sufficient Enhances 
equity 
266 Cancer and 
cirrhosis§ 
(Indigenous) 
Universal infant HBV vaccination Dominant Dominant Dominant 830 0.7 0.7 –8.3 Sufficient – 
267 Cancer and 
cirrhosis§ 
(Indigenous) 
Selective hepatitis B vaccination and 
immunoglobulin for infants born to 
carrier mothers 
Dominant Dominant Dominant 790 0.2 0.2 –7.7 Sufficient – 
268 Cancer and 
cirrhosis§ 
(Indigenous) 
Universal HBV vaccination, and 
additional immunoglobulin for infants 
born to carrier mothers 
Dominant Dominant Dominant 990 0.9 0.9 –10 Sufficient – 
269 Pre-diabetes 
(Indigenous) 
Screen and dietary advice 38,000 23,000 150,000 8200 310 26 –120 Sufficient Feasibility/ 
equity: limited 
capacity GPs 
and exercise 
physiologists, 
esp. in rural 
areas. 
270 Pre-diabetes 
(Indigenous) 
Screen and exercise physiologist 30,000 23,000 89,000 14,000 430 35 –180 Sufficient Feasibility/ 
equity: limited 
capacity GPs 
and exercise 
physiologists, 
esp. in rural 
areas. 
271 Pre-diabetes 
(Indigenous) 
Screen and dietary advice and 
exercise physiologist 
22,000 19,000 35,000 17,000 380 32 –210 Sufficient Feasibility/ 
equity: limited 
capacity GPs 
and exercise 
physiologists, 
esp. in rural 
areas. 
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 Topic area Intervention ICER (95% uncertainty interval) Lifetime 
DALYs 
Lifetime 
intervention 
costs  
(A$ million) 
Annual 
intervention 
costs  
(A$ million) 
Cost 
offsets  
(A$ 
million) 
Strength of 
evidence 
Second filter 
Median Lower limit Upper limit 
272 Pre-diabetes 
(Indigenous) 
Screen and drug: rosiglitazone Dominated Dominated 53,000 –21,470 2100 430 –49 Sufficient – 
273 Pre-diabetes 
(Indigenous) 
Screen and drug: metformin 21,000 17,000 36,000 15,000 330 27 –250 Sufficient – 
274 Pre-diabetes 
(Indigenous) 
Screen and drug: acarbose 37,000 25,000 130,000 20,000 760 63 –330 Sufficient – 
275 Pre-diabetes 
(Indigenous) 
Screen and drug: orlistat 100,000 94,000 130,000 25,000 2500 490 –400 Sufficient – 
276 Kidney disease 
(Indigenous) 
Screening and early treatment  with 
ACE inhibitors (remote, non-DM) 
Dominant Dominant 20,000 30 1.1 0.1 –1.5 Sufficient – 
277 Kidney disease 
(Indigenous) 
Screening and early treatment with 
ACE inhibitors (non-remote, non-DM) 
Dominant Dominant 12,000 60 2.8 0.2 –4.3 Sufficient – 
278 Kidney disease 
(Indigenous) 
Screening and early treatment  with 
ACE inhibitors (remote, DM) 
Dominant Dominant Dominant 130 3.1 0.3 –6.9 Sufficient – 
279 Kidney disease 
(Indigenous) 
Screening and early treatment with 
ACE inhibitors (non-remote, DM) 
Dominant Dominant Dominant 280 6.5 0.5 –16 Sufficient – 
280 Kidney disease 
(Indigenous) 
Current renal replacement therapy 
versus do nothing 
100,000 100,000 100,000 – – – – Sufficient – 
281 Kidney disease 
(Indigenous) 
Dialysis only 110,000 110,000 110,000 – – – – Sufficient – 
282 Kidney disease 
(Indigenous) 
Current renal replacement therapy 
versus dialysis 
17,000 10,000 24,000 – – – – Sufficient – 
ACCHS, Aboriginal controlled community health service; ACE, angiotensin-converting enzyme; BMI, body mass index; CCB, calcium channel blocker; CBT, cognitive 
behaviour therapy; CVD, cardiovascular disease; DALY, disability-adjusted life year; DM, diabetes mellitus; DWL, dead weight loss; HIV, human immunodeficiency virus; 
HPV, human papillomavirus; NA, not available; PSA, prostate-specific antigen; TCA, tricyclic antidepressant; SSRI, selective serotonin re-uptake inhibitor 
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Notes 
* Entries in blue indicate scenarios that are considered ‘variations’ rather than separate interventions and are not included in the results section of the report. 
† Interventions were modelled with the Australian population alive in 2003, or those eligible within that population, as the intervention population. This population was 
followed up over their remaining lifetime. Exceptions are mentioned in the following footnotes. In the estimation of annual intervention costs, it is assumed that interventions 
of which the effects wear off over time are repeated at regular intervals. 
‡ Work in progress.  
§ Comparator was no intervention rather than current practice. 
¶ As this intervention is the current practice scenario, it is compared to ‘do nothing’. The other cervical cancer interventions are compared to current practice (= this 
intervention). 
# Modelled with the 2003 cohort of 11-year-olds followed up over their lifetime. Disability-adjusted life years (DALYs) and costs reported here must therefore be interpreted 
as recurring annually. 
** These interventions save costs and cost DALYs compared to current practice. The ICERs are therefore ‘inverted‘; presented is the amount of money saved for every 
DALY that is lost. 
†† Prevention of cancer and cirrhosis by hepatitis B vaccination was modelled with the birth cohort of 2003 as the intervention population. DALYs and costs reported here 
must therefore be interpreted as recurring annually. 
‡‡ Costs and effects modelled as annually recurring. 
§§ Modelled with focus on individuals; no population estimates of health and cost consequences. 
¶¶ Modelled with the 2003 cohort of 50-year-olds followed up over their lifetime. DALYs and costs reported here must therefore be interpreted as recurring annually. 
## Modelled by simulating a period of 20 years and compared to no intervention. 
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Appendix 3  ACE–Prevention publications, briefing papers and pamphlets 
Topic area Documentation 
Methods Pamphlet A: The ACE–Prevention project 
Pamphlet B: ACE approach to priority-setting 
Pamphlet C: Key assumptions underlying the economic analysis 
Pamphlet D: Interpretation of ACE–Prevention cost-effectiveness results 
Pamphlet E: Indigenous Health Service Delivery 
Overall 
Results 
Pamphlet: League table 
Pamphlet: Combined effects 
Alcohol Cobiac LJ, Vos T, Doran C, Wallace A. Cost-effectiveness of interventions to prevent alcohol-related 
disease and injury in Australia. Addiction 2009;104:1646–1655. 
Byrnes J, Cobiac L, Doran C, Vos T, Shakeshaft A. The cost-effectiveness of volumetric alcohol 
taxation in Australia. Medical Journal of Australia 2010;192:439–443. 
Hall W, Wallace A, Cobiac L, Doran C, Vos T. How can we reduce alcohol-related road crashes 
among young Australians? Medical Journal of Australia 2010;192:464–466. 
Doran C, Hall W, Shakeshaft A, Vos T, Cobiac L. Alcohol policy reform in Australia: what can we 
learn from the evidence? Medical Journal of Australia 2010;192:468–470. 
Doran C, Cobiac L, Byrnes J, Vos T (2010) Alcohol taxation and distribution of gains. National Drug 
and Alcohol Research Centre, University of New South Wales; Centre for Burden of Disease and 
Cost-Effectiveness, The University of Queensland; VicHealth; Public Health Association of 
Australia. 
Pamphlet 2: Alcohol 
Tobacco Peer-reviewed publications in preparation 
Pamphlet 17: Tobacco 
Physical 
activity 
Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote physical activity: a 
modelling study. PLoS Med 2009;6:e1000110 
Pamphlet 11: Physical activity 
Fruit and 
vegetables 
Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to promote fruit and vegetable 
consumption. Under review 
Pamphlet 7: Fruit and vegetables 
Salt Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of interventions to reduce dietary salt intake. 
Heart 2010 (in press). 
Pamphlet 15: Salt 
Multi-
component 
Cobiac LJ, Vos T, Veerman JL. Cost-effectiveness of Weight Watchers and the Lighten Up to a 
Healthy Lifestyle program. Aust N Z J Public Health 2010;34(3):240–247. 
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Topic area Documentation 
Body mass Forster M, Veerman JL, Barendregt JJ, Vos T. Cost-effectiveness of diet and exercise interventions 
to reduce overweight and obesity. Under review 
Veerman JL, Forster M, Barendregt JJ, Vos T. Cost-effectiveness of pharmacological interventions 
to reduce overweight and obesity. In preparation 
Sacks G, Veerman JL, Moody M, Swinburn B. ‘Traffic-light’ nutrition labelling and ‘junk-food’ tax: a 
modelled comparison of cost-effectiveness for obesity prevention. Under review 
Peer-reviewed publication on gastric banding in preparation 
Pamphlet 9: Obesity 
Blood 
pressure 
and 
cholesterol 
Magnus A, Lim SS, Vos T, Carter R. Cost-effectiveness of strategies to prevent cardiovascular 
disease. In preparation 
Magnus A, Vos T, Carter R. The future use of a polypill in the prevention of cardiovascular disease. 
In preparation 
Pamphlet 3: Blood pressure and cholesterol lowering 
Bone 
mineral 
density 
Peer-reviewed publications in preparation 
Briefing paper Screen + alendronate 
Briefing paper Screen + raloxifene 
Briefing paper Physical activity via mass media campaign 
Pamphlet 10: Osteoporosis 
Illicit drugs Tay-Teo K, Bulfone L, Carter R, Doran C, Hall W. Modelling the public health consequences of 
cannabis use in Australia. In preparation 
Tay-Teo K, Carter R, Doran C, Pirkis J, Hall W. Evaluating the economic value of the random 
roadside drug-testing program in Victoria, Australia. In preparation 
Tay-Teo K, Carter R, Doran C, Pirkis J, Hall W. The cost-effectiveness of the Gatehouse 
intervention. In preparation 
Tay-Teo K, Carter R, Doran C, Pirkis J, Hall W. The cost-effectiveness of CBT for drug dependency. 
In preparation 
Briefing paper CBT for cannabis use disorders 
Briefing paper School-based drug prevention – Gatehouse 
Briefing paper Roadside drug-testing 
Briefing paper School-based cannabis use prevention 
Pamphlet 4: Cannabis 
Cervical 
cancer 
Shih S, Mihalopoulos C, Carter R. Costing on cervical cancer screening and management of screen 
detected abnormalities based on NHMRC guidelines. In preparation 
Shih S, Barendregt JJ, Mihalopoulos C, Carter R, Vos T. Options for change of cervical cancer 
screening strategy: cost-effectiveness results from a micro-simulation model. In preparation 
Shih S, Vos T, Magnus A, Carter R. Directions of Australian cervical screening policy in the context 
of HPV vaccination. In preparation 
Pamphlet 5: Cervical cancer screening, SunSmart and PSA screening 
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Topic area Documentation 
Skin cancer Shih S, Carter R, Sinclair C, Mihalopoulos C, Vos T. Economic evaluation of skin cancer prevention 
in Australia. Preventive Medicine 2009;49:449–453. 
Briefing paper Cervical cancer 
Briefing paper Skin cancer 
Pamphlet 5: Cervical cancer screening, SunSmart and PSA screening 
Prostate 
cancer 
Peer-reviewed publication in preparation 
Pamphlet 5: Cervical cancer screening, SunSmart and PSA screening 
Anal cancer Peer-reviewed publication in preparation 
Hepatitis B  Peer-reviewed publication in preparation 
Pre-diabetes Bertram MY, Lim SS, Barendregt JJ, Vos T. Assessing the cost-effectiveness of drug and lifestyle 
intervention following opportunistic screening for pre-diabetes in primary care. Diabetologia 
2010 May;53(5):875–881. 
Briefing paper Pre-diabetes 
Pamphlet 12: Pre-diabetes screening 
Chronic 
kidney 
disease 
Higashi H, Barendregt J, Vos T. Cost-effectiveness of screening and early treatment of chronic 
kidney disease in Australia: general and Indigenous populations. In preparation 
Pamphlet 14: Renal replacement therapy, screening and early treatment of chronic kidney 
disease 
Mental 
health 
Mihalopoulos C, Vos T, Pirkis J, Smit F, Carter R. The cost effectiveness of suicide prevention 
interventions. In preparation 
Mihalopoulos C, Vos T, Pirkis J, Smit F, Carter R. The cost-effectiveness of screening and 
treatment for the prevention of childhood/adolescent depression. In preparation 
Mihalopoulos C, Vos T, Pirkis J, Smit F, Carter R. The cost-effectiveness of prevention and 
treatment for post-natal depression. In preparation 
Mihalopoulos C, Vos T, Pirkis J, Smit F, Carter R. The cost-effectiveness of preventing psychosis. In 
preparation 
Mihalopoulos C, Vos T, Pirkis J, Smit F, Carter R. The economic analysis of prevention in mental 
health programs. In preparation 
Mihalopoulos C, Vos T, Pirkis J, Smit F, Carter R. The cost-effectiveness of screening and 
treatment for the prevention of childhood/adolescent anxiety. In preparation  
Mihalopoulos C, Vos T, Pirkis J, Smit F, Carter R. Does screening and treatment for the prevention 
of adult depression represent good value for money? ANZJP 2010 (in press) 
Briefing paper Childhood anxiety 
Briefing paper Childhood depression 
Briefing paper Youth psychosis 
Briefing paper Depression screening 
Briefing paper Post-partum depression 
Briefing paper Suicide prevention 
Briefing paper Depression treatment 
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Topic area Documentation 
 Pamphlet 1: Adult depression 
Pamphlet 6: Childhood mental disorders 
Pamphlet 13: Psychosis 
Pamphlet 16: Suicide prevention 
CVD 
treatment 
Peer-reviewed publications on rehabilitation, revascularisation, drug-eluting stents and PCI 
versus thrombolysis in preparation 
Vision loss Briefing paper Vision screening 
Briefing paper Ranibizumab for AMD 
Oral health Cobiac L, Veerman JL, Vos T. Cost-effectiveness of extending the coverage of public water supply 
fluoridation in Australia. In preparation 
Briefing paper Regular dental checks for adolescents 
Peptic ulcer 
disease 
In preparation 
Breast cancer In preparation 
Asthma In preparation 
Osteoarthritis Higashi H, Crawford S, Barendregt J. Cost-effectiveness of total hip and knee replacements for 
the Australian population with osteoarthritis: modelled analysis. In preparation 
Briefing paper Osteoarthritis hip and knee 
Shingles Briefing paper Varicella zoster vaccination 
Influenza Mogasale V, Barendregt JJ. Is universal influenza vaccination program for adults aged 50–64 in 
Australia really cost-effective? ANZJPH (under revision) 
HIV Peer-reviewed publications in preparation 
Pamphlet 8: HIV 
Diarrhoea In preparation 
Indigenous Ong K, Kelaher M, Anderson I, Carter R. A cost-based equity weight for use in the economic 
evaluation of primary health care interventions: case study of the Australian Indigenous 
population. International Journal for Equity in Health 2009, 8:34 
Peer-reviewed publication on Indigenous Health Service Delivery (IHSD) template in preparation 
Peer-reviewed publication on hepatitis B/cirrhosis and liver cancer in preparation 
Peer-reviewed publication on chronic kidney disease in preparation 
Briefing paper Blood pressure and cholesterol Indigenous 
Briefing paper Pre-diabetes 
Pamphlet Indigenous 1: Cardiovascular disease prevention 
Pamphlet Indigenous 2: Diabetes prevention 
Pamphlet Indigenous 3: Screening and early treatment of chronic kidney disease 
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